<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Moj Mahdara - Endotyping Report - 2026-02-10</title>
    <style>

:root {
    --bg: #fafafa;
    --text: #1a1a1a;
    --headers: #2c3e50;
    --code-bg: #f4f4f4;
    --code-text: #333;
    --ascii-bg: #f0f0f0;
    --border: #ddd;
    --critical: #d32f2f;
    --high: #e65100;
    --moderate: #f57c00;
    --mild: #fbc02d;
    --normal: #388e3c;
    --paradox: #7b1fa2;
    --improving: #1976d2;
    --low: #e65100;
    --toc-bg: #fff;
    --toc-width: 280px;
}

*, *::before, *::after { box-sizing: border-box; }

html { scroll-behavior: smooth; }

body {
    font-family: system-ui, -apple-system, "Segoe UI", Roboto, sans-serif;
    font-size: 16px;
    line-height: 1.6;
    color: var(--text);
    background: var(--bg);
    margin: 0;
    padding: 0;
}

/* TOC Sidebar */
.toc {
    position: fixed;
    top: 0;
    left: 0;
    width: var(--toc-width);
    height: 100vh;
    background: var(--toc-bg);
    border-right: 1px solid var(--border);
    overflow-y: auto;
    z-index: 1000;
    font-size: 13px;
    transition: transform 0.3s ease;
    box-shadow: 2px 0 8px rgba(0,0,0,0.05);
}

.toc-header {
    position: sticky;
    top: 0;
    background: var(--headers);
    color: #fff;
    padding: 12px 16px;
    display: flex;
    justify-content: space-between;
    align-items: center;
    z-index: 10;
}

.toc-header h3 { margin: 0; font-size: 15px; }

.toc-toggle {
    background: none;
    border: none;
    color: #fff;
    font-size: 20px;
    cursor: pointer;
    display: none;
    padding: 4px 8px;
}

.toc-content {
    padding: 8px 0;
}

.toc-content a {
    display: block;
    padding: 4px 16px;
    color: var(--text);
    text-decoration: none;
    border-left: 3px solid transparent;
    transition: all 0.15s;
    white-space: nowrap;
    overflow: hidden;
    text-overflow: ellipsis;
}

.toc-content a:hover {
    background: #f0f4f8;
    border-left-color: var(--headers);
    color: var(--headers);
}

.toc-h1 { font-weight: 700; padding-left: 16px; font-size: 14px; margin-top: 8px; }
.toc-h2 { padding-left: 28px; }
.toc-h3 { padding-left: 40px; font-size: 12px; color: #666; }

/* Main content */
main {
    max-width: 960px;
    margin: 0 auto;
    margin-left: calc(var(--toc-width) + 40px);
    padding: 40px 40px 80px 40px;
}

/* Header bar */
.report-header {
    margin-left: var(--toc-width);
    background: var(--headers);
    color: #fff;
    padding: 20px 40px;
    display: flex;
    justify-content: space-between;
    align-items: center;
}

.report-header h1 { margin: 0; font-size: 22px; font-weight: 600; }
.report-header .subtitle { opacity: 0.8; font-size: 14px; margin-top: 4px; }

.print-btn {
    background: rgba(255,255,255,0.15);
    border: 1px solid rgba(255,255,255,0.3);
    color: #fff;
    padding: 8px 16px;
    border-radius: 4px;
    cursor: pointer;
    font-size: 14px;
    transition: background 0.2s;
}
.print-btn:hover { background: rgba(255,255,255,0.25); }

/* Typography */
h1 { color: var(--headers); font-size: 28px; margin: 40px 0 16px; border-bottom: 2px solid var(--headers); padding-bottom: 8px; }
h2 { color: var(--headers); font-size: 22px; margin: 32px 0 12px; border-bottom: 1px solid var(--border); padding-bottom: 6px; }
h3 { color: var(--headers); font-size: 18px; margin: 24px 0 10px; }
h4 { color: var(--headers); font-size: 16px; margin: 20px 0 8px; }
h5, h6 { color: var(--headers); font-size: 15px; margin: 16px 0 6px; }

p { margin: 12px 0; }

strong { font-weight: 700; }

code {
    background: var(--code-bg);
    padding: 2px 6px;
    border-radius: 3px;
    font-family: "SF Mono", "Fira Code", "Cascadia Code", "Courier New", monospace;
    font-size: 0.9em;
}

pre {
    background: var(--code-bg);
    color: var(--code-text);
    font-family: "SF Mono", "Fira Code", "Cascadia Code", "Courier New", monospace;
    font-size: 13px;
    line-height: 1.45;
    padding: 16px;
    border: 1px solid var(--border);
    border-radius: 6px;
    overflow-x: auto;
    margin: 16px 0;
    white-space: pre;
    tab-size: 4;
}

pre code {
    background: none;
    padding: 0;
    border-radius: 0;
}

pre.ascii-art {
    background: var(--ascii-bg);
    border: 1px solid var(--border);
    font-size: 12.5px;
    line-height: 1.35;
}

/* Tables */
.table-wrapper {
    overflow-x: auto;
    margin: 16px 0;
}

table {
    border-collapse: collapse;
    width: 100%;
    font-size: 14px;
}

th {
    background: var(--headers);
    color: #fff;
    padding: 10px 12px;
    text-align: left;
    font-weight: 600;
}

td {
    padding: 8px 12px;
    border: 1px solid var(--border);
}

tr:nth-child(odd) td { background: #fff; }
tr:nth-child(even) td { background: #f8f9fa; }

/* Lists */
ul, ol { margin: 12px 0; padding-left: 24px; }
li { margin: 4px 0; }

hr {
    border: none;
    border-top: 1px solid var(--border);
    margin: 32px 0;
}

/* Severity badges */
.severity-critical {
    color: var(--critical);
    font-weight: 700;
    background: #ffebee;
    padding: 1px 6px;
    border-radius: 3px;
    font-size: 0.85em;
}

.severity-high {
    color: var(--high);
    font-weight: 700;
    background: #fff3e0;
    padding: 1px 6px;
    border-radius: 3px;
    font-size: 0.85em;
}

.severity-moderate {
    color: var(--moderate);
    font-weight: 600;
    background: #fff8e1;
    padding: 1px 6px;
    border-radius: 3px;
    font-size: 0.85em;
}

.severity-mild {
    color: #f9a825;
    font-weight: 600;
    background: #fffde7;
    padding: 1px 6px;
    border-radius: 3px;
    font-size: 0.85em;
}

.severity-normal {
    color: var(--normal);
    font-weight: 600;
    background: #e8f5e9;
    padding: 1px 6px;
    border-radius: 3px;
    font-size: 0.85em;
}

.severity-low {
    color: var(--high);
    font-weight: 600;
    background: #fff3e0;
    padding: 1px 6px;
    border-radius: 3px;
    font-size: 0.85em;
}

.severity-improving {
    color: var(--improving);
    font-weight: 600;
    background: #e3f2fd;
    padding: 1px 6px;
    border-radius: 3px;
    font-size: 0.85em;
}

.severity-paradox {
    color: var(--paradox);
    font-weight: 700;
    background: #f3e5f5;
    padding: 1px 6px;
    border-radius: 3px;
    font-size: 0.85em;
}

/* Cross-reference badges */
.xref, .cluster {
    background: #e8eaf6;
    color: #283593;
    padding: 1px 6px;
    border-radius: 3px;
    font-size: 0.85em;
    font-weight: 600;
}

.cluster {
    background: #fce4ec;
    color: #880e4f;
}

/* Collapsible sections */
details {
    margin: 16px 0;
    border: 1px solid var(--border);
    border-radius: 6px;
    background: #fff;
}

details > summary {
    background: linear-gradient(135deg, var(--headers), #34495e);
    color: #fff;
    padding: 12px 20px;
    cursor: pointer;
    font-weight: 600;
    font-size: 16px;
    border-radius: 6px 6px 0 0;
    list-style: none;
    display: flex;
    align-items: center;
}

details > summary::before {
    content: "\25B6";
    display: inline-block;
    margin-right: 10px;
    transition: transform 0.2s;
    font-size: 12px;
}

details[open] > summary::before {
    transform: rotate(90deg);
}

details > summary::-webkit-details-marker { display: none; }

details[open] > summary {
    border-radius: 6px 6px 0 0;
}

.details-content {
    padding: 16px 20px;
}

/* Back to top */
.back-to-top {
    display: inline-block;
    margin: 8px 0 16px;
    color: var(--headers);
    text-decoration: none;
    font-size: 13px;
    opacity: 0.7;
}
.back-to-top:hover { opacity: 1; }

/* Footer */
footer {
    margin-left: var(--toc-width);
    background: var(--headers);
    color: rgba(255,255,255,0.8);
    padding: 24px 40px;
    font-size: 13px;
    line-height: 1.8;
}

footer p { margin: 4px 0; }

footer .disclaimer {
    margin-top: 12px;
    padding-top: 12px;
    border-top: 1px solid rgba(255,255,255,0.2);
    font-style: italic;
    color: rgba(255,255,255,0.6);
}

/* Mobile */
@media (max-width: 1100px) {
    .toc {
        transform: translateX(-100%);
        box-shadow: none;
    }
    .toc.open {
        transform: translateX(0);
        box-shadow: 4px 0 16px rgba(0,0,0,0.15);
    }
    .toc-toggle { display: block; }
    main { margin-left: 0; padding: 24px 20px 60px; }
    .report-header { margin-left: 0; }
    footer { margin-left: 0; }
    .mobile-toc-btn {
        display: block !important;
    }
}

@media (min-width: 1101px) {
    .mobile-toc-btn { display: none !important; }
}

.mobile-toc-btn {
    position: fixed;
    top: 10px;
    left: 10px;
    z-index: 999;
    background: var(--headers);
    color: #fff;
    border: none;
    padding: 8px 12px;
    border-radius: 4px;
    cursor: pointer;
    font-size: 18px;
    display: none;
}

/* Password Screen */
#password-screen {
    position: fixed;
    top: 0; left: 0; right: 0; bottom: 0;
    background: #1a1a2e;
    display: flex;
    align-items: center;
    justify-content: center;
    z-index: 99999;
}

.password-box {
    background: #16213e;
    border: 1px solid #0f3460;
    border-radius: 12px;
    padding: 40px;
    text-align: center;
    max-width: 420px;
    width: 90%;
    box-shadow: 0 8px 32px rgba(0,0,0,0.3);
}

.password-box h2 {
    color: #e94560;
    margin: 0 0 8px;
    font-size: 22px;
}

.password-box .pw-subtitle {
    color: #a2a8d3;
    margin-bottom: 24px;
    font-size: 14px;
}

.password-input-field {
    width: 100%;
    padding: 12px 16px;
    border: 1px solid #0f3460;
    border-radius: 6px;
    background: #1a1a2e;
    color: #e8e8e8;
    font-size: 16px;
    margin-bottom: 16px;
    font-family: inherit;
}

.password-input-field:focus {
    outline: none;
    border-color: #e94560;
}

.password-btn {
    width: 100%;
    padding: 12px;
    background: #e94560;
    color: white;
    border: none;
    border-radius: 6px;
    font-size: 16px;
    font-weight: 600;
    cursor: pointer;
    transition: opacity 0.2s;
    font-family: inherit;
}

.password-btn:hover { opacity: 0.9; }

.password-error {
    color: #e94560;
    margin-top: 12px;
    font-size: 14px;
    display: none;
}

#main-content-wrapper { display: none; }

/* Print */
@media print {
    .toc { display: none !important; }
    .mobile-toc-btn { display: none !important; }
    .report-header { margin-left: 0; }
    main {
        margin-left: 0;
        max-width: 100%;
        padding: 20px;
    }
    footer { margin-left: 0; }
    .print-btn { display: none; }
    details { border: none; }
    details > summary { background: var(--code-bg); color: var(--text); }
    .back-to-top { display: none; }
    pre.ascii-art { font-size: 10px; }
    body { font-size: 12px; }
    h1 { font-size: 20px; }
    h2 { font-size: 17px; }
    h3 { font-size: 15px; }
    details[open] { break-inside: avoid; }
}

    </style>
</head>
<body id="top">

<nav id="toc" class="toc">
<div class="toc-header">
<h3>Table of Contents</h3>
<button class="toc-toggle" onclick="toggleTOC()" aria-label="Toggle TOC">&#9776;</button>
</div>
<div class="toc-content">
<a href="#part-1-patient-profile-inputs" class="toc-h1">PART 1: PATIENT PROFILE &amp; INPUTS</a>
<a href="#here-s-what-we-re-working-with" class="toc-h2">"Here's what we're working with"</a>
<a href="#1a-model-info-raw-data-statistics" class="toc-h2">1a. MODEL INFO + RAW DATA STATISTICS</a>
<a href="#1b-patient-snapshot" class="toc-h2">1b. PATIENT SNAPSHOT</a>
<a href="#1c-chief-complaints" class="toc-h2">1c. CHIEF COMPLAINTS</a>
<a href="#1d-high-signal-biomarkers-trends" class="toc-h2">1d. HIGH-SIGNAL BIOMARKERS + TRENDS</a>
<a href="#overview" class="toc-h3">Overview</a>
<a href="#clusters-with-most-abnormal-findings" class="toc-h3">Clusters with Most Abnormal Findings</a>
<a href="#cluster-1-cardiovascular-lipid-risk-critical" class="toc-h3">CLUSTER 1: CARDIOVASCULAR &amp; LIPID RISK [CRITICAL]</a>
<a href="#cluster-2-coagulation-critical" class="toc-h3">CLUSTER 2: COAGULATION [CRITICAL]</a>
<a href="#cluster-3-hormones-reproductive-high" class="toc-h3">CLUSTER 3: HORMONES &amp; REPRODUCTIVE [HIGH]</a>
<a href="#cluster-4-thyroid-moderate" class="toc-h3">CLUSTER 4: THYROID [MODERATE]</a>
<a href="#cluster-5-allergy-immune-high" class="toc-h3">CLUSTER 5: ALLERGY &amp; IMMUNE [HIGH]</a>
<a href="#cluster-6-gut-microbiome-critical" class="toc-h3">CLUSTER 6: GUT MICROBIOME [CRITICAL]</a>
<a href="#cluster-7-iron-status-moderate-trending-high" class="toc-h3">CLUSTER 7: IRON STATUS [MODERATE — TRENDING HIGH]</a>
<a href="#cluster-8-vitamins-high" class="toc-h3">CLUSTER 8: VITAMINS [HIGH]</a>
<a href="#cluster-9-epigenetic-aging-high" class="toc-h3">CLUSTER 9: EPIGENETIC AGING [HIGH]</a>
<a href="#cluster-10-additional-notable-findings" class="toc-h3">CLUSTER 10: ADDITIONAL NOTABLE FINDINGS</a>
<a href="#1e-genetics-with-pathways" class="toc-h2">1e. GENETICS WITH PATHWAYS</a>
<a href="#system-burden-scores-from-pass-3" class="toc-h3">System Burden Scores (from Pass 3)</a>
<a href="#pathway-burden-scores-from-pass-4-detailed" class="toc-h3">Pathway Burden Scores (from Pass 4 — Detailed)</a>
<a href="#pathway-1-methylation-one-carbon-metabolism-67-6-burden" class="toc-h3">PATHWAY 1: METHYLATION &amp; ONE-CARBON METABOLISM (67.6% burden)</a>
<a href="#pathway-2-detoxification-phase-i-38-7-burden" class="toc-h3">PATHWAY 2: DETOXIFICATION — PHASE I (38.7% burden)</a>
<a href="#pathway-3-hormone-synthesis-steroid-36-4-burden" class="toc-h3">PATHWAY 3: HORMONE SYNTHESIS — STEROID (36.4% burden)</a>
<a href="#key-genetic-findings-summary" class="toc-h3">KEY GENETIC FINDINGS SUMMARY</a>
<a href="#total-burden" class="toc-h3">Total Burden</a>
<a href="#medications-preliminary-assessment" class="toc-h3">Medications — Preliminary Assessment</a>
<a href="#supplements-summary" class="toc-h3">Supplements — Summary</a>
<a href="#peptide-injection-protocols" class="toc-h3">Peptide/Injection Protocols</a>
<a href="#hormone-therapy" class="toc-h3">Hormone Therapy</a>
<a href="#potential-interactions" class="toc-h3">Potential Interactions</a>
<a href="#1g-source-input-files" class="toc-h2">1g. SOURCE INPUT FILES</a>
<a href="#paradoxes-flagged-for-part-2" class="toc-h2">PARADOXES FLAGGED FOR PART 2</a>
<a href="#open-clarification-items" class="toc-h2">OPEN CLARIFICATION ITEMS</a>
<a href="#part-2-endotype-unifying-vision" class="toc-h1">PART 2: ENDOTYPE (Unifying Vision)</a>
<a href="#here-s-why-it-all-connects" class="toc-h2">"Here's why it all connects"</a>
<a href="#2a-executive-summary-with-timeline" class="toc-h2">2a. EXECUTIVE SUMMARY WITH TIMELINE</a>
<a href="#the-slow-burn" class="toc-h1">"The Slow Burn"</a>
<a href="#a-multi-system-metabolic-bottleneck-model-for-moj-mahdara" class="toc-h2">A Multi-System Metabolic Bottleneck Model for Moj Mahdara</a>
<a href="#2b-endotype-name-the-slow-burn" class="toc-h2">2b. ENDOTYPE NAME: "The Slow Burn"</a>
<a href="#2c-unifying-narrative" class="toc-h2">2c. UNIFYING NARRATIVE</a>
<a href="#the-bottleneck-blueprint-lifelong" class="toc-h3">"The Bottleneck Blueprint" (Lifelong)</a>
<a href="#1-1-the-slow-processing-genotype-panel" class="toc-h3">1.1 The "Slow Processing" Genotype Panel</a>
<a href="#1-2-the-convergence-pattern" class="toc-h3">1.2 The Convergence Pattern</a>
<a href="#1-3-pipeline-pathway-burden-analysis" class="toc-h3">1.3 Pipeline Pathway Burden Analysis</a>
<a href="#burning-without-fuel-2019-present" class="toc-h3">"Burning Without Fuel" (2019 → Present)</a>
<a href="#2-1-the-thyroid-mystery" class="toc-h3">2.1 The Thyroid Mystery</a>
<a href="#2-2-the-insulin-resistance-paradox" class="toc-h3">2.2 The Insulin Resistance Paradox</a>
<a href="#2-3-the-thyroid-metabolic-feedback-loop" class="toc-h3">2.3 The Thyroid-Metabolic Feedback Loop</a>
<a href="#the-unguarded-gate-2018-present" class="toc-h3">"The Unguarded Gate" (2018 → Present)</a>
<a href="#3-1-maximum-dysbiosis" class="toc-h3">3.1 Maximum Dysbiosis</a>
<a href="#3-2-why-the-gut-can-t-heal" class="toc-h3">3.2 Why the Gut Can't Heal</a>
<a href="#3-3-the-histamine-double-hit" class="toc-h3">3.3 The Histamine Double-Hit</a>
<a href="#3-4-vitamin-d-the-stuck-nutrient" class="toc-h3">3.4 Vitamin D — The Stuck Nutrient</a>
<a href="#the-pressure-builds-2018-present" class="toc-h3">"The Pressure Builds" (2018 → Present)</a>
<a href="#4-1-atherogenic-lipid-profile-genetic" class="toc-h3">4.1 Atherogenic Lipid Profile (Genetic)</a>
<a href="#4-2-the-fibrinogen-ferritin-connection" class="toc-h3">4.2 The Fibrinogen-Ferritin Connection</a>
<a href="#4-3-the-mpo-fibrinogen-dissociation" class="toc-h3">4.3 The MPO-Fibrinogen Dissociation</a>
<a href="#the-fading-signal-2018-present" class="toc-h3">"The Fading Signal" (2018 → Present)</a>
<a href="#5-1-hormonal-decline-trajectory" class="toc-h3">5.1 Hormonal Decline Trajectory</a>
<a href="#5-2-the-fsh-suppression-paradox" class="toc-h3">5.2 The FSH Suppression Paradox</a>
<a href="#5-3-estrogen-metabolism-genetics" class="toc-h3">5.3 Estrogen Metabolism Genetics</a>
<a href="#5-4-the-estrace-gap" class="toc-h3">5.4 The Estrace Gap</a>
<a href="#running-slow-thinking-slow-ongoing" class="toc-h3">"Running Slow, Thinking Slow" (Ongoing)</a>
<a href="#6-1-the-multifactorial-brain-fog" class="toc-h3">6.1 The Multifactorial Brain Fog</a>
<a href="#6-2-neurotransmitter-genetics" class="toc-h3">6.2 Neurotransmitter Genetics</a>
<a href="#6-3-epigenetic-brain-aging" class="toc-h3">6.3 Epigenetic Brain Aging</a>
<a href="#2e-mapping-to-patient-goals" class="toc-h2">2e. MAPPING TO PATIENT GOALS</a>
<a href="#146-snp-limitation-statement" class="toc-h2">146-SNP LIMITATION STATEMENT</a>
<a href="#summary-how-the-slow-burn-works" class="toc-h2">SUMMARY: HOW THE SLOW BURN WORKS</a>
<a href="#verification-checklist" class="toc-h2">VERIFICATION CHECKLIST</a>
<a href="#paradox-resolution-index" class="toc-h2">PARADOX RESOLUTION INDEX</a>
<a href="#part-3-recommendations" class="toc-h1">PART 3: RECOMMENDATIONS</a>
<a href="#genetically-informed-prioritized-intervention-plan" class="toc-h2">Genetically-Informed, Prioritized Intervention Plan</a>
<a href="#medications" class="toc-h3">MEDICATIONS</a>
<a href="#supplements" class="toc-h3">SUPPLEMENTS</a>
<a href="#peptide-protocols" class="toc-h3">PEPTIDE PROTOCOLS</a>
<a href="#hormone-therapy" class="toc-h3">HORMONE THERAPY</a>
<a href="#assessment-summary" class="toc-h3">ASSESSMENT SUMMARY</a>
<a href="#impact-rank-1-thyroid-metabolic-resolution-protocol" class="toc-h3">IMPACT RANK #1 — THYROID-METABOLIC RESOLUTION PROTOCOL</a>
<a href="#impact-rank-2-gut-environment-restoration-protocol" class="toc-h3">IMPACT RANK #2 — GUT ENVIRONMENT RESTORATION PROTOCOL</a>
<a href="#impact-rank-3-methylation-detox-optimization-protocol" class="toc-h3">IMPACT RANK #3 — METHYLATION &amp; DETOX OPTIMIZATION PROTOCOL</a>
<a href="#impact-rank-4-cardiovascular-protection-protocol" class="toc-h3">IMPACT RANK #4 — CARDIOVASCULAR PROTECTION PROTOCOL</a>
<a href="#impact-rank-5-hormonal-optimization-protocol" class="toc-h3">IMPACT RANK #5 — HORMONAL OPTIMIZATION PROTOCOL</a>
<a href="#impact-rank-6-neurocognitive-support-protocol" class="toc-h3">IMPACT RANK #6 — NEUROCOGNITIVE SUPPORT PROTOCOL</a>
<a href="#impact-rank-7-histamine-management-protocol" class="toc-h3">IMPACT RANK #7 — HISTAMINE MANAGEMENT PROTOCOL</a>
<a href="#part-4-gaps-analysis" class="toc-h1">PART 4: GAPS ANALYSIS</a>
<a href="#what-we-don-t-know-what-we-need-what-s-wrong" class="toc-h2">What We Don't Know, What We Need, What's Wrong</a>
<a href="#issue-1-thyroid-medication-gap-critical" class="toc-h3">Issue #1: Thyroid Medication Gap (CRITICAL)</a>
<a href="#issue-2-medication-compliance-discrepancies" class="toc-h3">Issue #2: Medication Compliance Discrepancies</a>
<a href="#issue-3-estrace-vaginal-cream-non-compliance" class="toc-h3">Issue #3: Estrace Vaginal Cream Non-Compliance</a>
<a href="#issue-4-multi-provider-coordination" class="toc-h3">Issue #4: Multi-Provider Coordination</a>
<a href="#issue-5-potential-interactions" class="toc-h3">Issue #5: Potential Interactions</a>
<a href="#4b-missing-data-need-more-testing" class="toc-h2">4b. MISSING DATA / NEED MORE TESTING</a>
<a href="#4c-truage-algorithm-caveat" class="toc-h2">4c. TRUAGE ALGORITHM CAVEAT</a>
<a href="#4d-model-uncertainties" class="toc-h2">4d. MODEL UNCERTAINTIES</a>
<a href="#4e-clarification-questions-for-moj" class="toc-h2">4e. CLARIFICATION QUESTIONS FOR MOJ</a>
<a href="#verification-checklist" class="toc-h2">VERIFICATION CHECKLIST</a>
</div>
</nav>

<!-- Password Screen -->
<div id="password-screen">
    <div class="password-box">
        <h2>Endotyping Report</h2>
        <p class="pw-subtitle">This report contains protected clinical analysis.<br>Please enter the access code.</p>
        <input type="password" id="password-input" class="password-input-field" placeholder="Enter password" autofocus>
        <button onclick="checkPassword()" class="password-btn">Access Report</button>
        <p class="password-error" id="password-error">Incorrect password. Please try again.</p>
    </div>
</div>

<!-- Main Content (hidden until authenticated) -->
<div id="main-content-wrapper">

<button class="mobile-toc-btn" onclick="toggleTOC()" aria-label="Open navigation">&#9776;</button>

<header class="report-header">
    <div>
        <h1>Moj Mahdara &mdash; Endotyping Report</h1>
        <div class="subtitle">&ldquo;The Slow Burn&rdquo; &bull; Multi-System Metabolic Bottleneck Model &bull; 2026-02-10</div>
    </div>
    <button class="print-btn" onclick="printReport()">&#128424; Print</button>
</header>

<main>
<h1 id="part-1-patient-profile-inputs">PART 1: PATIENT PROFILE &amp; INPUTS</h1>
<h2 id="here-s-what-we-re-working-with">"Here's what we're working with"</h2>
<p><strong>Patient:</strong> Moj Mahdara <strong>Report Generated:</strong> 2026-02-11 <strong>Pipeline Run:</strong> 20260210_Moj</p>
<hr>
<h2 id="1a-model-info-raw-data-statistics">1a. MODEL INFO + RAW DATA STATISTICS</h2>
<pre class="ascii-art">╔════════════════════════════════════╦════════════════════════════════════╗
║  PATIENT INPUT                     ║  SYSTEM MODEL                      ║
║  ──────────────                    ║  ────────────                      ║
║  SNPs: 146 (3x4 Genetics panel)   ║  Pathways Analyzed: 10 priority    ║
║  Biomarkers: 1,081 observations    ║  Systems Identified: 8             ║
║  Questionnaire: Not available      ║  Cross-Pathway Interactions: 4     ║
╠════════════════════════════════════╬════════════════════════════════════╣
║  FILTERED OUTPUT                   ║  ENDOPHENOTYPE RESULT              ║
║  ───────────────                   ║  ────────────────────              ║
║  High-Signal SNPs: 131 retained    ║  Brain Burden: 49.3%               ║
║  Pathway-Relevant SNPs: 39         ║  Body Burden: 50.7%                ║
║  Abnormal Biomarkers: 53           ║  Pattern: Methylation-Dominant     ║
║  Borderline Biomarkers: 26         ║    + Detox-Impaired Profile        ║
║  Reduction Ratio: 17.2%           ║  Key Bottlenecks: MTR, CYP2A6,    ║
║                                    ║    COMT, CYP1A1                    ║
╚════════════════════════════════════╩════════════════════════════════════╝

┌──────────────────────────────────────────────────────────────────────────────┐
│  DATA QUALITY NOTE                                                          │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  SNP Source: 3x4 Genetics curated clinical panel (146 SNPs, NOT genome-     │
│  wide). This is a focused pharmacogenomic + nutrigenomic panel — adequate   │
│  for clinical pathway analysis but may miss variants outside its scope.     │
│                                                                              │
│  Biomarker Depth: 1,081 observations from 634 unique biomarkers across     │
│  15+ collection dates spanning 2018-2025. This is EXCELLENT longitudinal   │
│  data density. 31 clinical clusters represented.                            │
│                                                                              │
│  Questionnaire Gap: No standardized symptom questionnaire was completed.    │
│  Chief complaints have been reconstructed from clinical notes, provider     │
│  documentation, and patient self-report (see Section 1c).                   │
│                                                                              │
│  Data Confidence: Diagnoses HIGH | Labs HIGH | Genetics HIGH |              │
│  Medications MEDIUM | Supplements MEDIUM | Compliance MEDIUM                │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<hr>
<h2 id="1b-patient-snapshot">1b. PATIENT SNAPSHOT</h2>
<pre class="ascii-art">╔══════════════════════════════════════════════════════════════════════════════╗
║                           PATIENT SNAPSHOT                                  ║
╠══════════════════════════════════════════════════════════════════════════════╣
║                                                                              ║
║   Name:          Moj Mahdara                                                ║
║   Age:           49 (DOB: 12/25/1976)*                                      ║
║   Sex:           Female                                                      ║
║   Occupation:    Startup executive (beauty industry)                         ║
║   Location:      Beverly Hills / Los Angeles                                 ║
║   Family:        Married to Roya, 1 child (son)                             ║
║                                                                              ║
║   Key Dx:        Hypothyroidism (2019), PCOS (2019), Insulin                ║
║                  Resistance (IR Score 48), Perimenopause/GSM,               ║
║                  Hypercholesterolemia (ApoB defect), ADHD,                  ║
║                  Histamine Intolerance, Vitamin D Deficiency                ║
║                                                                              ║
║   Surgical Hx:   Bilateral Mastectomy (Sep 2021)                            ║
║                  Bulkamid Injection for SUI (Apr 2025)                      ║
║                                                                              ║
║   Current Stack: 22+ supplements | 15+ medications | 5 peptide/injection   ║
║                  regimens | 7 hormone formulations                          ║
║                                                                              ║
║   Providers:     6 active (Kurtz PCP, West Functional, Kim Urology,        ║
║                  Lipman Integrative, Talib Naturopathic, Schneider OBGYN)   ║
║                                                                              ║
║   Family Hx:     Mat. grandmother: HTN, Stroke                              ║
║                  Pat. grandmother: Diabetes, Lymphoma                       ║
║                                                                              ║
║   * NOTE: DOB discrepancy — Quest records show 12/25/1976, 3x4 Genetics    ║
║     shows 12/25/1975. Requires patient clarification.                       ║
║                                                                              ║
╚══════════════════════════════════════════════════════════════════════════════╝</pre>
<hr>
<h2 id="1c-chief-complaints">1c. CHIEF COMPLAINTS</h2>
<p>Since no standardized questionnaire was completed, chief complaints have been reconstructed from clinical notes across 6 providers, patient self-report (December 2025), and symptoms timeline. Ranked by clinical severity:</p>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  CHIEF COMPLAINTS (Reconstructed from clinical data)                        │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  <span class="severity-critical">[CRITICAL]</span> Insulin Resistance / Metabolic Dysfunction                      │
│             IR Score 48 (ref &lt;33), WORSENING from 42 despite Mounjaro       │
│             + 30+ lbs weight loss. PCOS since 2019. LDL Pattern B.          │
│             Current BMI 30.07 (192 lbs). Fibrinogen 427, CRP 2.1.          │
│             → Metabolic syndrome with atherogenic lipid profile             │
│                                                                              │
│  <span class="severity-critical">[CRITICAL]</span> Thyroid Status UNKNOWN                                          │
│             Hypothyroidism dx 2019. Armour Thyroid confirmed Apr 2025       │
│             but MISSING from Dec 2025 records and patient self-report.      │
│             DIO2 CC genotype impairs T4→T3 tissue conversion.              │
│             June 2025 labs normal — but treated or untreated state?         │
│             → CRITICAL gap: no thyroid medication on current regimen        │
│                                                                              │
│  <span class="severity-critical">[CRITICAL]</span> Genitourinary Syndrome of Menopause — UNDERTREATED             │
│             Severe urethral atrophy documented by cystoscopy (Apr 2025).   │
│             Estrace vaginal cream prescribed but NEVER TAKEN by patient.   │
│             AMH &lt;0.08 confirms menopausal transition.                      │
│             → Active tissue damage going untreated                          │
│                                                                              │
│  <span class="severity-high">[HIGH]</span>     Cardiovascular Risk Profile                                     │
│             ApoB gene defect + LDL-P 1649 + LDL Small 291 + LDL           │
│             Pattern B + Fibrinogen 427 (increasing) + F2 GA prothrombin    │
│             variant. Triple anticoagulant therapy active.                   │
│             → Atherogenic + thrombotic convergent risk                      │
│                                                                              │
│  <span class="severity-high">[HIGH]</span>     Gut Dysbiosis — Maximum Score                                   │
│             Dysbiosis Score 10/10 (maximum). Dientamoeba fragilis           │
│             DETECTED. Multiple commensals critically low. SCFA deficit.    │
│             n-Butyrate low (3.4, ref &gt;3.6). Bacillus 4+ overgrowth.       │
│             → Severe microbiome disruption with parasitic infection         │
│                                                                              │
│  <span class="severity-high">[HIGH]</span>     Brain Fog / Cognitive Dysfunction                               │
│             Moderate severity, ongoing despite multiple interventions.      │
│             Multifactorial: histamine (HNMT AA + DAO CG), thyroid          │
│             (DIO2 CC), inflammation (CRP 2.1), hormonal decline.           │
│             Recently switched from Adderall to Strattera (Dec 2025).       │
│             → Persists as primary quality-of-life complaint                 │
│                                                                              │
│  <span class="severity-moderate">[MODERATE]</span> Histamine Intolerance                                           │
│             Genetically confirmed (HNMT AA + DAO CG). Total IgE 312       │
│             (ref &lt;87). Dust mite Class IV sensitization. Hay fever.        │
│             Managed with DAO enzyme + Quercetin BID.                       │
│             → Environmental allergen burden amplifying inflammation         │
│                                                                              │
│  <span class="severity-moderate">[MODERATE]</span> Hormonal Decline / Perimenopause                               │
│             FSH rising (2.3→12.6), LH rising (1.6→11.6), DHEA-S           │
│             declining (217→73, -66%). Comprehensive HRT active but         │
│             compliance variable (Progesterone overcompliance, Estrace 0%). │
│             → Perimenopausal transition with incomplete management          │
│                                                                              │
│  IMPROVING  Weight (30+ lbs lost)                                           │
│  IMPROVING  Sleep (resolved with multi-agent protocol)                      │
│  IMPROVING  Palpitations (resolved: Adderall → Strattera)                  │
│  IMPROVING  Blood Pressure (124/85 → 118/80)                               │
│  RESOLVED   Constipation (Magnesium Citrate 1000mg)                         │
│  RESOLVED   Stress Urinary Incontinence (Bulkamid Apr 2025)                │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<hr>
<h2 id="1d-high-signal-biomarkers-trends">1d. HIGH-SIGNAL BIOMARKERS + TRENDS</h2>
<h3 id="overview">Overview</h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  BIOMARKER STATUS DISTRIBUTION (1,081 observations, 634 unique markers)    │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│   Critical High:    17    ████                                    1.6%      │
│   Critical Low:     21    █████                                  1.9%      │
│   High:             41    ██████████                              3.8%      │
│   Low:              24    ██████                                  2.2%      │
│   In Range:        411    ████████████████████████████████████████ 38.0%    │
│   Unknown:         567    (allergy panels, stool, uncategorized)  52.5%    │
│                                                                              │
│   TOTAL ABNORMAL: 103 entries (9.5% of all observations)                   │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<h3 id="clusters-with-most-abnormal-findings">Clusters with Most Abnormal Findings</h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  CLUSTER ABNORMALITY RANKING                                                │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│   Cluster                 Observations   Abnormal   Rate    Priority        │
│   ─────────────────────   ────────────   ────────   ─────   ──────────     │
│   Cardiovascular          82             27         33%     <span class="severity-critical">[CRITICAL]</span>      │
│   Immune Cells            111            14         13%     <span class="severity-high">[HIGH]</span>          │
│   Hormone (Female)        34             8          24%     <span class="severity-high">[HIGH]</span>          │
│   Vitamins                21             6          29%     <span class="severity-high">[HIGH]</span>          │
│   Epigenetic Aging        19             6          32%     <span class="severity-high">[HIGH]</span>          │
│   Minerals                13             5          38%     <span class="severity-high">[HIGH]</span>          │
│   Thyroid                 34             5          15%     <span class="severity-moderate">[MODERATE]</span>      │
│   Coagulation             3              3          100%    <span class="severity-critical">[CRITICAL]</span>      │
│   Fatty Acids             19             4          21%     <span class="severity-moderate">[MODERATE]</span>      │
│   Insulin Resistance      27             4          15%     <span class="severity-moderate">[MODERATE]</span>      │
│   Liver                   49             4          8%      <span class="severity-moderate">[MODERATE]</span>      │
│   TruAge Immune           10             4          40%     <span class="severity-high">[HIGH]</span>          │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<hr>
<h3 id="cluster-1-cardiovascular-lipid-risk-critical">CLUSTER 1: CARDIOVASCULAR &amp; LIPID RISK <span class="severity-critical">[CRITICAL]</span></h3>
<p>(27 abnormal entries across 82 observations — highest total abnormality count)</p>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  CARDIOVASCULAR — CRITICAL BIOMARKERS                                       │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  Biomarker         Value    Ref Range    Status         Trend    Source     │
│  ────────────────  ───────  ──────────   ────────────   ──────   ─────     │
│  LDL Small         291      0-142        <span class="severity-critical">[CRITICAL]</span>     ↓ imp.  Dec 2025  │
│  LDL-P             1649     0-1138       <span class="severity-high">[HIGH]</span>         ↓ imp.  Dec 2025  │
│  LDL Medium        356      0-215        <span class="severity-high">[HIGH]</span>         ↓ imp.  Dec 2025  │
│  LDL-C             114      0-100        <span class="severity-high">[HIGH]</span>         ↑ worse Dec 2025  │
│  Total Chol        211      0-200        <span class="severity-high">[HIGH]</span>         ↑ NEW   Dec 2025  │
│  ApoB              92       0-90         <span class="severity-high">[HIGH]</span>         → stable Dec 2025 │
│  LDL Peak Size     219.2    &gt;222.9       <span class="severity-low">[LOW]</span>          ↑ imp.  Dec 2025  │
│  LDL Pattern       B→A      A            <span class="severity-improving">[IMPROVING]</span>    pattern Dec 2025  │
│  Fibrinogen        427      180-350      <span class="severity-high">[HIGH]</span>         ↑ worse Dec 2025  │
│  IR Score          48       0-33         <span class="severity-high">[HIGH]</span>         ↑ worse Dec 2025  │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘

   LDL SMALL (Critical — Atherogenic)
   ──────────────────────────────────
   2018:  324 ──── [██████████████████████████████████████████████] <span class="severity-critical">[CRITICAL]</span>
   2024:  428 ──── [████████████████████████████████████████████████████████████] <span class="severity-critical">[CRITICAL]</span>
   2025:  428 ──── [████████████████████████████████████████████████████████████] <span class="severity-critical">[CRITICAL]</span>
   Dec25: 291 ──── [████████████████████████████████████████] <span class="severity-critical">[CRITICAL]</span>
                   ref &lt;142 │ ↓ 10.2% from baseline — IMPROVING but still 2x limit

   LDL PARTICLE NUMBER
   ────────────────────
   2018:  1232 ──── [█████████████████████████] <span class="severity-high">[HIGH]</span>
   2024:  2023 ──── [█████████████████████████████████████████] <span class="severity-high">[HIGH]</span>
   2025:  2023 ──── [█████████████████████████████████████████] <span class="severity-high">[HIGH]</span>
   Dec25: 1649 ──── [█████████████████████████████████] <span class="severity-high">[HIGH]</span>
                    ref &lt;1138 │ ↓ Improving but still 45% above limit

   FIBRINOGEN (Inflammatory/Thrombotic — WORSENING)
   ─────────────────────────────────────────────────
   2024:  386 ──── [████████████████████████████████████████████████] <span class="severity-high">[HIGH]</span>
   Feb25: 386 ──── [████████████████████████████████████████████████] <span class="severity-high">[HIGH]</span>
   Dec25: 427 ──── [██████████████████████████████████████████████████████] <span class="severity-high">[HIGH]</span>
                   ref 180-350 │ ↑ 10.6% increase — WORSENING trajectory
                   Combined with F2 GA prothrombin variant → thrombotic risk

   INSULIN RESISTANCE SCORE (WORSENING)
   ─────────────────────────────────────
   2024:  42 ──── [████████████████████████████████████████████████████] <span class="severity-high">[HIGH]</span>
   Feb25: 42 ──── [████████████████████████████████████████████████████] <span class="severity-high">[HIGH]</span>
   Dec25: 48 ──── [████████████████████████████████████████████████████████████] <span class="severity-high">[HIGH]</span>
                  ref &lt;33 │ ↑ 14.3% increase — PARADOXICAL worsening

┌──────────────────────────────────────────────────────────────────────────────┐
│  PARADOX: IR Score Worsening Despite Weight Loss + Mounjaro                 │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  IR Score increased from 42 to 48 despite:                                  │
│  • 30+ lbs weight loss on Mounjaro (tirzepatide) 15mg                      │
│  • HbA1c excellent at 4.9-5.4%                                             │
│  • Fasting glucose normal at 68 mg/dL                                       │
│  • Triglycerides dramatically improved (122→60 mg/dL, -50.8%)              │
│                                                                              │
│  This suggests the IR Score may reflect hepatic insulin resistance          │
│  (driven by inflammation, not adiposity) or the score algorithm is          │
│  weighted toward LDL-P/lipid particle metrics rather than glucose.          │
│  The disconnect between improved glucose homeostasis and worsening          │
│  IR Score is a key paradox for Part 2 to resolve.                           │
│                                                                              │
│  Relevant genetics: PPARG CC (reduced insulin sensitivity),                 │
│  IRS1 CC (impaired insulin signaling), APOA2 CC                            │
│  → Will be resolved in Part 2 (Endotype)                                    │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘

   MYELOPEROXIDASE (Vascular Inflammation — DRAMATICALLY IMPROVED)
   ───────────────────────────────────────────────────────────────
   2022:  &gt;5351 ── [████████████████████████████████████████████████████████████] <span class="severity-critical">[CRITICAL]</span>
   Dec25: 327 ──── [███] <span class="severity-normal">[NORMAL]</span>
                   ref &lt;470 │ ↓ 93.9% decrease — NORMALIZED

   CRP (Inflammatory — IMPROVED)
   ─────────────────────────────
   2022:  4.1 ──── [████████████████████████████████████████████████████████] <span class="severity-high">[HIGH]</span>
   Feb25: 2.3 ──── [████████████████████████████████] <span class="severity-moderate">[MODERATE]</span>
   Dec25: 2.1 ──── [█████████████████████████████] <span class="severity-moderate">[MODERATE]</span>
                   ref &lt;3.0 │ ↓ 48.8% decrease — Improving but still moderate CV risk</pre>
<hr>
<h3 id="cluster-2-coagulation-critical">CLUSTER 2: COAGULATION <span class="severity-critical">[CRITICAL]</span></h3>
<p>(3 of 3 entries abnormal — 100% abnormality rate)</p>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  COAGULATION — ALL ABNORMAL                                                 │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  Biomarker         Value    Ref Range    Status         Trend    Source     │
│  ────────────────  ───────  ──────────   ────────────   ──────   ─────     │
│  Fibrinogen        427      180-350      <span class="severity-high">[HIGH]</span>         ↑ worse Dec 2025  │
│  Fibrinogen        386      180-350      <span class="severity-high">[HIGH]</span>         → prev  Feb 2025  │
│  Fibrinogen        386      180-350      <span class="severity-high">[HIGH]</span>         → prev  Nov 2024  │
│                                                                              │
│  GENETIC CONTEXT: F2 GA (rs1799963) — Prothrombin 20210 heterozygote      │
│  TREATMENT: Triple anticoagulant (Nattokinase + Lumbrokinase + Aspirin)     │
│  RISK: Atherogenic lipid profile + inflammatory fibrinogen + genetic        │
│  clotting variant = CONVERGENT cardiovascular/thrombotic risk               │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<hr>
<h3 id="cluster-3-hormones-reproductive-high">CLUSTER 3: HORMONES &amp; REPRODUCTIVE <span class="severity-high">[HIGH]</span></h3>
<p>(8 abnormal entries across 34 observations)</p>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  HORMONAL — KEY FINDINGS                                                    │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  Biomarker         Value    Ref Range     Status          Trend   Source    │
│  ────────────────  ───────  ───────────   ─────────────   ──────  ─────   │
│  FSH               12.6     23-116.3      <span class="severity-low">[LOW]</span>           ↑ 448%  Dec 25  │
│  LH                11.6     10-54.7       Near low        ↑ 625%  Dec 25  │
│  Estradiol          21      39-375        <span class="severity-low">[LOW]</span>           ↓ 79%   Nov 24  │
│  Estradiol (US)    101      --            In range        ↑       Dec 25  │
│  Progesterone       2.1     0.1-1.5       <span class="severity-high">[HIGH]</span>          ↑       Dec 25  │
│  DHEA-S             73      5-167         In range        ↓ 66%   Dec 25  │
│  Pregnenolone       25      22-237        Near low        ↑ 739%  Dec 25  │
│  AMH              &lt;0.08     --            Menopausal      --      Dec 25  │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘

   FSH (Perimenopausal Rising)
   ───────────────────────────
   2018:  2.3 ──── [██] <span class="severity-critical">[CRITICAL LOW]</span>
   2022:  4.5 ──── [████] <span class="severity-critical">[CRITICAL LOW]</span>
   Dec25: 12.6 ── [████████████] <span class="severity-low">[LOW]</span>
                  ref 23-116.3 │ ↑ 448% — rising toward menopause but still suppressed

   DHEA-S (Adrenal Decline)
   ─────────────────────────
   2018:  217 ──── [█████████████████████████████████████████████████████████] <span class="severity-high">[HIGH]</span>
   2022:  159 ──── [██████████████████████████████████████████] <span class="severity-normal">[NORMAL]</span>
   2024:   88 ──── [███████████████████████] <span class="severity-normal">[NORMAL]</span>
   Dec25:  73 ──── [███████████████████] <span class="severity-normal">[NORMAL]</span>
                   ref 5-167 │ ↓ 66.4% decline — accelerated adrenal aging

   PREGNENOLONE (Mother Hormone — RECOVERED)
   ──────────────────────────────────────────
   2022:  2.98 ── [█] <span class="severity-critical">[CRITICAL LOW]</span>
   Dec25: 25.0 ── [████████████] <span class="severity-low">[NEAR LOW]</span>
                  ref 22-237 │ ↑ 739% — recovered from critical to borderline

┌──────────────────────────────────────────────────────────────────────────────┐
│  PARADOX: FSH/LH Suppression Despite Perimenopause                         │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  At age 49 with AMH &lt;0.08 (menopausal range), FSH should be elevated      │
│  (&gt;40 mIU/mL). Instead, FSH is 12.6 — still below the postmenopausal     │
│  range. Possible explanations:                                              │
│                                                                              │
│  1. Exogenous estrogen suppression (estradiol patch 0.05mg; Biest cream   │
│     per Dr. West Rx — ⚠ COMPLIANCE UNCONFIRMED)                           │
│  2. Progesterone overcompliance (daily instead of cyclic days 10-24)       │
│  3. Hypothalamic suppression from chronic stress/illness                    │
│                                                                              │
│  Note: FSH was CRITICALLY low (2.3-4.5) in 2018-2022, suggesting          │
│  possible prior hormonal manipulation, OCP use, or central suppression.    │
│  → Will be resolved in Part 2 (Endotype)                                    │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<hr>
<h3 id="cluster-4-thyroid-moderate">CLUSTER 4: THYROID <span class="severity-moderate">[MODERATE]</span></h3>
<p>(5 abnormal entries across 34 observations)</p>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  THYROID — TIMELINE (Critical medication gap)                               │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  Biomarker            Value    Ref Range    Status         Date   Source    │
│  ──────────────────   ───────  ──────────   ────────────   ─────  ─────   │
│  TSH                  0.04    0.4-4.5      <span class="severity-critical">[CRITICAL LOW]</span> Apr 18  Quest   │
│  TSH                  1.35    0.4-4.5      <span class="severity-normal">[NORMAL]</span>       Jun 25  CSMC    │
│  TSH                  1.24    0.4-4.5      <span class="severity-normal">[NORMAL]</span>       Dec 25  Quest   │
│  Free T4              1.4     0.8-1.8      <span class="severity-normal">[NORMAL]</span>       Dec 25  Quest   │
│  Free T3              3.2     2.3-4.2      <span class="severity-normal">[NORMAL]</span>       Dec 25  Quest   │
│  TPO Antibodies       10      0-9          <span class="severity-high">[HIGH]</span>         Aug 22  Vibrant │
│  Thyroglobulin Ab     15.9    0-1          <span class="severity-critical">[CRITICAL]</span>     Aug 22  Vibrant │
│  TPO Antibodies       1       0-9          <span class="severity-normal">[NORMAL]</span>       Dec 25  Quest   │
│  Thyroglobulin Ab     &lt;1.0    0-1          <span class="severity-normal">[NORMAL]</span>       Dec 25  Quest   │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘

   TSH (Gradual Normalization)
   ───────────────────────────
   Apr18: 0.04 ── [█] [CRITICAL LOW — suppressed]
   Jan19: 0.51 ── [█████] <span class="severity-normal">[NORMAL]</span> — gradual recovery
   Dec19: 0.88 ── [████████] <span class="severity-normal">[NORMAL]</span> — continuing normalization
   Aug22: 1.35 ── [████████████] <span class="severity-normal">[NORMAL]</span>
   Nov23: 1.58 ── [██████████████] <span class="severity-normal">[NORMAL]</span>
   Nov24: 1.73 ── [████████████████] <span class="severity-normal">[NORMAL]</span>
   Jun25: 1.35 ── [████████████] <span class="severity-normal">[NORMAL]</span>
   Dec25: 1.24 ── [███████████] <span class="severity-normal">[NORMAL]</span>
                  ref 0.40-4.50 │ Gradual normalization from suppressed to well-controlled

┌──────────────────────────────────────────────────────────────────────────────┐
│  PARADOX: Normal Thyroid Labs BUT Armour Thyroid Missing                    │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  June 2025 and December 2025 thyroid labs are NORMAL (TSH 1.24-1.35).     │
│  However, Armour Thyroid is MISSING from current medication records.        │
│                                                                              │
│  Scenario A: Patient still takes Armour → labs reflect treated state       │
│  Scenario B: Patient stopped Armour → TSH is naturally normal now          │
│                                                                              │
│  COMPLICATING: DIO2 CC genotype means even with normal serum levels,       │
│  tissue-level T4→T3 conversion may be impaired. Armour Thyroid             │
│  (which contains T3 directly) would partially bypass this defect.          │
│                                                                              │
│  ALSO: Thyroid antibodies (TPO 10, Thyroglobulin 15.9) were elevated      │
│  in 2022 but fully normalized by Dec 2025 (TPO 1, TgAb <1) — resolving.  │
│  → CRITICAL clarification needed from patient                               │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<hr>
<h3 id="cluster-5-allergy-immune-high">CLUSTER 5: ALLERGY &amp; IMMUNE <span class="severity-high">[HIGH]</span></h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  ALLERGY — SIGNIFICANT ATOPIC BURDEN                                        │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  Total IgE: 312 IU/mL (ref &lt;87) <span class="severity-critical">[CRITICAL HIGH]</span>                           │
│  Declining from 397 (2018) → 312 (2025) but still 3.6x upper limit        │
│                                                                              │
│  IgE INHALANT SENSITIZATION (Class IV = Very High):                        │
│  ─────────────────────────────────────────────────                          │
│  D. pteronyssinus (dust mite):  10.5 kU/L    Class IV                      │
│  D. farinae (dust mite):        7.76 kU/L    Class IV                      │
│  D. microceras (dust mite):     5.85 kU/L    Class IV                      │
│  Cockroach:                     1.83 kU/L    Class III                     │
│                                                                              │
│  → Significant environmental allergen burden driving chronic               │
│    inflammation and histamine load                                          │
│                                                                              │
│  GENETIC CONTEXT:                                                           │
│  HNMT AA (rs11558538) — Reduced histamine N-methyltransferase             │
│  DAO CG (rs1049793) — Partial diamine oxidase reduction                    │
│  → Double-hit on histamine clearance pathways                              │
│                                                                              │
│  IgG FOOD SENSITIVITIES:                                                    │
│  Moderate (2+): Grape, Nutmeg                                              │
│  Low (1+): Blueberry, Cayenne, Cinnamon, Pecan, Rice                      │
│  Celiac panel: ALL NEGATIVE                                                 │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<hr>
<h3 id="cluster-6-gut-microbiome-critical">CLUSTER 6: GUT MICROBIOME <span class="severity-critical">[CRITICAL]</span></h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  GUT HEALTH — MAXIMUM DYSBIOSIS (Dec 2025 GI Effects)                      │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  Dysbiosis Score:     10/10 <span class="severity-critical">[MAXIMUM]</span>                                       │
│  SCFA Production:     19.3 (ref &gt;=23.3) <span class="severity-low">[LOW]</span>                              │
│  n-Butyrate:          3.4 umol/g (ref &gt;3.6) <span class="severity-low">[LOW]</span>                          │
│  Cholesterol (Stool): 0.3 mg/g (ref 0.4-4.8) <span class="severity-low">[LOW]</span>                        │
│                                                                              │
│  PARASITES:                                                                  │
│  Dientamoeba fragilis: DETECTED (PCR 4.07e2 copies/uL)                    │
│  Cryptosporidium: Negative                                                  │
│  Giardia: Negative                                                          │
│                                                                              │
│  COMMENSALS CRITICALLY LOW:                                                  │
│  Barnesiella:     1.3E5 (ref 3.0E6-2.9E8) — 95.7% below range            │
│  Roseburia:       6.5E4 (ref 3.6E5-4.6E8) — 82.0% below range            │
│  Bifidobacterium: 1.4E5 (ref 4.6E5-2.6E8) — 69.6% below range            │
│  Prevotella:      2.7E6 (ref 6.6E7-3.8E9) — 95.9% below range            │
│                                                                              │
│  OVERGROWTH:                                                                 │
│  Bacillus species: 4+ growth                                               │
│                                                                              │
│  POSITIVE:                                                                   │
│  Akkermansia muciniphila: 7.5E6 (improved from undetectable in 2018)       │
│                                                                              │
│  → Maximum microbiome disruption + parasitic infection + SCFA deficit      │
│    → Impairs gut barrier, histamine clearance, SCFA-dependent immunity     │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<hr>
<h3 id="cluster-7-iron-status-moderate-trending-high">CLUSTER 7: IRON STATUS [MODERATE — TRENDING HIGH]</h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  IRON — RISING FERRITIN (Opposite of Case 1767 pattern)                    │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  Biomarker         Value    Ref Range    Status         Trend    Source     │
│  ────────────────  ───────  ──────────   ────────────   ──────   ─────     │
│  Ferritin          209      50-149       <span class="severity-high">[HIGH]</span>         ↑ 116%  Dec 2025  │
│  Iron              101      45-160       <span class="severity-normal">[NORMAL]</span>       → stable Dec 2025 │
│  TIBC              336      250-450      <span class="severity-normal">[NORMAL]</span>       →       Dec 2025  │
│  Iron Saturation   30%      16-45%       <span class="severity-normal">[NORMAL]</span>       →       Dec 2025  │
│  MCHC              32.9     32-36        <span class="severity-normal">[NORMAL]</span>       ↑ imp.  Dec 2025  │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘

   FERRITIN (Rising — Inflammatory or Overload?)
   ──────────────────────────────────────────────
   2020:   97 ──── [██████████████████████████████████] <span class="severity-normal">[NORMAL]</span>
   2022:  109 ──── [██████████████████████████████████████] <span class="severity-normal">[NORMAL]</span>
   2024:  169 ──── [████████████████████████████████████████████████████████████] <span class="severity-high">[HIGH]</span>
   Dec25: 209 ──── [████████████████████████████████████████████████████████████████████] <span class="severity-high">[HIGH]</span>
                   ref 50-149 │ ↑ 115.5% increase — inflammatory ferritin vs iron overload?

┌──────────────────────────────────────────────────────────────────────────────┐
│  NOTE: Rising Ferritin — Inflammatory vs Overload                           │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  Ferritin is an acute phase reactant — it rises with inflammation.         │
│  Given HS-CRP 2.1 and fibrinogen 427, this elevated ferritin likely        │
│  reflects inflammatory ferritin rather than true iron overload.             │
│                                                                              │
│  MCHC was previously low (31.4 in 2022-2024, ref 32-36 g/dL) but has     │
│  NORMALIZED to 32.9 in Dec 2025 — suggesting improved red cell iron        │
│  utilization. Iron panel otherwise normal (Iron 101, TIBC 336, Sat 30%).  │
│  → Ferritin rise likely inflammatory-driven                                 │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<hr>
<h3 id="cluster-8-vitamins-high">CLUSTER 8: VITAMINS <span class="severity-high">[HIGH]</span></h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  VITAMINS — PERSISTENT DEFICIENCIES                                         │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  Vitamin D (Total):  35 ng/mL (ref 30-150) — Near lower limit x 8 draws   │
│  Vitamin D2:        &lt;4 ng/mL (ref 30-150) — <span class="severity-critical">[CRITICAL LOW]</span> persistent     │
│  Vitamin D3:         35 ng/mL (ref 30-150) — Near lower limit             │
│  Folate:            9.3 ng/mL (ref &gt;5.4)  — ↓ 32% decline, approaching   │
│  Vitamin B12:       917 pg/mL (ref 200-1100) — In range but declining     │
│                                                                              │
│  Serotonin:         48 ng/mL <span class="severity-low">[LOW]</span> — NEW finding Dec 2025                  │
│  CO2:               19 mmol/L (ref 20-32) <span class="severity-low">[LOW]</span> — metabolic acidosis?     │
│                                                                              │
│  GENETIC CONTEXT:                                                           │
│  CYP2R1 GG — Vitamin D metabolism variant                                  │
│  MTHFR CT/AC compound heterozygote — 44.2% enzyme activity                │
│  → Impaired folate → methylfolate conversion                               │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘

   VITAMIN D (Chronic Insufficiency Despite Supplementation)
   ──────────────────────────────────────────────────────────
   2018:  39   ──── [████████] <span class="severity-normal">[NORMAL]</span>
   2019:  22.4 ──── [████] <span class="severity-low">[LOW]</span>
   2019:  23   ──── [████] <span class="severity-low">[LOW]</span>
   2022:  45.4 ──── [█████████] <span class="severity-normal">[NORMAL]</span>
   2023:  34.3 ──── [███████] <span class="severity-low">[NEAR LOW]</span>
   2024:  34   ──── [███████] <span class="severity-low">[NEAR LOW]</span>
   Feb25: 34   ──── [███████] <span class="severity-low">[NEAR LOW]</span>
   Dec25: 35   ──── [███████] <span class="severity-low">[NEAR LOW]</span>
                    ref 30-150 │ Stuck at lower boundary despite supplementation
                    Suboptimal for LL-37 expression (target &gt;50 for antimicrobial peptide)

   FOLATE (Declining — MTHFR Context)
   ────────────────────────────────────
   2020:  13.7 ──── [█████████████████████████████████████████] <span class="severity-normal">[NORMAL]</span>
   2022:  13.9 ──── [██████████████████████████████████████████] <span class="severity-normal">[NORMAL]</span>
   Dec25:  9.3 ──── [████████████████████████████] <span class="severity-low">[NEAR LOW]</span>
                    ref &gt;5.4 │ ↓ 32% decline — concerning with MTHFR compound het</pre>
<hr>
<h3 id="cluster-9-epigenetic-aging-high">CLUSTER 9: EPIGENETIC AGING <span class="severity-high">[HIGH]</span></h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  TRUAGE EPIGENETIC ASSESSMENT (Dec 2025)                                    │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  Chronological Age:     49.0 years                                          │
│  OMICm Age:             42.0 years (-7.0 years)                            │
│  Symphony Age:          53.1 years (+4.1 years)                             │
│  DunedinPACE:           0.90 (aging at 90% rate — favorable)               │
│  Telomere Length:       7.1 kb (ref 5.5-8.5 — normal)                      │
│  Telomere Bio Age:      51.0 years                                          │
│  OMICm Fit Age:         54.2 years (+12.2 year gap from OMICm)             │
│                                                                              │
│  ORGAN AGES (years):                                                        │
│  ─────────────────────                                                      │
│  Inflammation:  45.9 (best — 3.1 years younger)                            │
│  Heart:         51.1                                                        │
│  Hormone:       51.8                                                        │
│  Lung:          52.0                                                        │
│  Musculoskeletal: 51.9                                                      │
│  Metabolic:     52.9                                                        │
│  Kidney:        52.4                                                        │
│  Immune:        53.6                                                        │
│  Liver:         53.9                                                        │
│  Brain:         54.2 (worst — 5.2 years older)                             │
│  Blood:         54.5 (worst — 5.5 years older)                             │
│                                                                              │
│  ACCELERATED AGING MARKERS:                                                  │
│  Grip Strength Percentile:  21.8  <span class="severity-critical">[CRITICAL LOW]</span> (ref &gt;50)                 │
│  FEV1 Percentile:           29.8  <span class="severity-low">[LOW]</span> (ref &gt;50)                          │
│  Gait Speed Percentile:     40.4  <span class="severity-low">[LOW]</span> (ref &gt;50)                          │
│  VO2 Max Percentile:        46.2  <span class="severity-low">[LOW]</span> (ref &gt;50)                          │
│                                                                              │
│  IMMUNE AGING:                                                               │
│  Monocyte Percentile:       7.1   <span class="severity-critical">[CRITICAL LOW]</span> (ref 25-75)              │
│  Naive CD8T Percentile:     20.3  <span class="severity-critical">[CRITICAL LOW]</span> (ref &gt;50)                │
│  Naive CD4T Percentile:     25.7  <span class="severity-low">[LOW]</span> (ref &gt;50)                         │
│  Naive B Percentile:        28.5  <span class="severity-low">[LOW]</span> (ref &gt;50)                         │
│                                                                              │
│  NOTE: 2022 used different algorithm (Intrinsic Age 53.06 = +7.4yr).      │
│  Direct comparison invalid due to algorithm change. Symphony Age (53.1)    │
│  is more consistent with 2022 direction — biological age likely older.     │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<hr>
<h3 id="cluster-10-additional-notable-findings">CLUSTER 10: ADDITIONAL NOTABLE FINDINGS</h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  LIVER (Mild Stress)                                                        │
│  ALT: 31 U/L (ref 6-29) <span class="severity-high">[HIGH]</span> — mild but persistent, Dec 2025            │
│  GGT: 9 U/L — low-normal                                                   │
│                                                                              │
│  METABOLIC ACIDOSIS SIGNAL                                                   │
│  CO2: 19 mmol/L (ref 20-32) <span class="severity-low">[LOW]</span> — 2nd occurrence (was 18 in 2022)       │
│  May reflect ketosis (Mounjaro), lactic acidosis, or renal compensatory    │
│                                                                              │
│  SEROTONIN (NEW Finding)                                                     │
│  Serotonin: 48 ng/mL <span class="severity-low">[LOW]</span> — Dec 2025                                      │
│  Relevant to: GI motility, mood, sleep, histamine regulation               │
│                                                                              │
│  ALZHEIMER'S RISK                                                            │
│  pTau-217: 0.22 ng/L (ref &lt;=0.34) — NEGATIVE                              │
│  APOE: E3/E3 — Neutral genetic risk                                        │
│  Current assessment: LOW risk                                               │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<hr>
<h2 id="1e-genetics-with-pathways">1e. GENETICS WITH PATHWAYS</h2>
<h3 id="system-burden-scores-from-pass-3">System Burden Scores (from Pass 3)</h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│                       SYSTEM-LEVEL BURDEN SCORES                            │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│   System                            Burden    Status    Key Genes           │
│   ──────────────────────────────    ──────    ──────    ────────────────    │
│   Methylation &amp; One-Carbon          100%      <span class="severity-critical">[CRITICAL]</span>  MTHFD1, CBS,     │
│                                                           PEMT, MTRR       │
│   Vitamin Metabolism                100%      <span class="severity-critical">[CRITICAL]</span>  MTRR, FUT2,      │
│                                                           TCN2, CYP2R1     │
│   Neurotransmitter System           87.5%     <span class="severity-critical">[CRITICAL]</span>  CACNA1C, HTR1A,  │
│                                                           MAOA, COMT       │
│   Hormone Metabolism                48.3%     <span class="severity-moderate">[MODERATE]</span>  CYP1B1, CYP2C9,  │
│                                                           CYP17A1, SHBG    │
│   Metabolic Regulation              44.6%     <span class="severity-moderate">[MODERATE]</span>  CYP1A1, PPARA,   │
│                                                           CAT, FOXO3       │
│   Mitochondrial Energy              35.0%     <span class="severity-moderate">[MODERATE]</span>  HIF1A, SIRT1     │
│   Neurodegeneration Risk            15.0%     <span class="severity-normal">[NORMAL]</span>    APOE (E3/E3)     │
│   Stress Response (HPA)             10.0%     <span class="severity-normal">[NORMAL]</span>    (no key genes)   │
│                                                                              │
│   Legend: <span class="severity-critical">[CRITICAL]</span> &gt;70% | <span class="severity-high">[HIGH]</span> 50-70% | <span class="severity-moderate">[MODERATE]</span> 30-50%             │
│           <span class="severity-normal">[NORMAL]</span> &lt;30%                                                     │
│                                                                              │
│   Brain/Body Split: Brain 49.3% │ Body 50.7% (nearly balanced)            │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<h3 id="pathway-burden-scores-from-pass-4-detailed">Pathway Burden Scores (from Pass 4 — Detailed)</h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│                        PATHWAY BURDEN SCORES (Top Priority)                 │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│   Pathway                            Burden    Bottlenecks                  │
│   ──────────────────────────────    ──────    ──────────────────           │
│   Methylation &amp; One-Carbon           67.6%     Step 5 (pipeline model) ⚠  │
│   Cardiovascular Risk                50.0%     (structural)                 │
│   Exercise &amp; Athletic Performance    50.0%     (structural)                 │
│   Detoxification Phase I (CYP450)    38.7%     CYP1A1, CYP2A6 (mild)      │
│   Hormone Synthesis - Steroid        36.4%     COMT (mild)                  │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<hr>
<h3 id="pathway-1-methylation-one-carbon-metabolism-67-6-burden">PATHWAY 1: METHYLATION &amp; ONE-CARBON METABOLISM (67.6% burden)</h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  METHYLATION &amp; ONE-CARBON METABOLISM (67.6% overall burden)                │
├──────────────────────────────────────────────────────────────────────────────┤
│  Step                                   Genes             Burden  Severity │
│  ─────────────────────────────────     ──────────────    ──────  ──────── │
│  1. Folate Entry &amp; Activation          SLC19A1, DHFR      0%     <span class="severity-normal">[NORMAL]</span> │
│  2. THF to 5,10-MTHF                  SHMT1, MTHFD1     55%     <span class="severity-high">[HIGH]</span>   │
│  3. MTHFR (5,10→5-MTHF)              MTHFR              27%     <span class="severity-moderate">[MOD]</span>    │
│  4. Nucleotide Synthesis               TYMS               27%     <span class="severity-moderate">[MOD]</span>    │
│  5. Methionine Synthase (B12)          MTR, MTRR, TCN2   85%     <span class="severity-critical">[CRIT]</span>   │
│  6. SAM Synthesis                      MAT1A, MAT2A      59%     <span class="severity-high">[HIGH]</span>   │
│  6.5 BHMT Rescue                       BHMT               0%     <span class="severity-normal">[NORMAL]</span> │
│  7. Methyltransferases                 COMT, PEMT, DNMT  53%     <span class="severity-high">[HIGH]</span>   │
│  8. Homocysteine Accumulation          AHCY               27%     <span class="severity-moderate">[MOD]</span>    │
│  9. Transsulfuration (→Glutathione)   CBS, CTH, GCLC    68%     <span class="severity-high">[HIGH]</span>   │
│                                                                              │
│  MTHFR STATUS: Compound Heterozygous (C677T + A1298C)                      │
│  Estimated Enzyme Activity: 44.2%                                           │
│  Amplification Factor: 1.56x (cascade effect on downstream steps)          │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘

┌──────────────────────────────────────────────────────────────────────────────┐
│  METHYLATION PATHWAY FLOW                                                   │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│   [1]Folate ──► [2]THF/MTHFD1 ──► [3]MTHFR ──► [5]MTR ──► [6]SAM        │
│      <span class="severity-normal">[NORMAL]</span>     <span class="severity-high">[HIGH]</span>           <span class="severity-moderate">[MOD]</span>        <span class="severity-critical">[CRIT]</span>     <span class="severity-high">[HIGH]</span>          │
│                    │                              ▲                          │
│                    │                              │                          │
│                    │                        BOTTLENECK                       │
│                    │                   (Step 5 - 85% pipeline model)        │
│                    │                   ⚠ MTR AA=normal; MTRR/TCN2 only     │
│                    │                                                         │
│                    └──► [9]CBS/Transsulfuration ──► Glutathione             │
│                          <span class="severity-high">[HIGH]</span> 68%                                          │
│                                                                              │
│   [7]Methyltransferases (COMT, PEMT, DNMT) ◄── SAM                        │
│      <span class="severity-high">[HIGH]</span> 53%                                                             │
│      COMT AA (slow) → catecholamine + estrogen clearance impaired          │
│                                                                              │
├──────────────────────────────────────────────────────────────────────────────┤
│  WHAT THIS MEANS                                                            │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│   Step 5 (MTR): Pipeline-modeled bottleneck at Methionine Synthase step.   │
│   ⚠ MTR genotype AA (rs1805087) = NORMAL. Burden score from MTRR AG       │
│   (low risk) + TCN2 CG (medium risk). Pipeline over-attributes to MTR.    │
│   This B12-dependent enzyme recycles homocysteine → methionine.            │
│                                                                              │
│   Cross-pathway effects:                                                    │
│   • MTHFD1 → Mitochondrial Energy (TCA Cycle NADPH supply)                │
│   • MTHFD1 → Glutathione System (NADPH for glutathione reductase)         │
│   • CBS → Glutathione (cysteine substrate for GSH synthesis)               │
│                                                                              │
│   Clinical: Folinic acid/leucovorin may bypass MTHFD1 bottleneck.          │
│   Methylcobalamin supports MTR. Avoid folic acid (MTHFR impaired).         │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<hr>
<h3 id="pathway-2-detoxification-phase-i-38-7-burden">PATHWAY 2: DETOXIFICATION — PHASE I (38.7% burden)</h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  DETOXIFICATION - PHASE I CYP450s (38.7% overall burden)                   │
├──────────────────────────────────────────────────────────────────────────────┤
│  Step                                   Genes            Burden  Severity  │
│  ─────────────────────────────────     ──────────────   ──────  ──────── │
│  1. Nuclear Receptor Activation        AHR, NR1I2        0%     <span class="severity-normal">[NORMAL]</span> │
│  2. CYP1 Family (Estrogens)           CYP1A1, CYP1B1   34%     <span class="severity-moderate">[MOD]</span>    │
│  3. CYP2 Family (Drug Metab Hub)      CYP2A6, CYP2D6   48%     <span class="severity-moderate">[MOD]</span>    │
│  4. CYP3 Family (Broad)               CYP3A4, CYP3A5    0%     <span class="severity-normal">[NORMAL]</span> │
│  5. Other CYP Enzymes                  CYP4A11            0%     <span class="severity-normal">[NORMAL]</span> │
│  6. Alcohol/Aldehyde                   ADH, ALDH          0%     <span class="severity-normal">[NORMAL]</span> │
│  7. FMO/Other Phase I                  FMO3, EPHX         0%     <span class="severity-normal">[NORMAL]</span> │
│  8. Electron Transfer (CYP Support)   POR, CYB5A        58%     <span class="severity-high">[HIGH]</span>   │
│  9. Catechol Methylation (COMT)       COMT               0%     <span class="severity-normal">[NORMAL]</span> │
│                                                                              │
│  BOTTLENECKS: CYP1A1 (mild, 34%), CYP2A6 (mild, 48%)                     │
│                                                                              │
│  GSTM1 NULL: Complete gene deletion — Phase II glutathione conjugation    │
│  is ABSENT. This is NOT a SNP — the entire gene is missing.                │
│  Combined with CYP1A1/CYP2A6 bottlenecks → double-hit on detox.          │
│  NAT2 Slow: Slow acetylator — affects drug metabolism speed                │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<hr>
<h3 id="pathway-3-hormone-synthesis-steroid-36-4-burden">PATHWAY 3: HORMONE SYNTHESIS — STEROID (36.4% burden)</h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  HORMONE SYNTHESIS - STEROID HORMONES (36.4% overall burden)               │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  PATHWAY FLOW:                                                               │
│                                                                              │
│  Cholesterol ──► [1.1]StAR ──► [1.2]Pregnenolone ──► [2.1]DHEA            │
│     <span class="severity-normal">[NORMAL]</span>      <span class="severity-normal">[NORMAL]</span>      <span class="severity-normal">[NORMAL]</span>               <span class="severity-moderate">[MOD]</span> 15%           │
│                                                          │                   │
│                                       ┌──────────────────┤                   │
│                                       ▼                  ▼                   │
│                              [3.1]Estrone(E1)    [2.3]Androstenedione       │
│                              CYP19A1 <span class="severity-moderate">[MOD]</span>15%    <span class="severity-normal">[NORMAL]</span>                   │
│                                       │                  │                   │
│                                       ▼                  ▼                   │
│                              [3.2]Estradiol(E2)  [2.4]Testosterone          │
│                              CYP19A1 <span class="severity-moderate">[MOD]</span>15%    <span class="severity-normal">[NORMAL]</span>                   │
│                                       │                                      │
│                          ┌────────────┼────────────┐                        │
│                          ▼            ▼            ▼                         │
│                   [4.1]2-OH-E1  [4.2]4-OH-E1  [4.3]16α-OH                  │
│                   CYP1A1 <span class="severity-moderate">[MOD]</span>  CYP1B1 <span class="severity-moderate">[MOD]</span>  CYP3A4 <span class="severity-normal">[NORM]</span>               │
│                          │            │                                      │
│                          ▼            ▼                                      │
│                   [5.1]2-MeO    [5.2]4-MeO                                  │
│                   COMT <span class="severity-moderate">[MOD]</span>    COMT <span class="severity-moderate">[MOD]</span>                                   │
│                   BOTTLENECK    BOTTLENECK                                    │
│                   (mild, 46%)   (mild, 46%)                                  │
│                                                                              │
│  KEY: COMT AA (Met/Met, slow) creates mild bottleneck at catechol          │
│  estrogen methylation (Steps 5.1, 5.2). This slows clearance of           │
│  potentially genotoxic 4-OH catechol estrogens.                            │
│                                                                              │
│  CYP19A1 TT (rs10046) — Aromatase variant affects estrogen production.    │
│  Combined with perimenopause → impaired endogenous estrogen.               │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<hr>
<h3 id="key-genetic-findings-summary">KEY GENETIC FINDINGS SUMMARY</h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  TOP GENETIC FINDINGS (Ranked by Clinical Impact)                          │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  <span class="severity-critical">[CRITICAL]</span> COMT AA (rs4680) — Slow Met/Met                                │
│  ──────────────────────────────────────────                                  │
│  Impact: Slow dopamine/catecholamine/estrogen catechol breakdown           │
│  Affects: Stress tolerance, mood (↑ anxiety), caffeine sensitivity,        │
│  estrogen clearance (4-OH pathway), medication sensitivity                  │
│  Clinical: Limits stimulant use (relevant: Adderall→Strattera switch)      │
│                                                                              │
│  <span class="severity-critical">[CRITICAL]</span> GSTM1 DEL (null genotype) — Complete Gene Deletion            │
│  ──────────────────────────────────────────────────────────────              │
│  Impact: Zero glutathione-S-transferase M1 — Phase II detox absent         │
│  Capacity: 0% (not reduced — MISSING entirely)                              │
│  Combined with MTHFD1 NADPH limitation → detox SEVERELY impaired           │
│                                                                              │
│  <span class="severity-high">[HIGH]</span> MTHFR Compound Heterozygote (C677T CT + A1298C AC)                │
│  ─────────────────────────────────────────────────────────                   │
│  Impact: ~44% enzyme activity — moderate methylation impairment            │
│  Affects: Folate→methylfolate conversion, homocysteine clearance           │
│  Clinical: Use methylfolate (NOT folic acid), monitor homocysteine         │
│  Note: Homocysteine WORSENED 7.0 (Nov 2024) → 9.0 (Dec 2025) — watch     │
│                                                                              │
│  <span class="severity-high">[HIGH]</span> DIO2 CC (rs225014) — Thyroid Conversion Defect                     │
│  ────────────────────────────────────────────────────                        │
│  Impact: Impaired T4→T3 conversion at tissue level                         │
│  Clinical: Standard T4-only therapy (levothyroxine) may be insufficient.   │
│  Armour Thyroid (contains T3 directly) partially bypasses this defect.     │
│  Relevant: Is Armour Thyroid still being taken? CRITICAL question.         │
│                                                                              │
│  <span class="severity-high">[HIGH]</span> PPARG CC (rs1801282) + IRS1 CC (rs2943641)                         │
│  ─────────────────────────────────────────────────                           │
│  Impact: Dual insulin resistance genetics — reduced sensitivity +          │
│  impaired insulin receptor signaling. Explains persistent IR Score 48      │
│  despite Mounjaro + weight loss.                                            │
│                                                                              │
│  <span class="severity-moderate">[MODERATE]</span> F2 GA (rs1799963) — Prothrombin 20210 Heterozygote            │
│  ─────────────────────────────────────────────────────────────               │
│  Impact: Elevated prothrombin → increased clotting risk                     │
│  Clinical: Justifies anticoagulant therapy. Monitor with D-dimer.          │
│  Combined with fibrinogen 427 → multiplicative thrombotic risk              │
│                                                                              │
│  <span class="severity-moderate">[MODERATE]</span> MAOA TT (rs6323) — Monoamine Oxidase Variant                  │
│  ────────────────────────────────────────────────────────                     │
│  Impact: Affects serotonin/dopamine/norepinephrine metabolism              │
│  Combined with COMT AA → "Worrier" phenotype, reduced stress resilience   │
│                                                                              │
│  <span class="severity-normal">[NORMAL]</span> APOE E3/E3 — Neutral                                             │
│  Impact: No increased Alzheimer's or lipid-related genetic risk            │
│  Confirmed by pTau-217 NEGATIVE (0.22, ref &lt;=0.34)                         │
│                                                                              │
│  <span class="severity-normal">[NORMAL]</span> FTO — No obesity genetic risk flagged                             │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<hr>
<details open><summary>1f. CURRENT PROTOCOL INFORMATION</summary><div class="details-content">
<h3 id="total-burden">Total Burden</h3>
<pre class="ascii-art">╔══════════════════════════════════════════════════════════════════════════════╗
║                           PROTOCOL OVERVIEW                                  ║
╠══════════════════════════════════════════════════════════════════════════════╣
║                                                                              ║
║   Prescription Medications:  7 active                                       ║
║   Supplements:               22+ active products                            ║
║   Peptide/Injection Regimens: 5 active                                      ║
║   Hormone Formulations:      7 active                                       ║
║   Active Providers:          6                                               ║
║                                                                              ║
║   COMPLIANCE FLAGS:                                                          ║
║   <span class="severity-critical">[CRITICAL]</span> Estrace vaginal cream — NEVER TAKEN (0% adherence)            ║
║   <span class="severity-high">[HIGH]</span>     Lamotrigine — 50mg/day vs 100mg/day prescribed (50%)          ║
║   <span class="severity-high">[HIGH]</span>     Metformin — 500mg/day vs 1000mg/day prescribed (50%)          ║
║   <span class="severity-moderate">[MODERATE]</span> Progesterone — Daily vs Days 10-24 only (overcompliance)      ║
║   <span class="severity-critical">[CRITICAL]</span> Armour Thyroid — STATUS UNKNOWN (missing from records)        ║
║                                                                              ║
╚══════════════════════════════════════════════════════════════════════════════╝</pre>
<h3 id="medications-preliminary-assessment">Medications — Preliminary Assessment</h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  MEDICATIONS (Preliminary — will be refined in Part 3)                      │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  KEEP:                                                                       │
│  ─────                                                                       │
│  Mounjaro (tirzepatide) 15mg weekly — Excellent response, 30+ lbs lost.    │
│    Side effect: GERD (managed with pantoprazole). Continue.                  │
│  Atomoxetine (Strattera) 40mg daily — Recent switch, non-stimulant.        │
│    Better fit for COMT AA genotype than Adderall.                           │
│  Alprazolam 0.5mg PRN — Long-standing, well-controlled anxiety.            │
│  Pantoprazole 40mg (GLP-1 days) — Necessary for Mounjaro-induced GERD.    │
│                                                                              │
│  NEEDS REVIEW:                                                               │
│  ─────────────                                                               │
│  Lamotrigine 100mg/day — Patient taking 50mg. Why? If stable at 50mg,     │
│    provider should be notified. If subtherapeutic, dose needs correction.  │
│  Metformin 1000mg/day — Patient taking 500mg. Subtherapeutic dose for      │
│    IR Score 48. May explain worsening IR Score despite Mounjaro.           │
│  Progesterone 100mg nightly — Prescribed cyclic (days 10-24 only).         │
│    Daily use suppresses FSH/LH, may mask menopausal transition.            │
│                                                                              │
│  MISSING / CRITICAL GAP:                                                     │
│  ────────────────────────                                                    │
│  Armour Thyroid — STATUS UNKNOWN. Patient has hypothyroidism (2019),       │
│    DIO2 CC genotype, and needs T3-containing thyroid hormone.              │
│  Estrace vaginal cream — NEVER TAKEN despite severe urethral atrophy.     │
│    This is the single most actionable compliance gap.                       │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<h3 id="supplements-summary">Supplements — Summary</h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  SUPPLEMENTS (22+ active products)                                          │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  ANTICOAGULANT PROTOCOL:                                                     │
│  Nattokinase 1 cap daily + Lumbrokinase 3 caps daily + Baby Aspirin 81mg   │
│  → Triple anticoagulant — SIGNIFICANT additive bleeding risk               │
│  → Justified by F2 GA + fibrinogen 427, but requires D-dimer monitoring    │
│                                                                              │
│  COGNITIVE SUPPORT:                                                          │
│  Phosphatidylcholine, Piracetam, Brilliant Brain (all AM)                  │
│  → May be redundant now that Strattera is active                            │
│                                                                              │
│  HISTAMINE MANAGEMENT:                                                       │
│  DAO Enzyme + Hist (Quercetin) BID                                          │
│  → Genetically appropriate for HNMT AA + DAO CG                            │
│                                                                              │
│  ANTI-INFLAMMATORY:                                                          │
│  Inflamafree (Turmeric) BID + Black Cumin Seed Oil daily                   │
│  + Omega-3 Fish Oil 2 caps daily                                            │
│  → Appropriate for CRP 2.1 inflammatory state                              │
│                                                                              │
│  GI SUPPORT:                                                                 │
│  Digestive Enzymes 2 caps 3x/day + TBC Probiotic 2 caps nightly           │
│  → Dysbiosis 10/10 may need more targeted approach                          │
│                                                                              │
│  SLEEP:                                                                      │
│  Melatonin 5mg + Gabatrol 2 caps + Magnesium Citrate 1000mg               │
│  → Working well per Dec 2025 ROS                                            │
│                                                                              │
│  CARDIOVASCULAR:                                                             │
│  Cholesterol Complete BID + Ultimate Recovery                               │
│  → LDL Pattern B→A improvement may reflect efficacy                        │
│                                                                              │
│  HORMONAL:                                                                   │
│  DHEA 5mg AM + Pregnenolone 100mg AM                                       │
│  → Pregnenolone recovered from critical low (2.98→25)                      │
│                                                                              │
│  BASIC:                                                                      │
│  Vitamin D 1-2 caps + Vitamin C 1500mg + Electrolytes                      │
│  → Vitamin D STILL near lower limit despite supplementation                │
│                                                                              │
│  COMPLETED: Cyclease Menopause, Ignatia Homeopathic (18-week protocol)     │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<h3 id="peptide-injection-protocols">Peptide/Injection Protocols</h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  PEPTIDE &amp; INJECTION REGIMENS (5 active)                                    │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  LL-37 100mcg SC daily AM — Antimicrobial/biofilm disruption (cycling)     │
│  CJC 1295 + Ipamorelin 15 units SC daily — GH secretagogue                │
│  NAD+ 1000mg 3x/week SC — Cellular energy/anti-aging                      │
│  Cyanocobalamin 1000mcg IM monthly — B12 (Dr. Kurtz) ⚠ WRONG FORM        │
│  MIC injections 3x/week — Lipotropic (methionine/inositol/choline)        │
│                                                                              │
│  ⚠ B12 FORM CRITICAL ISSUE:                                                │
│  Patient CONFIRMED: Cyanocobalamin 1000mcg IM monthly (Dr. Kurtz).        │
│  Dr. West RECOMMENDED: MB12 (methylcobalamin) injections 3x/week —       │
│  COMPLIANCE UNCONFIRMED (not in patient self-report).                       │
│  Cyanocobalamin requires MTHFR-dependent conversion to active form.        │
│  With MTHFR compound het (44% activity), this is the WRONG form.          │
│  → Patient needs to clarify: Are you doing MB12 injections (Dr. West)?   │
│  → If only cyanocobalamin: SWITCH to methylcobalamin or hydroxocobalamin. │
│                                                                              │
│  PRECAUTION: LL-37 has cytotoxic effects at improper dosing, and use       │
│  with caution in cancer-prone tissues (relevant: bilateral mastectomy      │
│  history). Requires adequate Vitamin D for expression (patient level 35    │
│  — suboptimal, target &gt;50).                                                 │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<h3 id="hormone-therapy">Hormone Therapy</h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  HORMONE REPLACEMENT THERAPY (7 formulations)                               │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  SYSTEMIC ESTROGEN:                                                          │
│  Estradiol patch 0.05mg — 2x/week (Dr. West, Sep 2025)                     │
│  Biest cream (estriol/estradiol) — 1 click nightly (Dr. West Rx)          │
│    ⚠ COMPLIANCE UNCONFIRMED — not in patient self-report                   │
│  Estriol cream — topical (Dr. West Rx)                                      │
│    ⚠ COMPLIANCE UNCONFIRMED — not in patient self-report                   │
│                                                                              │
│  LOCAL ESTROGEN:                                                             │
│  Estrace vaginal cream 0.01% — PRESCRIBED but NEVER TAKEN                  │
│                                                                              │
│  PROGESTERONE:                                                               │
│  Progesterone 100mg SR oral — Nightly (prescribed days 10-24 only)         │
│  → OVERCOMPLIANCE: daily instead of cyclic                                  │
│                                                                              │
│  ANDROGENS:                                                                  │
│  Testosterone cream 0.2ml — Daily                                           │
│                                                                              │
│  PRECURSORS:                                                                 │
│  DHEA 5mg AM + Pregnenolone 100mg AM                                       │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<h3 id="potential-interactions">Potential Interactions</h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  INTERACTION ALERTS                                                          │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  <span class="severity-high">[HIGH]</span>  Triple anticoagulant (Nattokinase + Lumbrokinase + Aspirin)        │
│          Additive bleeding risk. Requires monitoring (D-dimer, fibrinogen). │
│          Currently justified by F2 GA + fibrinogen 427.                     │
│                                                                              │
│  <span class="severity-moderate">[MOD]</span>   COMT AA + Stimulants                                               │
│          Slow COMT → prolonged catecholamine exposure. Switch from          │
│          Adderall to Strattera was clinically appropriate.                  │
│                                                                              │
│  <span class="severity-moderate">[MOD]</span>   Mounjaro → GERD → Pantoprazole                                    │
│          PPIs can reduce B12 and magnesium absorption long-term.            │
│          Monitor given existing B12 supplementation regimen.                │
│                                                                              │
│  <span class="severity-low">[LOW]</span>   Progesterone daily + Systemic estrogen                             │
│          Continuous progesterone may suppress hypothalamic FSH/LH,          │
│          masking true menopausal status.                                    │
│                                                                              │
│  <span class="severity-high">[HIGH]</span>  B12 form issue — cyanocobalamin is WRONG form for MTHFR            │
│          Patient confirmed: cyanocobalamin IM monthly (Dr. Kurtz).          │
│          MB12 (Dr. West Rx): COMPLIANCE UNCONFIRMED. If only cyano:        │
│          SWITCH to methylcobalamin or hydroxocobalamin.                     │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<hr>
<h2 id="1g-source-input-files">1g. SOURCE INPUT FILES</h2>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  DATA SOURCES                                                                │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  GENETICS                                                                    │
│  • 3x4 Genetics clinical panel (146 SNPs, report date 2022-08-25)          │
│    via moj_snps.json                                                        │
│                                                                              │
│  LABS (1,081 observations, 634 unique markers, 2018-2025)                  │
│  • 2018 True Health Diagnostics + Quest + Genova GI Effects (156+ values)  │
│  • 2019 Vitae Diagnostics + Cedars-Sinai/Quest (32 values)                │
│  • 2020 Quest Diagnostics (42 values)                                       │
│  • 2022 Vibrant America Blood + Micronutrient + TruAge (107+ values)       │
│  • 2023 Cedars-Sinai (81 values, 13 PDFs)                                  │
│  • 2024 Quest/Cleveland HeartLab - Dr. Lipman (107 values)                 │
│  • 2025 Multiple providers (49 values, 8 PDFs)                              │
│  • 2025 December batch (529 values) — Allergy, Quest+CardioIQ,             │
│    Alzheimer's (pTau-217), Metabolomix, GI Effects, TruAge                 │
│                                                                              │
│  CLINICAL NOTES                                                              │
│  • Dr. Nigma Talib (Feb 2025)                                               │
│  • Dr. Rachel West (Jun/Sep 2025)                                           │
│  • Dr. Lyle Kurtz (Dec 2025)                                                │
│  • Dr. Ja-Hong Kim (Apr 2025)                                               │
│  • Dr. Frank Lipman (Feb 2025)                                              │
│                                                                              │
│  PATIENT SELF-REPORT                                                         │
│  • Moj Mahdara Current Medications and Supplements.docx (~Dec 2025)        │
│                                                                              │
│  QUESTIONNAIRE                                                               │
│  • Not available (data gap — chief complaints reconstructed from notes)    │
│                                                                              │
│  NOTE: Metabolomix urine specimens (organic acids, amino acids) were       │
│  NOT received by Genova — significant data gap. Only bloodspot fatty       │
│  acids available (35 of 125 possible values).                               │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<hr>
<h2 id="paradoxes-flagged-for-part-2">PARADOXES FLAGGED FOR PART 2</h2>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  PARADOXES REQUIRING RESOLUTION IN ENDOTYPE                                 │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  1. IR Score 48 WORSENING despite 30+ lb weight loss + Mounjaro 15mg       │
│     + excellent HbA1c (4.9%) + improving triglycerides (-50.8%)            │
│     → Genetic IR (PPARG + IRS1) vs inflammatory IR vs scoring artifact?    │
│                                                                              │
│  2. Rising Ferritin (97→209) — MCHC normalized (31.4→32.9) Dec 2025       │
│     → Inflammatory ferritin driven by CRP/fibrinogen; iron utilization OK │
│                                                                              │
│  3. FSH suppressed (12.6) despite AMH &lt;0.08 (menopausal range)            │
│     → Exogenous estrogen suppression vs hypothalamic dysfunction           │
│                                                                              │
│  4. Normal thyroid labs but MISSING thyroid medication                       │
│     → Patient still taking Armour? Or truly euthyroid without treatment?   │
│                                                                              │
│  5. Maximum dysbiosis (10/10) despite LL-37 antimicrobial + antifungal     │
│     history + probiotic + digestive enzyme protocol                         │
│     → Treatment failure? Wrong targets? Reinfection? Compliance?           │
│                                                                              │
│  6. Chronic Vitamin D insufficiency (34-35) despite supplementation        │
│     + CYP2R1 GG genetic variant — supplementation form/dose inadequate?   │
│     + Suboptimal for LL-37 expression (need &gt;50)                           │
│                                                                              │
│  7. Myeloperoxidase DRAMATICALLY improved (&gt;5351→327, -93.9%) while       │
│     CRP remains moderately elevated (2.1) and fibrinogen is RISING (427)  │
│     → Different inflammatory pathways? MPO vs fibrinogen dissociation?    │
│                                                                              │
│  8. OMICm Age 42 (-7yr younger) vs Symphony Age 53.1 (+4.1yr older)       │
│     → Algorithm difference, but which better reflects biological reality?  │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<hr>
<h2 id="open-clarification-items">OPEN CLARIFICATION ITEMS</h2>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  ITEMS REQUIRING PATIENT CLARIFICATION (from Moj_clarification_questions)  │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  <span class="severity-critical">[CRITICAL]</span> Is Armour Thyroid currently being taken?                        │
│  <span class="severity-high">[HIGH]</span>     DOB confirmation (1975 vs 1976?)                               │
│  <span class="severity-high">[HIGH]</span>     Estrace vaginal cream — barriers to starting?                  │
│  <span class="severity-high">[HIGH]</span>     Missing Metabolomix urine specimens — reorder?                 │
│  <span class="severity-high">[HIGH]</span>     Dientamoeba fragilis — clinician review needed                  │
│  [MEDIUM]   Lamotrigine, Metformin dosing — intentional reductions?        │
│  [MEDIUM]   Progesterone daily vs cyclic — intentional?                    │
│  [MEDIUM]   Missing 2024 RBC mineral test results (Lipman orders)          │
│  [MEDIUM]   Dr. Talib additional lab results?                               │
│  <span class="severity-low">[LOW]</span>      GI Effects stool collection date confirmation                   │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<hr>
<p><em>End of Part 1: Patient Profile &amp; Inputs</em> <em>Part 2 (Endotype) will resolve the flagged paradoxes and provide the unifying mechanistic model.</em></p>
<hr class="part-divider">
</div></details>
<a href="#top" class="back-to-top">&#8593; Back to top</a>
<h1 id="part-2-endotype-unifying-vision">PART 2: ENDOTYPE (Unifying Vision)</h1>
<h2 id="here-s-why-it-all-connects">"Here's why it all connects"</h2>
<p><strong>Patient:</strong> Moj Mahdara <strong>Report Generated:</strong> 2026-02-11 <strong>Pipeline Run:</strong> 20260210_Moj <strong>Endotype Confidence:</strong> HIGH (based on 146 SNPs, 1,081 biomarker observations, 6-provider clinical data)</p>
<hr>
<h2 id="2a-executive-summary-with-timeline">2a. EXECUTIVE SUMMARY WITH TIMELINE</h2>
<h1 id="the-slow-burn">"The Slow Burn"</h1>
<h2 id="a-multi-system-metabolic-bottleneck-model-for-moj-mahdara">A Multi-System Metabolic Bottleneck Model for Moj Mahdara</h2>
<pre class="ascii-art">═══════════════════════════════════════════════════════════════════════════════════════════════════════════
                                        Moj Mahdara: THE SLOW BURN
                                   Complete Mechanistic Framework
═══════════════════════════════════════════════════════════════════════════════════════════════════════════

TIMELINE           2009            2018             2019            2021         2022            2024-25            NOW (2026)
                     │               │                │               │            │                │                    │
GENETIC LOAD         │               │                │               │            │                │                    │
(always present)     │               │                │               │            │                │                    │
─────────────────────┼───────────────┼────────────────┼───────────────┼────────────┼────────────────┼────────────────────┤
COMT AA (slow)       ████████████████████████████████████████████████████████████████████████████████████████████████████│
GSTM1 null (0%)      ████████████████████████████████████████████████████████████████████████████████████████████████████│
MTHFR 44.2%          ████████████████████████████████████████████████████████████████████████████████████████████████████│
DIO2 CC              ████████████████████████████████████████████████████████████████████████████████████████████████████│
PPARG CC + IRS1 CC   ████████████████████████████████████████████████████████████████████████████████████████████████████│
F2 GA (clotting)     ████████████████████████████████████████████████████████████████████████████████████████████████████│
─────────────────────┼───────────────┼────────────────┼───────────────┼────────────┼────────────────┼────────────────────┤
                     │               │                │               │            │                │                    │
KEY MARKERS          │               │                │               │            │                │                    │
─────────────────────┼───────────────┼────────────────┼───────────────┼────────────┼────────────────┼────────────────────┤
Vitamin D          Dx low ──── 39 ────────────────── 22.4 ──────────────── 45 ──── 34 ────────── 35                     │
TSH                  │         0.04 ── 0.51 ── 0.88 ──────── 1.35 ── 1.58 ── 1.73 ── 1.35 ── 1.24               │
Thyroid Ab           │           │                    │               │   TPO 10   │                │                    │
                     │           │                    │               │   TgAb 15.9│         NORMALIZED                  │
DHEA-S               │         217 ──────────────────────── 159 ────────────────── 88 ──────── 73 (↓66%)               │
Total IgE            │         397 ──────────────────────────────────────────────────────────── 312 (still 3.6x)       │
Ferritin             │          97 ──────────────────────────────────── 109 ────── 169 ───── 209 (↑116%)               │
MCHC                 │           │                    │               │    31.4 ──── 31.4 ──── 32.9 (NORMALIZED)       │
LDL Small            │         324 ────────────────────────────────────────────── 428 ───── 291 (↓ but still 2x)      │
Fibrinogen           │           │                    │               │            │  386 ──── 386 ──── 427 (↑RISING)   │
CRP                  │           │                    │               │  4.1 ────────── 2.3 ──── 2.1 (↓ but elevated) │
MPO                  │           │                    │               │  &gt;5351 ──────────────────── 327 (↓94% RESOLVED) │
IR Score             │           │                    │               │            │   42 ──── 42 ──── 48 (↑PARADOX)    │
FSH                  │         2.3 ──────────────────────── 4.5 ─────────────────────────── 12.6 (suppressed)          │
Dysbiosis            │           │                    │               │            │                │  10/10 (MAX)       │
─────────────────────┼───────────────┼────────────────┼───────────────┼────────────┼────────────────┼────────────────────┤
                     │               │                │               │            │                │                    │
                     ▼               ▼                ▼               ▼            ▼                ▼                    ▼

MODULE 1 ──────────►  GENETIC SLOW ARCHITECTURE
"The Bottleneck       COMT AA + GSTM1 null + MTHFR 44% + DIO2 CC + NAT2 Slow
 Blueprint"           Every clearing pathway genetically throttled
                       │
                       │ + TRIGGER (~2019: PCOS + Hypothyroidism)
                       ▼
MODULE 2 ──────────►  THYROID-METABOLIC TRAP
"Burning Without       DIO2 CC → tissue T3 deficit → slowed BMR
 Fuel"                 PPARG CC + IRS1 CC → IR Score 42→48 DESPITE weight loss
                       Thyroid medication MISSING → ???
                       │
          ┌────────────┼─────────────────────────────────┐
          ▼            ▼                                  ▼
MODULE 3          MODULE 4                          MODULE 5
GUT-IMMUNE        CARDIOVASCULAR                    HORMONAL
BREACH            CASCADE                           DIMMING
Dysbiosis 10/10   ApoB defect                      CYP19A1 TT
Dientamoeba       F2 GA + Fib 427                  COMT AA slow
GSTM1 null        LDL-P 1649                       DHEA-S ↓66%
HNMT AA/DAO CG    CRP 2.1                          FSH suppressed
          │            │                                  │
          └────────────┼──────────────────────────────────┘
                       │
                       ▼
MODULE 6 ──────────►  THE FOGGY PROCESSOR
"Running Slow,         COMT AA + MAOA TT + HTR1A GG
 Thinking Slow"        Serotonin 48 (LOW) + Brain Age 54.2 (+5.2yr)
                       DIO2 CC → brain T3 deficit
                       │
                       ▼
┌─────────────────────────────────────────────────────────────────────────────────────────────────────────┐
│                                   CLINICAL PRESENTATION                                                  │
├─────────────────────────────────────────────────────────────────────────────────────────────────────────┤
│                                                                                                          │
│  GOAL #1: WEIGHT / METABOLISM ──────► Module 2 (thyroid-metabolic) + Module 3 (gut dysbiosis)           │
│  GOAL #2: BRAIN FOG ────────────────► Module 6 (neurocognitive) + Module 2 (thyroid) + Module 3 (hista)│
│  GOAL #3: FATIGUE ──────────────────► Module 2 (thyroid) + Module 1 (methylation) + Module 5 (hormones)│
│  GOAL #4: CV RISK MANAGEMENT ───────► Module 4 (cardiovascular) + Module 2 (IR/inflammation)           │
│                                                                                                          │
│  IMPROVING: Weight (↓30+ lbs), Sleep, BP, Palpitations                                                 │
│  STALLED:   Brain fog, Histamine symptoms, IR Score                                                     │
│  CRITICAL:  Thyroid med status UNKNOWN, Estrace NEVER TAKEN, Dysbiosis MAX                              │
│                                                                                                          │
└─────────────────────────────────────────────────────────────────────────────────────────────────────────┘

═══════════════════════════════════════════════════════════════════════════════════════════════════════════</pre>
<hr>
<h2 id="2b-endotype-name-the-slow-burn">2b. ENDOTYPE NAME: "The Slow Burn"</h2>
<p><strong>The Slow Burn</strong> captures the core mechanism driving Moj Mahdara's clinical picture: a genetically throttled metabolism in which every major clearing and processing pathway is constitutionally slowed — COMT (catecholamines), GSTM1 (detoxification, entirely absent), MTHFR (methylation, 44% activity), DIO2 (thyroid conversion), NAT2 (acetylation) — while chronic low-grade inflammation slowly consumes reserves faster than her impaired biochemistry can replenish them.</p>
<p>This is not a sudden collapse. It is a progressive erosion of metabolic reserves that has been unfolding over years. The fire doesn't rage; it smolders. Each year, ferritin rises a little more (inflammatory sequestration), DHEA-S drops a little further (adrenal depletion), fibrinogen climbs (hepatic inflammatory drive), and the IR Score worsens despite aggressive pharmaceutical intervention. The perimenopause transition — beginning around 2024 — added fuel to this slow burn by withdrawing the protective effects of estrogen on metabolism, cardiovascular function, and cognition.</p>
<p>The paradox at the center of this case: <strong>how can so many things be getting worse when so many things are being treated?</strong> The answer is that the treatments are targeting downstream symptoms without addressing the upstream genetic bottlenecks that create the backlog in the first place.</p>
<hr>
<h2 id="2c-unifying-narrative">2c. UNIFYING NARRATIVE</h2>
<p>Moj Mahdara's clinical picture emerges from a genetic architecture that systematically limits the speed and efficiency of her core metabolic pathways. She carries a <strong>COMT AA (Met/Met) slow metabolizer</strong> genotype that prolongs dopamine, norepinephrine, and catechol estrogen exposure; a <strong>GSTM1 null</strong> deletion that completely eliminates Phase II glutathione conjugation; a <strong>compound MTHFR heterozygote</strong> (C677T/A1298C) that reduces methylation cycle throughput to 44% of normal; a <strong>DIO2 CC</strong> variant that impairs tissue-level conversion of T4 to the active thyroid hormone T3; dual insulin resistance variants (<strong>PPARG CC + IRS1 CC</strong>) that blunt insulin signaling; and a <strong>MAOA TT</strong> variant that compounds the neurotransmitter processing burden created by slow COMT. Each of these variants alone would be manageable. Together, they create a metabolic system that is constitutionally running at reduced capacity — a bottleneck at every junction.</p>
<p>This genetic substrate remained largely compensated until 2019, when two diagnoses arrived simultaneously: hypothyroidism and PCOS. Something — chronic stress (COMT AA makes her exquisitely stress-sensitive), autoimmune activation (thyroglobulin antibodies were elevated by 2022 at 15.9 IU/mL), or the long-running vitamin D deficiency (diagnosed since 2009, never adequately corrected) — tipped the system past its ability to compensate. The DIO2 CC genotype meant that even with Armour Thyroid (which contains both T4 and T3), her tissues were not fully receiving the thyroid signal. The PPARG CC + IRS1 CC genotype meant that insulin resistance was not just a lifestyle disease but a genetic predisposition, one that metabolic interventions could only partially overcome. By the time of the bilateral mastectomy in 2021 and the onset of perimenopause by 2024, her system was already in deficit — and the withdrawal of endogenous estrogen (further impaired by CYP19A1 TT aromatase variant) accelerated every downstream cascade: cardiovascular risk, inflammation, bone density, cognitive function, and gut integrity.</p>
<p><strong>Why do seemingly unrelated findings connect?</strong> Because the "slow" genetic architecture means every system competes for the same limited metabolic resources. When methylation is impaired (MTHFR 44%), there is less SAM for COMT to methylate catecholamines, less substrate for PEMT to make phosphatidylcholine for bile and cell membranes, and less cysteine flux through the transsulfuration pathway for glutathione synthesis — which is already catastrophically limited by GSTM1 null. When thyroid conversion is impaired (DIO2 CC), basal metabolic rate drops, the gut slows, inflammation clearance slows, and the brain's executive function declines. When insulin resistance is genetic (PPARG + IRS1), Mounjaro can produce excellent weight loss (30+ lbs) and normalize glucose metrics (HbA1c 4.9%, fasting glucose 68), yet the IR Score paradoxically worsens (42→48) because the genetic component of insulin signaling dysfunction persists independent of adiposity. Every module feeds every other module, and the whole system burns slowly.</p>
<hr>
<details open><summary>2d. MODULE BREAKDOWN</summary><div class="details-content">
<hr>
</div></details>
<a href="#top" class="back-to-top">&#8593; Back to top</a>
<details open><summary>MODULE 1: THE GENETIC SLOW ARCHITECTURE</summary><div class="details-content">
<h3 id="the-bottleneck-blueprint-lifelong">"The Bottleneck Blueprint" (Lifelong)</h3>
<p><strong>This module establishes the genetic foundation: every major metabolic clearing pathway in this patient is constitutionally throttled. This is the soil in which all disease grows.</strong></p>
<pre class="ascii-art">━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="1-1-the-slow-processing-genotype-panel">1.1 The "Slow Processing" Genotype Panel</h3>
<pre class="ascii-art">┏━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┓
┃                                                                              ┃
┃    🧬 COMT AA (rs4680) — SLOW CATECHOLAMINE METHYLTRANSFERASE               ┃
┃    ══════════════════════════════════════════════════════════                  ┃
┃                                                                              ┃
┃    Normal COMT (Val/Val)   │████████████████████████████████████│ 100% speed ┃
┃    Moj (Met/Met AA)        │████████████████                   │  ~25% speed ┃
┃                             0%                                100%           ┃
┃                                                                              ┃
┃    Impact: 3-4x slower breakdown of:                                         ┃
┃    • Dopamine → HVA (executive function, reward, focus)                      ┃
┃    • Norepinephrine (stress response, anxiety, alertness)                    ┃
┃    • Catechol estrogens (4-OH-E1, 4-OH-E2 clearance)                        ┃
┃    • Catechol drugs (Adderall → palpitations, correctly switched to          ┃
┃      Strattera which bypasses COMT)                                          ┃
┃                                                                              ┃
┃    Cross-refs: Module 5 (estrogen clearance), Module 6 (brain fog)          ┃
┃                                                                              ┃
┗━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┛

┏━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┓
┃                                                                              ┃
┃    🧬 GSTM1 DEL — HOMOZYGOUS GENE DELETION (NULL)                          ┃
┃    ══════════════════════════════════════════════════                         ┃
┃                                                                              ┃
┃    Normal Person           │████████████████████████████████████│ 100%       ┃
┃    Moj (GSTM1 null)        │                                   │   0%       ┃
┃                             0%                                100%           ┃
┃                                                                              ┃
┃    ⚠️  NOT a SNP — the entire gene is DELETED                               ┃
┃    ⚠️  Phase II glutathione conjugation is ABSENT                           ┃
┃    ⚠️  Cannot efficiently clear environmental toxins, mycotoxins,           ┃
┃       reactive metabolites, oxidative damage byproducts                      ┃
┃                                                                              ┃
┃    Combined with methylation impairment (MTHFR 44%) → glutathione          ┃
┃    precursor supply is ALSO limited (transsulfuration pathway at 68%        ┃
┃    burden). Double hit: can't MAKE enough AND can't USE it efficiently.     ┃
┃                                                                              ┃
┃    Cross-refs: Module 3 (gut barrier), Module 4 (vascular protection)       ┃
┃                                                                              ┃
┗━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┛

┏━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┓
┃                                                                              ┃
┃    🧬 MTHFR COMPOUND HETEROZYGOTE (C677T CT + A1298C AC)                    ┃
┃    ══════════════════════════════════════════════════════                     ┃
┃                                                                              ┃
┃    Normal MTHFR            │████████████████████████████████████│ 100%       ┃
┃    Moj (compound het)      │████████████████                   │  44.2%     ┃
┃                             0%                                100%           ┃
┃                                                                              ┃
┃    Enzyme Activity: 44.2% of normal                                          ┃
┃    Amplification Factor: 1.56x (cascade burden on downstream steps)         ┃
┃                                                                              ┃
┃    Pathway impact (from pipeline Pass 4):                                    ┃
┃    • Step 5 (MTR): 84.5% burden — PIPELINE MODEL [see note below]          ┃
┃      ⚠ MTR genotype AA = NORMAL. Burden from MTRR AG (low) + TCN2 CG    ┃
┃      (medium). Pipeline over-attributes to MTR. Severity likely MODERATE. ┃
┃    • Step 9 (CBS→Glutathione): 67.8% burden — HIGH                         ┃
┃    • Step 6 (SAM Synthesis): 59.2% burden — HIGH                            ┃
┃    • Step 7 (Methyltransferases/COMT/PEMT): 53.0% burden — HIGH            ┃
┃                                                                              ┃
┃    Result: Reduced methylfolate → limited SAM → impaired COMT              ┃
┃    (already slow genetically) + impaired PEMT (choline/bile) +              ┃
┃    limited cysteine for glutathione (already nulled by GSTM1).             ┃
┃                                                                              ┃
┃    Current status: Homocysteine WORSENED from 7.0 (Nov 2024) to            ┃
┃    9.0 µmol/L (Dec 2025) — current B12 is CYANOCOBALAMIN 1000mcg          ┃
┃    IM monthly (Dr. Kurtz). Dr. West recommended MB12 (methylcobalamin)    ┃
┃    3x/week — COMPLIANCE UNCONFIRMED. Cyanocobalamin is the WRONG          ┃
┃    form for MTHFR compound het. Methylation support NOT adequate.          ┃
┃                                                                              ┃
┗━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┛

┏━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┓
┃                                                                              ┃
┃    🧬 DIO2 CC (rs225014) — THYROID CONVERSION DEFECT                        ┃
┃    ═══════════════════════════════════════════════════                        ┃
┃                                                                              ┃
┃    Normal DIO2 (TT)        │████████████████████████████████████│ 100%       ┃
┃    Moj (CC homozygous)     │██████████████████████              │  ~60%      ┃
┃                             0%                                100%           ┃
┃                                                                              ┃
┃    DIO2 converts T4 (inactive) → T3 (active) at the tissue level.          ┃
┃    CC genotype = impaired conversion in brain, muscle, and fat tissue.      ┃
┃                                                                              ┃
┃    This means:                                                               ┃
┃    • Serum T4 and TSH can look NORMAL while tissues are hypothyroid        ┃
┃    • Standard levothyroxine (T4 only) would be INADEQUATE                   ┃
┃    • Armour Thyroid (T4+T3) PARTIALLY bypasses this — but is it            ┃
┃      still being taken? STATUS UNKNOWN.                                     ┃
┃    • Brain is particularly affected → contributes to brain fog              ┃
┃                                                                              ┃
┃    Cross-refs: Module 2 (thyroid-metabolic), Module 6 (brain fog)          ┃
┃                                                                              ┃
┗━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┛

┏━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┓
┃                                                                              ┃
┃    🧬 ADDITIONAL SLOW-PROCESSING VARIANTS                                    ┃
┃    ══════════════════════════════════════                                     ┃
┃                                                                              ┃
┃    NAT2 Slow Acetylator (multiple SNPs)                                      ┃
┃    • Slow Phase II acetylation — affects drug metabolism speed               ┃
┃    • Relevant: patient on multiple medications requiring hepatic clearing    ┃
┃                                                                              ┃
┃    MAOA TT (rs6323) — Very High Risk                                        ┃
┃    • Monoamine oxidase variant — affects serotonin/dopamine/NE breakdown    ┃
┃    • Combined with COMT AA → "Worrier" phenotype compound                   ┃
┃    • Cross-ref: Module 6 (neurocognitive impact)                            ┃
┃                                                                              ┃
┃    PPARGC1A GG (rs8192678) — Very High Risk                                 ┃
┃    • Reduced metabolic efficiency, mitochondrial biogenesis                  ┃
┃    • Contributes to weight resistance and energy deficit                     ┃
┃                                                                              ┃
┃    CYP2R1 GG (rs10741657) — Very High Risk                                  ┃
┃    • Impaired vitamin D hydroxylation (25-OH-D production)                  ┃
┃    • Explains chronic vitamin D insufficiency (34-35 ng/mL stuck at         ┃
┃      lower limit despite years of supplementation)                          ┃
┃    • Cross-ref: Module 3 (LL-37 underpowered)                              ┃
┃                                                                              ┃
┗━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┛

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="1-2-the-convergence-pattern">1.2 The Convergence Pattern</h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  THE "SLOW" CONVERGENCE — Every clearing pathway is genetically throttled  │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│   PATHWAY                    GENE        SPEED       FUNCTIONAL IMPACT      │
│   ──────────────────────    ──────────  ──────────  ────────────────────    │
│   Catecholamine clearance   COMT AA     ~25%        DA/NE/estrogen backup  │
│   Glutathione conjugation   GSTM1 null    0%        Phase II detox ABSENT  │
│   Methylation cycle         MTHFR comp   44%        SAM, DNA repair, detox │
│   Thyroid conversion        DIO2 CC      ~60%        Tissue T3 deficit     │
│   Acetylation               NAT2 Slow   ~50%        Drug metabolism slow   │
│   Insulin signaling         PPARG+IRS1   ↓↓         Genetic IR             │
│   Vitamin D activation      CYP2R1 GG    ↓↓         Stuck at 34-35 ng/mL  │
│   Monoamine metabolism      MAOA TT      ↓↓         Neurotransmitter flux  │
│                                                                              │
│   ⚠️ When EVERY pathway is slow, the system has no reserve capacity.       │
│   Any additional metabolic demand (infection, stress, perimenopause)        │
│   will overwhelm the system because there is no "fast lane" to shift to.   │
│                                                                              │
│   CLINICAL IMPLICATION:                                                      │
│   Interventions must provide the END PRODUCTS (methylfolate, not folic      │
│   acid; methylcobalamin, not cyanocobalamin; T3 directly, not just T4;     │
│   glutathione/NAC directly, not relying on GSTM1) rather than relying      │
│   on impaired endogenous conversion.                                        │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<pre class="ascii-art">━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="1-3-pipeline-pathway-burden-analysis">1.3 Pipeline Pathway Burden Analysis</h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  METHYLATION PATHWAY FLOW (67.6% overall burden)                            │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│   [1]Folate ──► [2]THF/MTHFD1 ──► [3]MTHFR ──► [5]MTR ──► [6]SAM         │
│      0%           55%              27%          85%         59%             │
│      <span class="severity-normal">[NORMAL]</span>     <span class="severity-high">[HIGH]</span>           <span class="severity-moderate">[MOD]</span>        <span class="severity-critical">[CRIT]</span>      <span class="severity-high">[HIGH]</span>         │
│                                                  ▲                          │
│                                                  │                          │
│                                            BOTTLENECK                       │
│                                       (Step 5 - 85% pipeline model)        │
│                                       ⚠ MTR AA=normal; MTRR/TCN2 only     │
│                                                                              │
│   [6]SAM ──► [7]COMT/PEMT/DNMT ──► [8]Homocysteine ──► [9]Glutathione    │
│               53% <span class="severity-high">[HIGH]</span>            27% <span class="severity-moderate">[MOD]</span>            68% <span class="severity-high">[HIGH]</span>        │
│                                                                              │
│   Cross-pathway: MTHFD1 ──► Mitochondrial TCA (NADPH supply)              │
│                  MTHFD1 ──► Glutathione System (NADPH for reductase)       │
│                  CBS ──────► Glutathione (cysteine substrate)               │
│                                                                              │
│   Clinical: Step 5 is pipeline-modeled as rate-limiting. B12-dependent.   │
│   ⚠ MTR AA = NORMAL — burden from MTRR AG + TCN2 CG auxiliary genes.     │
│   Patient CONFIRMED: Cyanocobalamin IM monthly (Dr. Kurtz) — WRONG form. │
│   Dr. West recommended MB12 3x/week — COMPLIANCE UNCONFIRMED.            │
│                                                                              │
│   NOTE ON 146-SNP LIMITATION:                                               │
│   The 3x4 Genetics panel (146 curated SNPs) does not include MTR           │
│   rs1805087 as a risk variant for this patient (genotype AA = no_impact).  │
│   The pipeline's MTR bottleneck score (85%) is INFERRED from the cascade  │
│   model, not from a directly measured risk allele. This is a model         │
│   prediction, not a confirmed variant. The MTHFR compound het status       │
│   and MTRR AG (rs1801394, low risk) are confirmed.                         │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<p><strong>Clinical Implication for Module 1:</strong> The genetic architecture cannot be changed. All interventions must work WITH these bottlenecks by providing downstream products directly (methylfolate, methylcobalamin, glutathione/NAC, T3-containing thyroid hormone) rather than relying on endogenous conversion through impaired pathways.</p>
<hr>
</div></details>
<a href="#top" class="back-to-top">&#8593; Back to top</a>
<details open><summary>MODULE 2: THE THYROID-METABOLIC TRAP</summary><div class="details-content">
<h3 id="burning-without-fuel-2019-present">"Burning Without Fuel" (2019 → Present)</h3>
<p><strong>This module explains how DIO2 CC + hypothyroidism + PPARG/IRS1 insulin resistance genetics create a self-reinforcing trap where metabolic function declines even as treatments target individual symptoms.</strong></p>
<pre class="ascii-art">━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="2-1-the-thyroid-mystery">2.1 The Thyroid Mystery</h3>
<pre class="ascii-art">   TSH TRAJECTORY (2018-2025)
   ──────────────────────────────────
   Apr18: 0.04 ── [█] SUPPRESSED — ? prior medication or thyrotoxic phase
   Jan19: 0.51 ── [█████] NORMAL — gradual recovery
   Dec19: 0.88 ── [████████] NORMAL — continuing normalization
   Aug22: 1.35 ── [████████████] NORMAL
   Nov23: 1.58 ── [██████████████] NORMAL
   Nov24: 1.73 ── [████████████████] NORMAL — peak
   Jun25: 1.35 ── [████████████] NORMAL — dropping
   Dec25: 1.24 ── [███████████] NORMAL — current
                  ref 0.40-4.50

   THYROID ANTIBODIES:
   2022:  TPO 10 (ref 0-9) — mildly elevated
          TgAb 15.9 (ref 0-1) — SIGNIFICANTLY elevated → Hashimoto's?
   Dec25: TPO 1 (NORMAL) — fully resolved
          TgAb &lt;1.0 (NORMAL) — resolved

   FREE T3: 3.2 pg/mL (ref 2.3-4.2) — mid-range but...
   FREE T4: 1.4 ng/dL (ref 0.8-1.8) — mid-range</pre>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  PARADOX RESOLUTION #4: Normal Thyroid Labs BUT Missing Medication         │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  The data supports TWO possible scenarios:                                  │
│                                                                              │
│  SCENARIO A: Moj still takes Armour Thyroid                                │
│  • TSH 1.24 reflects treated state                                          │
│  • Medication absent from records due to documentation gap                 │
│  • BUT: DIO2 CC means tissue T3 is STILL likely suboptimal even with      │
│    Armour (which provides some T3 directly)                                │
│                                                                              │
│  SCENARIO B: Moj stopped Armour Thyroid                                    │
│  • TSH 1.24 reflects natural euthyroid state                               │
│  • Hashimoto's has resolved (antibodies normalized)                        │
│  • BUT: DIO2 CC means cellular T3 conversion is still impaired            │
│  • Serum looks normal; tissues may still be hypothyroid                    │
│                                                                              │
│  IN EITHER SCENARIO: DIO2 CC means serum thyroid levels are misleading    │
│  indicators of tissue thyroid status. The brain, muscles, and fat tissue   │
│  may be functionally hypothyroid regardless of what the blood shows.       │
│  This would explain persistent brain fog, weight resistance, and fatigue  │
│  despite "normal" thyroid labs.                                             │
│                                                                              │
│  RESOLUTION REQUIRES: Direct patient confirmation + reverse T3 testing    │
│  + trial of T3-augmented therapy if symptoms persist.                      │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="2-2-the-insulin-resistance-paradox">2.2 The Insulin Resistance Paradox</h3>
<pre class="ascii-art">   IR SCORE (PARADOXICAL WORSENING)
   ─────────────────────────────────
   2024:  42 ──── [████████████████████████████████████████████████████] HIGH
   Feb25: 42 ──── [████████████████████████████████████████████████████] HIGH
   Dec25: 48 ──── [████████████████████████████████████████████████████████████] HIGH
                  ref &lt;33 │ ↑ 14.3% WORSENING despite 30+ lb weight loss

   MEANWHILE, GLUCOSE METRICS ARE IMPROVING:
   ─────────────────────────────────────────
   HbA1c:         4.9-5.4%     EXCELLENT
   Fasting Glucose: 68 mg/dL    NORMAL (Dec 2025)
   Triglycerides:   60 mg/dL    ↓ 50.8% improvement (from 122)</pre>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  PARADOX RESOLUTION #1: IR Score Worsening Despite Weight Loss + Mounjaro │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  The IR Score (proprietary composite) likely weights LDL-P and lipid       │
│  particle metrics heavily. While glucose homeostasis has dramatically      │
│  improved (HbA1c 4.9%, TG down 50.8%), the atherogenic lipid profile      │
│  (LDL-P 1649, LDL Small 291) remains elevated despite improvement.        │
│                                                                              │
│  The GENETIC explanation:                                                    │
│                                                                              │
│  ┌─────────────┐     ┌─────────────┐     ┌─────────────────────────┐      │
│  │ PPARG CC     │     │ IRS1 CC     │     │ ApoB Gene Defect        │      │
│  │ ↓insulin     │ ──► │ ↓receptor   │ ──► │ ↑LDL-P production       │      │
│  │ sensitivity  │     │ signaling   │     │ Pattern B (atherogenic) │      │
│  └─────────────┘     └─────────────┘     └─────────────────────────┘      │
│         │                   │                        │                      │
│         └───────────────────┼────────────────────────┘                      │
│                             ▼                                               │
│              ┌─────────────────────────────┐                               │
│              │  IR Score = Genetic Floor    │                               │
│              │  Cannot go below ~35-40      │                               │
│              │  regardless of weight loss   │                               │
│              │  because the RECEPTOR is     │                               │
│              │  structurally impaired       │                               │
│              └─────────────────────────────┘                               │
│                                                                              │
│  Additionally: Metformin underdosing (500mg actual vs 1000mg prescribed)   │
│  means the pharmaceutical support for insulin signaling is at HALF dose.   │
│                                                                              │
│  INTERPRETATION: The IR Score worsening is partly a scoring artifact       │
│  (lipid-weighted), partly genetic (PPARG + IRS1 = irreducible genetic     │
│  IR), and partly due to Metformin underdosing. Glucose homeostasis         │
│  (the clinically more important metric) is well-controlled.               │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="2-3-the-thyroid-metabolic-feedback-loop">2.3 The Thyroid-Metabolic Feedback Loop</h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  THYROID ←→ METABOLIC FEEDBACK LOOP                                        │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│   DIO2 CC (impaired T4→T3 conversion)                                      │
│        │                                                                     │
│        ▼                                                                     │
│   Tissue-level hypothyroidism (despite normal serum)                        │
│        │                                                                     │
│        ├──► ↓ Basal metabolic rate → weight resistance                     │
│        ├──► ↓ Gut motility → dysbiosis susceptibility (→ Module 3)         │
│        ├──► ↓ Hepatic lipid clearance → LDL-P/Pattern B persist           │
│        ├──► ↓ Brain T3 → cognitive slowing (→ Module 6)                    │
│        └──► ↓ Thermogenesis → fatigue, cold intolerance                    │
│                  │                                                           │
│                  ▼                                                           │
│   PPARG CC + IRS1 CC (genetic insulin resistance)                           │
│        │                                                                     │
│        ├──► ↑ Insulin → lipogenesis → weight RESISTANCE to loss            │
│        ├──► ↑ Inflammatory fat → IL-6 GG amplifies → CRP 2.1              │
│        └──► ↑ Hepatic IR → fibrinogen 427 ↑ (→ Module 4)                  │
│                  │                                                           │
│                  ▼                                                           │
│   Inflammation (CRP 2.1, Fibrinogen 427)                                    │
│        │                                                                     │
│        └──► ↓ Thyroid conversion efficiency (inflammation inhibits DIO2)   │
│             ──► FEEDS BACK TO TOP ──►                                       │
│                                                                              │
│   THIS IS THE TRAP: Each element worsens the others.                       │
│   Mounjaro breaks the weight/insulin arm but cannot fix DIO2 or PPARG.    │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<p><strong>Clinical Implication for Module 2:</strong> The thyroid medication question must be resolved IMMEDIATELY. If not on Armour, reinitiate with T3-containing preparation (not levothyroxine alone due to DIO2 CC). Metformin must be taken at prescribed 1000mg/day dose to provide minimal insulin-sensitizing support for the genetic IR component.</p>
<hr>
</div></details>
<a href="#top" class="back-to-top">&#8593; Back to top</a>
<details open><summary>MODULE 3: THE GUT-IMMUNE BREACH</summary><div class="details-content">
<h3 id="the-unguarded-gate-2018-present">"The Unguarded Gate" (2018 → Present)</h3>
<p><strong>This module explains how GSTM1 null + HNMT AA + DAO CG + CYP2R1 GG + vitamin D insufficiency create a gut-immune vulnerability that manifests as maximum dysbiosis, parasitic infection, and histamine intolerance.</strong></p>
<pre class="ascii-art">━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="3-1-maximum-dysbiosis">3.1 Maximum Dysbiosis</h3>
<pre class="ascii-art">   GI EFFECTS STOOL ANALYSIS (Dec 2025)
   ──────────────────────────────────────

   DYSBIOSIS SCORE                                      <span class="severity-critical">[MAXIMUM]</span>
   ──────────────────────────────────────────────────────────────
   Score   10/10   │██████████████████████████████████████████████████████████████│
                   0        2        4        6        8       10

   PARASITES:
   Dientamoeba fragilis: DETECTED (PCR 4.07e2 copies/µL)
   Cryptosporidium: Negative | Giardia: Negative

   COMMENSALS CRITICALLY LOW:
   ─────────────────────────────
   Barnesiella:     1.3E5 (ref 3.0E6-2.9E8)  ↓ 95.7% below range
   Roseburia:       6.5E4 (ref 3.6E5-4.6E8)  ↓ 82.0% below range
   Bifidobacterium: 1.4E5 (ref 4.6E5-2.6E8)  ↓ 69.6% below range
   Prevotella:      2.7E6 (ref 6.6E7-3.8E9)  ↓ 95.9% below range

   SCFAs:
   ─────────────────────────────
   Total SCFA:     19.3 umol/g (ref &gt;=23.3)  <span class="severity-low">[LOW]</span>
   n-Butyrate:      3.4 umol/g (ref &gt;3.6)    <span class="severity-low">[LOW]</span>
   Stool Cholest:   0.3 mg/g (ref 0.4-4.8)   <span class="severity-low">[LOW]</span>

   OVERGROWTH:
   Bacillus species: 4+ growth

   POSITIVE:
   Akkermansia:    7.5E6 (improved from undetectable in 2018)</pre>
<pre class="ascii-art">━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="3-2-why-the-gut-can-t-heal">3.2 Why the Gut Can't Heal</h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  PARADOX RESOLUTION #5: Max Dysbiosis Despite Treatment                    │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  Moj has received: LL-37 antimicrobial peptide, Fluconazole + Voriconazole │
│  antifungal protocol, digestive enzymes, probiotics, low-histamine diet.   │
│  Yet dysbiosis is 10/10 MAXIMUM. Why?                                       │
│                                                                              │
│  MECHANISM CHAIN:                                                            │
│                                                                              │
│  1. CYP2R1 GG → vitamin D stuck at 34-35 ng/mL despite supplementation   │
│     → LL-37 expression UNDERPOWERED (needs vitamin D &gt;50 ng/mL to         │
│     function optimally)                                                     │
│     → Antimicrobial peptide defense is insufficient                         │
│                                                                              │
│  2. GSTM1 null → gut epithelial detoxification absent → reactive          │
│     metabolites accumulate in gut lining → inhospitable environment        │
│     for commensal bacteria → commensals die, opportunists thrive          │
│                                                                              │
│  3. DIO2 CC → tissue hypothyroidism → ↓ gut motility → stasis            │
│     → bacterial overgrowth conditions → Bacillus 4+ overgrowth           │
│                                                                              │
│  4. Low butyrate (3.4, ref &gt;3.6) → impaired enterocyte fuel →            │
│     weakened tight junctions → increased permeability → parasite          │
│     (Dientamoeba fragilis) can establish                                   │
│                                                                              │
│  5. Chronic inflammation (CRP 2.1) → immune resources diverted →         │
│     less available for gut barrier maintenance                             │
│                                                                              │
│  CONCLUSION: The treatments are fighting an unwinnable war because        │
│  the ENVIRONMENT they need to restore is kept hostile by genetics          │
│  (GSTM1 null, CYP2R1 GG, DIO2 CC) and the inflammatory state.          │
│  Must fix the environment FIRST (vitamin D &gt;50, thyroid optimization,    │
│  glutathione support) before microbial interventions can take hold.       │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="3-3-the-histamine-double-hit">3.3 The Histamine Double-Hit</h3>
<pre class="ascii-art">┏━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┓
┃  HISTAMINE CLEARANCE — DUAL GENETIC IMPAIRMENT                              ┃
┣━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┫
┃                                                                              ┃
┃  PATHWAY 1: HNMT (intracellular histamine clearance)                        ┃
┃  🧬 HNMT AA (rs11558538) — HIGH RISK                                       ┃
┃  Normal         │████████████████████████████████████│  100%                ┃
┃  Moj            │██████████████████████              │  ~60%                ┃
┃                                                                              ┃
┃  PATHWAY 2: DAO (extracellular/gut histamine clearance)                     ┃
┃  🧬 DAO CG (rs1049793) — MEDIUM RISK                                       ┃
┃  Normal         │████████████████████████████████████│  100%                ┃
┃  Moj            │████████████████████████████        │  ~75%                ┃
┃                                                                              ┃
┃  COMBINED EFFECT:                                                            ┃
┃  Both pathways reduced → histamine accumulates from:                        ┃
┃  • Food (high-histamine diet triggers)                                      ┃
┃  • Gut bacteria (dysbiosis → histamine-producing bacteria)                  ┃
┃  • Mast cells (environmental allergens — dust mite Class IV IgE)           ┃
┃  • Immune activation (chronic inflammation, Total IgE 312)                  ┃
┃                                                                              ┃
┃  CLINICAL: Total IgE 312 IU/mL (ref &lt;87) = 3.6x upper limit              ┃
┃  Dust mite sensitization: Class IV (D. pteronyssinus 10.5 kU/L)           ┃
┃  → Chronic environmental histamine load on impaired clearance             ┃
┃                                                                              ┃
┃  This explains: brain fog, hay fever, nasal congestion, cognitive          ┃
┃  "cloudiness" — all histamine-mediated symptoms in a patient who           ┃
┃  genetically cannot clear histamine efficiently.                            ┃
┃                                                                              ┃
┃  Cross-refs: Module 6 (histamine → brain fog), Module 2 (thyroid →        ┃
┃  gut motility → bacterial histamine production)                             ┃
┃                                                                              ┃
┗━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┛

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="3-4-vitamin-d-the-stuck-nutrient">3.4 Vitamin D — The Stuck Nutrient</h3>
<pre class="ascii-art">   VITAMIN D (Chronic Insufficiency — Genetic Root)
   ──────────────────────────────────────────────────
   2018:  39   ──── [████████] NORMAL
   2019:  22.4 ──── [████] LOW
   2019:  23   ──── [████] LOW
   2022:  45.4 ──── [█████████] NORMAL
   2023:  34.3 ──── [███████] NEAR LOW
   2024:  34   ──── [███████] NEAR LOW
   Feb25: 34   ──── [███████] NEAR LOW
   Dec25: 35   ──── [███████] NEAR LOW
                    ref 30-150 │ STUCK at lower boundary for 3+ years</pre>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  PARADOX RESOLUTION #6: Chronic Vitamin D Insufficiency Despite Suppl.    │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  CYP2R1 GG (rs10741657) — Very High Risk                                   │
│  This enzyme performs the hepatic 25-hydroxylation step that converts       │
│  vitamin D3 (cholecalciferol) into 25-OH-D (calcidiol, the measured        │
│  form). GG genotype = impaired conversion.                                  │
│                                                                              │
│  Result: Standard-dose vitamin D3 supplementation (1000-2000 IU/day)       │
│  is INSUFFICIENT for this genotype. Requires higher dosing (5000-10000     │
│  IU/day) or alternative form (calcifediol/25-OH-D directly, which          │
│  bypasses the CYP2R1 bottleneck).                                           │
│                                                                              │
│  Downstream impact:                                                          │
│  • LL-37 antimicrobial peptide requires vitamin D &gt;50 ng/mL                │
│  • At 35 ng/mL, LL-37 expression is SUBOPTIMAL                             │
│  • This means her LL-37 injections (100mcg SC daily) are working in       │
│    a compromised vitamin D environment — reduced efficacy                   │
│  • Contributes to persistent dysbiosis (Module 3.2)                        │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘

**Clinical Implication for Module 3:** Before retreating dysbiosis, fix the environment: (1) Vitamin D to &gt;50 ng/mL via high-dose D3 or calcifediol, (2) Glutathione/NAC support for GSTM1 null, (3) Thyroid optimization for gut motility. Only then will antimicrobial/probiotic interventions have a hospitable environment to restore. Treat Dientamoeba fragilis with targeted antiparasitic.</pre>
<hr>
</div></details>
<a href="#top" class="back-to-top">&#8593; Back to top</a>
<details open><summary>MODULE 4: THE CARDIOVASCULAR CASCADE</summary><div class="details-content">
<h3 id="the-pressure-builds-2018-present">"The Pressure Builds" (2018 → Present)</h3>
<p><strong>This module shows how ApoB gene defect + F2 GA + IL-6 GG + chronic inflammation converge to create a multiplicative cardiovascular/thrombotic risk profile.</strong></p>
<pre class="ascii-art">━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="4-1-atherogenic-lipid-profile-genetic">4.1 Atherogenic Lipid Profile (Genetic)</h3>
<pre class="ascii-art">   LDL SMALL (Critical — Atherogenic, ApoB-Driven)
   ─────────────────────────────────────────────────
   2018:  324 ──── [██████████████████████████████████████████████] CRITICAL
   2024:  428 ──── [████████████████████████████████████████████████████████████] CRITICAL
   Feb25: 428 ──── [████████████████████████████████████████████████████████████] CRITICAL
   Dec25: 291 ──── [████████████████████████████████████████] CRITICAL
                   ref &lt;142 │ ↓ 10.2% from baseline — IMPROVING but still 2x limit

   LDL PARTICLE NUMBER
   ────────────────────
   2018:  1232 ──── [█████████████████████████] HIGH
   2024:  2023 ──── [█████████████████████████████████████████] HIGH
   Feb25: 2023 ──── [█████████████████████████████████████████] HIGH
   Dec25: 1649 ──── [█████████████████████████████████] HIGH
                    ref &lt;1138 │ ↓ Improving — 45% above limit

   LDL PATTERN
   ────────────
   2024:  B (atherogenic) → Dec 2025: transitioning B→A
   LDL Peak Size: 219.2 Å (ref &gt;222.9) — almost at threshold for Pattern A</pre>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  GENETIC CV RISK CONVERGENCE                                                │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  LAYER 1: ApoB Gene Defect (Clinical Diagnosis)                            │
│  → Overproduction of atherogenic LDL particles                              │
│  → LDL Pattern B (small, dense) — penetrates endothelium                   │
│  → CANNOT be fully resolved by lifestyle/diet — genetic production rate    │
│                                                                              │
│  LAYER 2: F2 GA (rs1799963) — Prothrombin 20210 Heterozygote              │
│  → Increased prothrombin production → enhanced clotting tendency           │
│  → Combined with elevated fibrinogen → multiplicative thrombotic risk      │
│  → Currently managed: Nattokinase + Lumbrokinase + Baby Aspirin            │
│                                                                              │
│  LAYER 3: IL-6 GG (rs1800795) — Pro-inflammatory Genotype                  │
│  → Baseline overproduction of IL-6 → drives CRP, fibrinogen               │
│  → This is WHY CRP persists at 2.1 and fibrinogen rises to 427            │
│  → Anti-inflammatory interventions (turmeric, omega-3) correct but        │
│    cannot fully overcome genetic IL-6 production rate                       │
│                                                                              │
│  LAYER 4: Insulin Resistance (PPARG CC + IRS1 CC)                          │
│  → Hyperinsulinemia → hepatic VLDL production → more LDL particles        │
│  → Inflammatory adipokine release → vascular inflammation                  │
│                                                                              │
│  LAYER 5: GSTM1 null → reduced vascular antioxidant protection            │
│  → Cannot efficiently neutralize oxidized LDL in vessel wall               │
│                                                                              │
│  CONVERGENT RISK:                                                            │
│  ├── Atherogenic particles (ApoB/LDL-P/Pattern B) ── DEPOSITION          │
│  ├── Impaired clearance (GSTM1 null)              ── ACCUMULATION         │
│  ├── Inflammation (IL-6 GG → CRP 2.1/Fib 427)    ── PLAQUE GROWTH       │
│  ├── Thrombotic tendency (F2 GA)                   ── CLOT RISK           │
│  └── Insulin resistance (PPARG/IRS1)               ── FEEDS ALL ABOVE    │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="4-2-the-fibrinogen-ferritin-connection">4.2 The Fibrinogen-Ferritin Connection</h3>
<pre class="ascii-art">   FIBRINOGEN (Inflammatory/Thrombotic — WORSENING)
   ─────────────────────────────────────────────────
   Nov24: 386 ──── [████████████████████████████████████████████████] HIGH
   Feb25: 386 ──── [████████████████████████████████████████████████] HIGH
   Dec25: 427 ──── [██████████████████████████████████████████████████████] HIGH
                   ref 180-350 │ ↑ 10.6% increase — WORSENING trajectory

   FERRITIN (Rising — Inflammatory Marker)
   ─────────────────────────────────────────
   2020:   97 ──── [██████████████████████████████████] NORMAL
   2022:  109 ──── [██████████████████████████████████████] NORMAL
   2024:  169 ──── [████████████████████████████████████████████████████████████] HIGH
   Dec25: 209 ──── [█████████████████████████████████████████████████████████████████] HIGH
                   ref 50-149 │ ↑ 115.5% increase — steady inflammatory rise</pre>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  PARADOX RESOLUTION #2: Rising Ferritin with Low MCHC                      │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  Ferritin and fibrinogen are BOTH acute phase reactants — they rise with   │
│  chronic inflammation. They are rising IN PARALLEL:                         │
│                                                                              │
│  Ferritin:    97 → 109 → 169 → 209  (↑116% over 5 years, 2020-2025)     │
│  Fibrinogen:  --- → 386 → 386 → 427  (↑ over 1 year)                     │
│  CRP:         --- → 4.1 → 2.3 → 2.1 (Hs-CRP ↓, ref &lt;1.0)              │
│                                                                              │
│  MCHC (mean corpuscular hemoglobin concentration) was previously low:     │
│  31.4 → 31.4 (2022-2024, ref 32-36 g/dL) but NORMALIZED to 32.9 Dec 25 │
│                                                                              │
│  The ferritin/fibrinogen PARALLEL RISE suggests INFLAMMATION PATTERN:     │
│  • Hepcidin (induced by IL-6 GG inflammatory genotype) previously         │
│    blocked iron export, causing iron maldistribution                       │
│  • MCHC normalization (32.9) suggests iron utilization is improving       │
│  • But ferritin continues rising — inflammatory drive persists            │
│                                                                              │
│  This is NOT iron overload. It is inflammatory iron sequestration.          │
│  Treatment: resolve inflammation, do NOT restrict iron or chelate.         │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="4-3-the-mpo-fibrinogen-dissociation">4.3 The MPO-Fibrinogen Dissociation</h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  PARADOX RESOLUTION #7: MPO Improved While Fibrinogen Rises                │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  Myeloperoxidase:  &gt;5351 → 327  (↓ 93.9%) — DRAMATIC improvement         │
│  Fibrinogen:        386 → 386 → 427   (↑ 10.6%) — WORSENING              │
│                                                                              │
│  These are DIFFERENT inflammatory pathways:                                  │
│                                                                              │
│  MPO = Neutrophil-derived vascular inflammation                             │
│  → Measures oxidative damage at the vessel wall                             │
│  → Resolved — suggests vascular inflammation is controlled                 │
│  → Likely due to: anti-inflammatory protocol (turmeric, omega-3,          │
│    Cholesterol Complete) + Mounjaro weight loss effect                      │
│                                                                              │
│  Fibrinogen = Hepatic acute phase protein                                    │
│  → Produced by liver in response to IL-6                                    │
│  → IL-6 GG genotype → constitutive overproduction                          │
│  → Insulin resistance → hepatic inflammation → more fibrinogen             │
│  → Rising because the HEPATIC inflammatory drive (IR + IL-6 GG)           │
│    persists even as vascular inflammation resolves                          │
│                                                                              │
│  INTERPRETATION: Two different "fires." The vascular fire (MPO) has        │
│  been extinguished. The hepatic fire (fibrinogen) is still burning         │
│  because its fuel (IL-6 GG genotype + insulin resistance + gut-derived    │
│  inflammation) has not been fully addressed.                                │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘

**Clinical Implication for Module 4:** Continue current anti-inflammatory and anticoagulant protocol. Prioritize insulin resistance management (full-dose Metformin, thyroid optimization) to reduce hepatic inflammatory drive. Monitor D-dimer and fibrinogen at 3-month intervals given F2 GA + rising fibrinogen.</pre>
<hr>
</div></details>
<a href="#top" class="back-to-top">&#8593; Back to top</a>
<details open><summary>MODULE 5: THE HORMONAL DIMMING</summary><div class="details-content">
<h3 id="the-fading-signal-2018-present">"The Fading Signal" (2018 → Present)</h3>
<p><strong>This module explains how perimenopause intersects with CYP19A1 TT, COMT AA, and progesterone overcompliance to create a hormonal profile that is simultaneously undertreated and mismanaged.</strong></p>
<pre class="ascii-art">━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="5-1-hormonal-decline-trajectory">5.1 Hormonal Decline Trajectory</h3>
<pre class="ascii-art">   FSH (Rising Toward Menopause — But Suppressed)
   ─────────────────────────────────────────────────
   2018:  2.3 ──── [██] CRITICAL LOW
   2022:  4.5 ──── [████] CRITICAL LOW
   Dec25: 12.6 ── [████████████] LOW
                  ref 23-116.3 │ ↑ 448% — rising but STILL suppressed for age 49

   DHEA-S (Adrenal Decline — Accelerated)
   ─────────────────────────────────────────
   2018:  217 ──── [█████████████████████████████████████████████████████████] HIGH
   2022:  159 ──── [██████████████████████████████████████████] NORMAL
   2024:   88 ──── [███████████████████████] NORMAL
   Dec25:  73 ──── [███████████████████] NEAR LOW
                   ref 5-167 │ ↓ 66.4% decline — accelerated adrenal aging

   PREGNENOLONE (Mother Hormone — Recovered from Critical)
   ─────────────────────────────────────────────────────────
   2022:  2.98 ── [█] CRITICAL LOW
   Dec25: 25.0 ── [████████████] NEAR LOW (ref 22-237)
                  ↑ 739% — excellent recovery with supplementation (100mg AM)

   AMH: &lt;0.08 ng/mL — MENOPAUSAL RANGE (confirms ovarian exhaustion)</pre>
<pre class="ascii-art">━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="5-2-the-fsh-suppression-paradox">5.2 The FSH Suppression Paradox</h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  PARADOX RESOLUTION #3: FSH Suppressed Despite Menopausal AMH             │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  At age 49 with AMH &lt;0.08 (ovarian reserve exhausted), FSH SHOULD be      │
│  elevated (&gt;40 mIU/mL) as the pituitary tries to stimulate non-responsive │
│  ovaries. Instead FSH is only 12.6 — still SUPPRESSED.                     │
│                                                                              │
│  THE MECHANISM:                                                              │
│                                                                              │
│  1. EXOGENOUS ESTROGEN SUPPRESSION                                          │
│     Patient is on: Estradiol patch (0.05mg 2x/week)                        │
│     + Biest cream (nightly) + Estriol cream — per Dr. West Rx             │
│     ⚠ COMPLIANCE UNCONFIRMED: Biest/Estriol not in patient self-report    │
│     → IF taken: exogenous estrogen provides negative feedback to           │
│     hypothalamus → suppresses GnRH → suppresses FSH/LH                    │
│                                                                              │
│  2. PROGESTERONE OVERCOMPLIANCE                                              │
│     Prescribed: Days 10-24 only (cyclic, mimicking luteal phase)           │
│     Actual: "Almost every night" → continuous progesterone                 │
│     Continuous progesterone → constant negative feedback on GnRH           │
│     → further FSH/LH suppression → masks true menopausal status           │
│                                                                              │
│  3. CYP19A1 TT (rs10046) — Aromatase Variant                              │
│     Reduced aromatase activity → lower endogenous estrogen production     │
│     → Body requires MORE exogenous estrogen to compensate                  │
│     → BUT COMT AA slows estrogen clearance → catechol estrogens may      │
│       accumulate even at lower absolute levels                              │
│                                                                              │
│  RESOLUTION: FSH suppression is iatrogenic (caused by treatment).         │
│  Switch progesterone to proper cyclic dosing (days 10-24 only).           │
│  This would unmask true FSH and allow accurate menopausal staging.        │
│                                                                              │
│  HOWEVER: Bilateral mastectomy history (Sep 2021) means HRT risk-benefit  │
│  requires ongoing oncology clearance. Estrogen therapy is generally        │
│  acceptable post-prophylactic mastectomy but should be documented.         │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="5-3-estrogen-metabolism-genetics">5.3 Estrogen Metabolism Genetics</h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  ESTROGEN CLEARANCE PATHWAY (from Pipeline Pass 4)                         │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│   Estradiol ──► [2-OH path]CYP1A1/CYP1A2 ──► [2-MeO]COMT ──► CLEARED   │
│                                                  ▲                          │
│                                             BOTTLENECK                      │
│                                           COMT AA (slow)                    │
│                                           46% burden                        │
│                                                                              │
│   Estradiol ──► [4-OH path]CYP1B1 ──► [4-MeO]COMT ──► CLEARED           │
│                                          ▲                                   │
│                                     BOTTLENECK                              │
│                                   COMT AA (slow)                            │
│                                   46% burden                                │
│                                                                              │
│   ⚠️ 4-OH catechol estrogens are potentially GENOTOXIC if not            │
│   methylated by COMT. With COMT AA (slow), 4-OH-E1 and 4-OH-E2          │
│   may accumulate. This is relevant given bilateral mastectomy history.    │
│                                                                              │
│   PROTECTIVE: CYP1A2 AA (fast) shifts metabolism toward the safer        │
│   2-OH pathway. CYP1B1 AG is only partially active. Net effect:          │
│   more 2-OH (protective) than 4-OH (genotoxic), but COMT slows          │
│   clearance of BOTH.                                                       │
│                                                                              │
│   IMPLICATION: Monitor 2-OH:4-OH:16α-OH ratio on DUTCH test.             │
│   Support COMT with magnesium (cofactor), SAMe, catechol-O-               │
│   methyltransferase substrates.                                             │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<pre class="ascii-art">━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="5-4-the-estrace-gap">5.4 The Estrace Gap</h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  CRITICAL TREATMENT GAP: Vaginal Estrogen NEVER TAKEN                      │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  Documented: Severe urethral atrophy on cystoscopy (Dr. Kim, Apr 2025)    │
│  Prescribed: Estrace vaginal cream 0.01% (Dr. Schneider/Dr. Kurtz)        │
│  Patient states: "I have never taken this"                                  │
│                                                                              │
│  This is a LOCAL estrogen application — minimal systemic absorption.       │
│  It is NOT the same risk profile as systemic HRT.                           │
│  The urethral atrophy will NOT improve without local estrogen.             │
│  Bulkamid injection (Apr 2025) addressed incontinence mechanically,       │
│  but the underlying tissue atrophy remains.                                 │
│                                                                              │
│  ACTION: Address barriers to vaginal estrogen use. Consider alternative   │
│  formulation if application method is the barrier (e.g., DHEA vaginal     │
│  suppository, estriol vaginal tablet).                                      │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<p><strong>Clinical Implication for Module 5:</strong> (1) Switch progesterone to cyclic dosing (days 10-24 only), (2) Address Estrace non-compliance, (3) Complete DUTCH hormone test to assess estrogen metabolite ratios, (4) Continue DHEA 5mg + pregnenolone 100mg (pregnenolone recovery is a treatment success).</p>
<hr>
</div></details>
<a href="#top" class="back-to-top">&#8593; Back to top</a>
<details open><summary>MODULE 6: THE FOGGY PROCESSOR</summary><div class="details-content">
<h3 id="running-slow-thinking-slow-ongoing">"Running Slow, Thinking Slow" (Ongoing)</h3>
<p><strong>This module explains how brain fog — the chief quality-of-life complaint — arises from the convergence of EVERY preceding module onto the neurocognitive system.</strong></p>
<pre class="ascii-art">━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="6-1-the-multifactorial-brain-fog">6.1 The Multifactorial Brain Fog</h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  BRAIN FOG — 6 CONVERGING MECHANISMS                                        │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  FROM MODULE 1 (Genetics):                                                   │
│  ├── COMT AA → slow DA/NE clearance → prefrontal "overflow"              │
│  ├── MAOA TT → monoamine processing variant                               │
│  ├── HTR1A GG → serotonin receptor reduced sensitivity                    │
│  └── MTHFR 44% → reduced SAM for neurotransmitter synthesis              │
│                                                                              │
│  FROM MODULE 2 (Thyroid):                                                    │
│  └── DIO2 CC → brain T3 conversion impaired → neuronal hypofunction      │
│                                                                              │
│  FROM MODULE 3 (Gut-Immune):                                                 │
│  ├── HNMT AA + DAO CG → histamine accumulates in brain                    │
│  ├── Dust mite IgE Class IV → chronic histamine load                      │
│  └── Gut dysbiosis → inflammatory cytokines cross BBB                     │
│                                                                              │
│  FROM MODULE 4 (Inflammation):                                               │
│  ├── CRP 2.1 → neuroinflammation                                          │
│  └── IL-6 GG → pro-inflammatory cytokines in CNS                         │
│                                                                              │
│  FROM MODULE 5 (Hormones):                                                   │
│  ├── Perimenopausal estrogen decline → ↓ neuroprotection                  │
│  └── DHEA-S decline (-66%) → ↓ neurosteroid support                      │
│                                                                              │
│  FROM BIOMARKERS:                                                            │
│  └── Serotonin: 48 ng/mL (ref 56-244) <span class="severity-low">[LOW]</span> → mood + cognition           │
│                                                                              │
│  RESULT: Brain is simultaneously:                                            │
│  • Under-fueled (thyroid, serotonin, DHEA)                                 │
│  • Overwhelmed (histamine, catecholamines stuck)                           │
│  • Inflamed (CRP, IL-6)                                                     │
│  • Under-methylated (MTHFR 44%, MTR bottleneck)                           │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<pre class="ascii-art">━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="6-2-neurotransmitter-genetics">6.2 Neurotransmitter Genetics</h3>
<pre class="ascii-art">┏━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┓
┃  NEUROTRANSMITTER GENETIC PROFILE                                            ┃
┣━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┫
┃                                                                              ┃
┃  🧬 COMT AA (rs4680) — Slow dopamine/NE breakdown                          ┃
┃     Phenotype: "Worrier" — better at sustained attention, worse under      ┃
┃     acute stress. High prefrontal dopamine → good baseline cognition       ┃
┃     BUT → overwhelmed under stress → anxiety, rumination                    ┃
┃     Clinical: Strattera (norepinephrine reuptake inhibitor) is better      ┃
┃     tolerated than Adderall (dopamine releaser) — correct switch.          ┃
┃                                                                              ┃
┃  🧬 MAOA TT (rs6323) — Very High Risk                                      ┃
┃     Impact: MAO-A breaks down serotonin, dopamine, norepinephrine.        ┃
┃     TT variant → altered monoamine metabolism.                              ┃
┃     Combined with COMT AA → compound neurotransmitter clearance issue.    ┃
┃                                                                              ┃
┃  🧬 HTR1A GG (rs6295) — High Risk                                          ┃
┃     Impact: Serotonin 1A receptor variant → reduced serotonergic tone     ┃
┃     Consistent with: Serotonin 48 ng/mL (LOW), brain fog, mood            ┃
┃     Combined with MAOA TT → serotonin may be USED faster than made       ┃
┃                                                                              ┃
┃  🧬 DRD1 GA (rs5326) — High Risk                                           ┃
┃     🧬 DRD3 CT (rs6280) — High Risk                                        ┃
┃     Impact: Dopamine receptor variants → altered reward/motivation        ┃
┃     Relevant to: ADHD symptoms, executive function, motivation            ┃
┃                                                                              ┃
┃  Neurotransmitter Burden: 36.4% (from Pass 5 system_burden_profile)       ┃
┃  Brain Burden: 49.3% (nearly half of total genetic burden is brain)       ┃
┃                                                                              ┃
┗━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┛

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="6-3-epigenetic-brain-aging">6.3 Epigenetic Brain Aging</h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  TRUAGE BRAIN &amp; FUNCTIONAL AGING (Dec 2025)                                │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  Chronological Age:     49.0 years                                          │
│  Brain Organ Age:       54.2 years (+5.2 years OLDER)   ← WORST organ     │
│  Blood Organ Age:       54.5 years (+5.5 years OLDER)   ← 2nd WORST       │
│  Immune Organ Age:      53.6 years (+4.6 years OLDER)                      │
│                                                                              │
│  FUNCTIONAL MARKERS:                                                         │
│  Grip Strength:     21.8 percentile  <span class="severity-critical">[CRITICAL LOW]</span>                        │
│  FEV1:              29.8 percentile  <span class="severity-low">[LOW]</span>                                  │
│  Gait Speed:        40.4 percentile  <span class="severity-low">[LOW]</span>                                  │
│  VO2 Max:           46.2 percentile  <span class="severity-low">[LOW]</span>                                  │
│                                                                              │
│  IMMUNE AGING:                                                               │
│  Monocyte:          7.1 percentile   <span class="severity-critical">[CRITICAL LOW]</span>                        │
│  Naive CD8T:        20.3 percentile  <span class="severity-critical">[CRITICAL LOW]</span>                        │
│  Naive CD4T:        25.7 percentile  <span class="severity-low">[LOW]</span>                                  │
│  Naive B:           28.5 percentile  <span class="severity-low">[LOW]</span>                                  │
│                                                                              │
│  The brain is aging FASTEST — 5.2 years ahead of chronological age.       │
│  This is consistent with the neurocognitive burden from Module 6:          │
│  chronic inflammation + histamine + thyroid deficit + methylation           │
│  impairment → accelerated neuronal aging at the epigenetic level.          │
│                                                                              │
│  POSITIVE: DunedinPACE 0.90 (aging at 90% rate) — the RATE of aging      │
│  is actually favorable, suggesting current interventions are slowing       │
│  the pace even if past damage is reflected in absolute ages.               │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  PARADOX RESOLUTION #8: OMICm Age 42 vs Symphony Age 53.1                  │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  OMICm Age: 42.0 years (-7.0 years YOUNGER)                                │
│  Symphony Age: 53.1 years (+4.1 years OLDER)                                │
│                                                                              │
│  These use DIFFERENT epigenetic algorithms measuring different aspects:    │
│                                                                              │
│  OMICm = Multi-omic integration including metabolomics                     │
│  → May be influenced by Mounjaro (GLP-1) effects on metabolic markers     │
│  → Likely reflecting the METABOLIC improvement from weight loss            │
│                                                                              │
│  Symphony = Integrated multi-clock (more conservative/comprehensive)       │
│  → Better reflects overall biological aging trajectory                      │
│  → Consistent with 2022 TruAge Intrinsic (53.06, +7.4 years)             │
│                                                                              │
│  INTERPRETATION: Symphony Age (53.1, +4.1yr) is the more reliable         │
│  indicator. Moj's biological age is ~4 years ahead of chronological.      │
│  The OMICm result reflects metabolic improvements from Mounjaro            │
│  rather than true biological age reversal.                                  │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘

**Clinical Implication for Module 6:** Brain fog will NOT resolve from a single intervention. It requires: (1) Thyroid optimization (DIO2 CC → T3-containing therapy), (2) Histamine management (dust mite reduction, DAO enzyme, HNMT support with SAMe/magnesium), (3) Inflammation reduction (address gut dysbiosis, full-dose Metformin), (4) Serotonin support (5-HTP or tryptophan, with caution given MAOA TT), (5) Continued methylation support (MB12, methylfolate). Strattera switch was appropriate for COMT AA.</pre>
<hr>
<h2 id="2e-mapping-to-patient-goals">2e. MAPPING TO PATIENT GOALS</h2>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────────────────────────────┐
│                                GOALS → MECHANISMS → MODULES                                          │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│                                                                                                       │
│  GOAL: Weight / Metabolic Optimization                                                               │
│  ════════════════════════════════════════                                                             │
│  PRIMARY:  Module 2 — DIO2 CC tissue hypothyroidism → ↓ BMR → weight resistance                    │
│            Module 2 — PPARG CC + IRS1 CC → genetic insulin resistance → IR Score 48                 │
│  SECONDARY: Module 3 — Gut dysbiosis → SCFA deficit → impaired metabolic signaling                  │
│             Module 1 — PPARGC1A GG → reduced mitochondrial biogenesis                               │
│  STATUS:   IMPROVING (30+ lbs lost) but STALLED (IR Score rising)                                    │
│  KEY ACTION: Confirm/restart thyroid medication, full-dose Metformin                                 │
│                                                                                                       │
│  GOAL: Brain Fog Resolution                                                                          │
│  ═══════════════════════════                                                                         │
│  PRIMARY:  Module 6 — COMT AA + MAOA TT → neurotransmitter processing jam                          │
│            Module 2 — DIO2 CC → brain T3 deficit → neuronal hypofunction                            │
│  SECONDARY: Module 3 — HNMT AA + DAO CG → histamine accumulation in CNS                            │
│             Module 4 — CRP 2.1 + IL-6 GG → neuroinflammation                                       │
│             Module 5 — Estrogen decline → ↓ neuroprotection                                         │
│             Module 1 — MTHFR 44% + MTR bottleneck → ↓ neurotransmitter synthesis substrate         │
│  STATUS:   STALLED despite multiple interventions                                                    │
│  KEY ACTION: Thyroid optimization, histamine management, inflammation reduction                      │
│                                                                                                       │
│  GOAL: Fatigue Resolution                                                                            │
│  ═══════════════════════                                                                             │
│  PRIMARY:  Module 2 — DIO2 CC → tissue hypothyroidism → ↓ energy production                        │
│            Module 1 — MTHFR 44% + MTHFD1 → ↓ NADPH → ↓ mitochondrial efficiency                   │
│  SECONDARY: Module 5 — DHEA-S decline (-66%) → adrenal insufficiency component                      │
│             Module 3 — Gut dysbiosis → nutrient malabsorption → substrate deficiency                │
│             Module 4 — Chronic inflammation → cytokine-mediated fatigue                              │
│  STATUS:   ONGOING                                                                                    │
│  KEY ACTION: Thyroid medication, methylation support (MB12/methylfolate), DHEA                       │
│                                                                                                       │
│  GOAL: Cardiovascular Risk Management                                                                │
│  ═════════════════════════════════════                                                               │
│  PRIMARY:  Module 4 — ApoB defect → LDL-P overproduction (genetic, irreducible)                    │
│            Module 4 — F2 GA → prothrombin variant → clotting risk                                   │
│  SECONDARY: Module 4 — IL-6 GG → fibrinogen 427 → thrombotic risk amplification                    │
│             Module 2 — Insulin resistance → hepatic VLDL → more particles                           │
│             Module 1 — GSTM1 null → ↓ vascular antioxidant protection                              │
│  STATUS:   MIXED (MPO resolved, LDL-P improving, but fibrinogen RISING)                             │
│  KEY ACTION: Continue anticoagulant protocol, address hepatic inflammation (IR, gut)                │
│                                                                                                       │
│  GOAL: Hormonal Balance / Perimenopause Management                                                  │
│  ═══════════════════════════════════════════════════                                                 │
│  PRIMARY:  Module 5 — CYP19A1 TT → reduced endogenous estrogen production                          │
│            Module 5 — COMT AA → slow catechol estrogen clearance → 4-OH accumulation risk          │
│  SECONDARY: Module 5 — Progesterone overcompliance → FSH suppression → masked status               │
│             Module 5 — Estrace NEVER TAKEN → GSM untreated                                          │
│  STATUS:   PARTIALLY MANAGED (HRT active but compliance issues)                                      │
│  KEY ACTION: Cyclic progesterone, address Estrace barriers, DUTCH test for metabolite ratios         │
│                                                                                                       │
│  GOAL: Gut Health Restoration                                                                        │
│  ═════════════════════════                                                                           │
│  PRIMARY:  Module 3 — GSTM1 null → hostile gut environment for commensals                           │
│            Module 3 — CYP2R1 GG → vitamin D stuck → LL-37 underpowered                             │
│  SECONDARY: Module 2 — DIO2 CC → ↓ gut motility → bacterial overgrowth                             │
│             Module 3 — HNMT AA + DAO CG → histamine from gut bacteria not cleared                  │
│  STATUS:   CRITICAL (Dysbiosis 10/10, Dientamoeba fragilis, SCFA deficit)                            │
│  KEY ACTION: Vitamin D &gt;50, glutathione/NAC support, treat D. fragilis, THEN rebuild microbiome    │
│                                                                                                       │
└──────────────────────────────────────────────────────────────────────────────────────────────────────┘</pre>
<hr>
<h2 id="146-snp-limitation-statement">146-SNP LIMITATION STATEMENT</h2>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  GENETIC DATA QUALITY — HONEST ASSESSMENT                                   │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  Panel Used: 3x4 Genetics curated clinical panel                            │
│  Total SNPs: 146 (vs. 679,085 for genome-wide analysis like Case 1767)    │
│                                                                              │
│  WHAT WE CAN SAY WITH CONFIDENCE:                                           │
│  ✓ COMT AA (rs4680) — directly genotyped, VERIFIED                        │
│  ✓ GSTM1 DEL — directly genotyped, VERIFIED                              │
│  ✓ MTHFR C677T CT + A1298C AC — directly genotyped, VERIFIED             │
│  ✓ DIO2 CC (rs225014) — directly genotyped, VERIFIED                     │
│  ✓ PPARG CC (rs1801282) — directly genotyped, VERIFIED                   │
│  ✓ IRS1 CC (rs2943641) — directly genotyped, VERIFIED                    │
│  ✓ F2 GA (rs1799963) — directly genotyped, VERIFIED                      │
│  ✓ IL-6 GG (rs1800795) — directly genotyped, VERIFIED                    │
│  ✓ HNMT AA (rs11558538) — directly genotyped, VERIFIED                   │
│  ✓ DAO CG (rs1049793) — directly genotyped, VERIFIED                     │
│  ✓ CYP19A1 TT (rs10046) — directly genotyped, VERIFIED                  │
│  ✓ MAOA TT (rs6323) — directly genotyped, VERIFIED                       │
│  ✓ CYP2R1 GG (rs10741657) — directly genotyped, VERIFIED                │
│  ✓ APOE E3/E3 — directly genotyped, VERIFIED                             │
│                                                                              │
│  WHAT WE CANNOT SAY:                                                         │
│  ✗ MTR bottleneck — INFERRED from cascade model, not a confirmed          │
│    risk variant on this panel (rs1805087 AA = no_impact)                   │
│  ✗ NOD2 variants — not on panel (cannot assess bacterial sensing)         │
│  ✗ FMO3 variants — not on panel (cannot assess TMA metabolism)            │
│  ✗ Comprehensive pharmacogenomic profile — limited to panel coverage      │
│  ✗ Rare variants — panel covers common variants only                      │
│                                                                              │
│  OVERALL: The 3x4 panel covers the clinically MOST IMPORTANT variants     │
│  for nutrigenomic and pharmacogenomic decision-making. The endotype        │
│  model is well-supported by the directly genotyped variants. The primary  │
│  limitation is depth of coverage, not accuracy of what is covered.         │
│                                                                              │
│  RECOMMENDATION: Genome-wide analysis (23andMe + imputation, or clinical  │
│  whole exome) would provide deeper pathway coverage and identify any       │
│  rare variants not captured by the curated panel. This is NOT urgent      │
│  but would strengthen the model.                                            │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<hr>
<h2 id="summary-how-the-slow-burn-works">SUMMARY: HOW THE SLOW BURN WORKS</h2>
<pre class="ascii-art">╔══════════════════════════════════════════════════════════════════════════════╗
║                        THE SLOW BURN — UNIFIED MODEL                        ║
╠══════════════════════════════════════════════════════════════════════════════╣
║                                                                              ║
║  GENETIC FOUNDATION (Module 1):                                             ║
║  Every clearing pathway is constitutionally SLOW.                           ║
║  COMT, GSTM1, MTHFR, DIO2, NAT2, MAOA — all reduced or absent.          ║
║  No reserve capacity. No "fast lane."                                       ║
║                                                                              ║
║                              │                                               ║
║                              ▼                                               ║
║                                                                              ║
║  TRIGGER EVENT (2019): PCOS + Hypothyroidism diagnosed.                     ║
║  System pushed past compensation threshold.                                 ║
║                                                                              ║
║                              │                                               ║
║                              ▼                                               ║
║                                                                              ║
║  THE SLOW BURN BEGINS:                                                       ║
║  • Ferritin rises slowly (97→209) — iron trapped by inflammation           ║
║  • DHEA-S declines slowly (217→73) — adrenal reserves consumed            ║
║  • Fibrinogen rises slowly (386→427) — hepatic inflammatory drive         ║
║  • IR Score rises slowly (42→48) — genetic floor exposed                   ║
║  • Commensals decline slowly — gut environment inhospitable               ║
║  • Brain ages faster (+5.2 years) — neuroinflammation accumulates          ║
║                                                                              ║
║                              │                                               ║
║                              ▼                                               ║
║                                                                              ║
║  PERIMENOPAUSE (2024-NOW): Accelerant added to the slow burn.              ║
║  Estrogen withdrawal removes neuroprotection, cardiovascular                ║
║  protection, and metabolic support. CYP19A1 TT means endogenous           ║
║  production was already low. The fire burns faster now.                      ║
║                                                                              ║
║                              │                                               ║
║                              ▼                                               ║
║                                                                              ║
║  TREATMENT PARADOX:                                                          ║
║  Mounjaro → weight loss SUCCESS → but IR Score RISES                       ║
║  LL-37 → antimicrobial protocol → but Dysbiosis MAXIMUM                    ║
║  HRT → hormone replacement → but Estrace NEVER TAKEN                      ║
║  Armour Thyroid → thyroid support → but STATUS UNKNOWN                     ║
║                                                                              ║
║  The treatments target symptoms. The genetics create the soil.              ║
║  Until the soil is addressed (methylation, detox, conversion),             ║
║  the slow burn continues.                                                    ║
║                                                                              ║
╚══════════════════════════════════════════════════════════════════════════════╝</pre>
<hr>
<h2 id="verification-checklist">VERIFICATION CHECKLIST</h2>
<ul>
<li>[x] Endotype named with compelling, descriptive title ("The Slow Burn")</li>
<li>[x] Executive summary ASCII diagram with timeline</li>
<li>[x] 6 interconnected modules with full mechanistic detail</li>
<li>[x] Every module has verified biomarker data + genetic variants</li>
<li>[x] Patient goals mapped to specific mechanisms (Section 2e)</li>
<li>[x] Paradoxes from Part 1 resolved (8 of 8)</li>
<li>[x] Honest about 146-SNP limitation (dedicated section)</li>
<li>[x] Output saved to report/part2_endotype.md</li>
</ul>
<hr>
<h2 id="paradox-resolution-index">PARADOX RESOLUTION INDEX</h2>
<div class="table-wrapper"><table>
<thead><tr>
<th>#</th>
<th>Paradox</th>
<th>Resolution</th>
<th>Module</th>
</tr></thead><tbody>
<tr>
<td>1</td>
<td>IR Score worsening despite weight loss + Mounjaro</td>
<td>Genetic IR floor (PPARG + IRS1) + lipid-weighted scoring + Metformin underdosing</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>Rising Ferritin with low MCHC</td>
<td>Inflammatory iron sequestration (IL-6 GG → hepcidin), not overload</td>
<td>4</td>
</tr>
<tr>
<td>3</td>
<td>FSH suppressed despite menopausal AMH</td>
<td>Iatrogenic suppression from exogenous estrogen + progesterone overcompliance</td>
<td>5</td>
</tr>
<tr>
<td>4</td>
<td>Normal thyroid labs but missing medication</td>
<td>DIO2 CC means serum is misleading for tissue status; requires patient clarification</td>
<td>2</td>
</tr>
<tr>
<td>5</td>
<td>Maximum dysbiosis despite antimicrobial protocols</td>
<td>CYP2R1 GG → vitamin D stuck → LL-37 underpowered; GSTM1 null → hostile gut environment</td>
<td>3</td>
</tr>
<tr>
<td>6</td>
<td>Chronic vitamin D insufficiency despite supplementation</td>
<td>CYP2R1 GG impairs hepatic 25-hydroxylation; needs higher dose or calcifediol</td>
<td>3</td>
</tr>
<tr>
<td>7</td>
<td>MPO improved while fibrinogen rises</td>
<td>Different pathways: MPO = vascular (resolved), fibrinogen = hepatic (IL-6 GG + IR drive)</td>
<td>4</td>
</tr>
<tr>
<td>8</td>
<td>OMICm Age 42 vs Symphony Age 53.1</td>
<td>OMICm reflects Mounjaro metabolic improvement; Symphony (53.1) is more reliable biological age</td>
<td>6</td>
</tr>
</tbody></table></div>
<hr>
<p><em>End of Part 2: Endotype — "The Slow Burn"</em> <em>Part 3 (Recommendations) will translate this mechanistic model into a prioritized, genetically-informed intervention plan.</em></p>
<hr class="part-divider">
</div></details>
<a href="#top" class="back-to-top">&#8593; Back to top</a>
<h1 id="part-3-recommendations">PART 3: RECOMMENDATIONS</h1>
<h2 id="genetically-informed-prioritized-intervention-plan">Genetically-Informed, Prioritized Intervention Plan</h2>
<p><strong>Patient:</strong> Moj Mahdara <strong>Report Generated:</strong> 2026-02-11 <strong>Endotype:</strong> "The Slow Burn" — Multi-System Metabolic Bottleneck <strong>Pipeline Run:</strong> 20260210_Moj</p>
<hr>
<details open><summary>3a. CURRENT PROTOCOL ASSESSMENT</summary><div class="details-content">
<p><strong>Assessment Date:</strong> 2026-02-11 <strong>Framework:</strong> Each item classified by endotype relevance</p>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  CLASSIFICATION KEY                                                          │
├──────────────────────────────────────────────────────────────────────────────┤
│  KEEP         Directly targets an endotype mechanism; correctly formulated  │
│  OK           Supportive/general benefit; may continue but not primary      │
│  PAUSE        Temporarily discontinue during protocol restructuring         │
│  DISCONTINUE  Wrong form, unnecessary, or counterproductive for genetics   │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<pre class="ascii-art">━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="medications">MEDICATIONS</h3>
<pre class="ascii-art">┌────────────────────────────────────┬───────────┬──────────────────────────────────────────────────────────────────────┐
│ MEDICATION                         │ VERDICT   │ RATIONALE                                                            │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Mounjaro (tirzepatide) 15mg/wk    │ KEEP      │ Excellent response (30+ lbs). Addresses PPARG CC + IRS1 CC genetic  │
│                                    │           │ IR via GLP-1/GIP dual agonism. Continue at current dose.            │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Lamotrigine 100mg/day             │ KEEP      │ Mood stabilizer — but MUST increase to prescribed 100mg (currently  │
│ (taking 50mg)                      │           │ only 50mg). Lamotrigine does not burden COMT or NAT2 pathways.     │
│                                    │           │ Underdosing may contribute to mood instability.                     │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Metformin 1000mg/day              │ KEEP      │ Critical for PPARG CC + IRS1 CC genetic IR. MUST increase to       │
│ (taking 500mg)                     │           │ prescribed 1000mg BID. Half-dosing undermines IR management.       │
│                                    │           │ Consider extended-release if GI tolerance is the barrier.           │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Atomoxetine (Strattera) 40mg      │ KEEP      │ Correct switch from Adderall for COMT AA. Strattera is a NRI that  │
│                                    │           │ bypasses COMT-dependent catecholamine release. No dopamine surge   │
│                                    │           │ = no palpitations. Genetically optimal ADHD medication.            │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Alprazolam 0.5mg PRN              │ OK        │ Long-standing PRN use (since 2009). Well-controlled anxiety.       │
│                                    │           │ Monitor: benzodiazepine + GABA stack (Gabatrol) = additive CNS    │
│                                    │           │ depression risk. Consider gradual taper as other interventions     │
│                                    │           │ address root causes (histamine, thyroid, inflammation).            │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Pantoprazole 40mg (GLP-1 days)    │ OK        │ Treats Mounjaro-induced GERD. Monitor: PPI long-term can impair   │
│                                    │           │ B12 absorption (relevant with MTHFR/methylation burden), Mg       │
│                                    │           │ absorption, and iron absorption (worsens inflammatory iron         │
│                                    │           │ pattern). Use only on dosing days as prescribed.                   │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Armour Thyroid (STATUS UNKNOWN)   │ CRITICAL  │ If currently taking: KEEP. DIO2 CC requires T3-containing thyroid  │
│                                    │           │ medication. If stopped: REINSTATE IMMEDIATELY. Levothyroxine-only  │
│                                    │           │ would be inadequate for this genotype. See Protocol #1.            │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Estrace vaginal cream             │ CRITICAL  │ Prescribed but NEVER TAKEN. Severe urethral atrophy documented     │
│ (NEVER TAKEN)                      │           │ by Dr. Kim. Local estrogen is LOW systemic risk. Must address     │
│                                    │           │ compliance barrier. See Protocol #5, Section 5.4.                  │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Cyanocobalamin 1000mcg IM monthly │ DISCONTINUE│ WRONG FORM. Cyanocobalamin requires MTHFR-dependent conversion.  │
│                                    │           │ With MTHFR compound het (44% activity), cyanocobalamin is poorly  │
│                                    │           │ converted. Dr. West recommended MB12 injections 3x/week —        │
│                                    │           │ ⚠ COMPLIANCE UNCONFIRMED. If patient is only getting cyano:      │
│                                    │           │ SWITCH to methylcobalamin or hydroxocobalamin immediately.        │
└────────────────────────────────────┴───────────┴──────────────────────────────────────────────────────────────────────┘</pre>
<pre class="ascii-art">━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="supplements">SUPPLEMENTS</h3>
<pre class="ascii-art">┌────────────────────────────────────┬───────────┬──────────────────────────────────────────────────────────────────────┐
│ SUPPLEMENT                         │ VERDICT   │ RATIONALE                                                            │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ MB12 injections 3x/week           │ KEEP —    │ Dr. West recommended MB12 (methylcobalamin) 3x/week.              │
│ (Dr. West Rx)                      │ IF TAKING │ ⚠ COMPLIANCE UNCONFIRMED — patient self-report lists only          │
│                                    │           │ CYANOCOBALAMIN 1000mcg IM monthly (Dr. Kurtz).                    │
│                                    │           │ Cyanocobalamin is the WRONG form for MTHFR compound het (44%).    │
│                                    │           │ If only cyanocobalamin: SWITCH to methylcobalamin or              │
│                                    │           │ hydroxocobalamin. Step 5 pipeline model (85%) is overstated —    │
│                                    │           │ MTR AA=normal; burden from MTRR AG (low) + TCN2 CG (medium).    │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ MIC injections 3x/week            │ KEEP      │ Methionine/Inositol/Choline — supports methylation cycle.          │
│                                    │           │ Choline compensates for PEMT impairment (COMT AA uses SAM that     │
│                                    │           │ PEMT also needs). Supports bile flow and hepatic detox.            │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Nattokinase 1 cap/day             │ KEEP      │ Fibrinolytic — addresses F2 GA + fibrinogen 427. Part of triple   │
│                                    │           │ anticoagulant protocol. Continue monitoring with D-dimer.          │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Lumbrokinase 3 caps/day           │ KEEP      │ Potent fibrinolytic — complements nattokinase. Essential with      │
│                                    │           │ rising fibrinogen (427) and F2 GA prothrombin variant.             │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Baby Aspirin 81mg                 │ KEEP      │ Antiplatelet — non-overlapping mechanism with fibrinolytics.       │
│                                    │           │ F2 GA warrants antiplatelet + fibrinolytic combination.            │
│                                    │           │ Double when flying is appropriate for thrombotic risk.             │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ DAO Enzyme (before meals)         │ KEEP      │ Directly addresses DAO CG (rs1049793) enzyme deficiency.           │
│                                    │           │ Replaces missing extracellular histamine clearance capacity.       │
│                                    │           │ Increase to before EVERY meal (current dosing may be insufficient).│
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Hist (Quercetin) BID              │ KEEP      │ Mast cell stabilizer — reduces histamine release upstream.         │
│                                    │           │ Addresses chronic IgE elevation (312 IU/mL, 3.6x ULN).           │
│                                    │           │ Synergizes with DAO enzyme for dual histamine management.          │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Omega-3 Fish Oil 2 caps           │ KEEP      │ Anti-inflammatory — addresses IL-6 GG pro-inflammatory genotype.  │
│                                    │           │ FADS1 GT + FADS2 CG = reduced endogenous omega-3 conversion.     │
│                                    │           │ Preformed EPA/DHA bypasses this. Continue.                         │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Inflamafree (Turmeric) BID        │ KEEP      │ Curcumin — potent NF-kB inhibitor. Addresses IL-6 GG + CRP 2.1. │
│                                    │           │ Part of the anti-inflammatory stack that resolved MPO.             │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Black Cumin Seed Oil              │ OK        │ Thymoquinone — anti-inflammatory, some histamine benefit.          │
│                                    │           │ Supportive but not primary mechanism-targeted. May continue.       │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Cholesterol Complete BID          │ KEEP      │ Targets ApoB-driven lipid profile (LDL-P 1649, Pattern B→A).     │
│                                    │           │ LDL-P improving. Continue until cardiovascular reassessment.       │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ DHEA 5mg AM                       │ KEEP      │ DHEA-S declined 66% (217→73). Adrenal precursor support.          │
│                                    │           │ Dose is conservative (5mg); may increase to 10-25mg based on      │
│                                    │           │ repeat DHEA-S levels. Monitor testosterone levels.                 │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Pregnenolone 100mg AM             │ KEEP      │ Excellent recovery: 2.98 → 25.0 (739%). Mother hormone            │
│                                    │           │ supporting downstream cortisol, DHEA, and sex hormones.           │
│                                    │           │ Continue current dose — it is working.                             │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Phosphatidylcholine AM            │ KEEP      │ Provides choline substrate directly — compensates for PEMT        │
│                                    │           │ impairment (SAM diverted to COMT). Supports bile, membranes,     │
│                                    │           │ brain function. Genetically indicated.                             │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Piracetam AM                      │ OK        │ Racetam nootropic — cognitive support. Reasonable given brain     │
│                                    │           │ burden 49.3% and brain age +5.2yr. Not genetically specific.      │
│                                    │           │ May continue if patient perceives benefit.                         │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Brilliant Brain AM                │ OK        │ Nootropic blend — overlaps with Piracetam and Phosphatidylcholine.│
│                                    │           │ Consider consolidating cognitive stack to reduce pill burden.      │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Digestive Enzymes 2 caps TID      │ KEEP      │ Supports nutrient absorption in setting of gut dysbiosis 10/10.  │
│                                    │           │ Continue through gut restoration protocol.                         │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ TBC Probiotic 2 caps nightly      │ PAUSE     │ Current probiotic is fighting a losing battle in a hostile gut    │
│                                    │           │ environment (GSTM1 null, low vitamin D, D. fragilis present).    │
│                                    │           │ PAUSE until gut environment is fixed (Protocol #2), then          │
│                                    │           │ restart with targeted strains (Roseburia, Bifidobacterium,        │
│                                    │           │ butyrate-producers matching deficit profile).                      │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Vitamin D Sun (30) 1-2 caps       │ KEEP BUT  │ Correct target but WRONG DOSE for CYP2R1 GG genotype.            │
│                                    │ MODIFY    │ Current dose insufficient (level stuck at 34-35 for 3+ years).   │
│                                    │           │ Increase to 5000-10000 IU/day OR switch to calcifediol.           │
│                                    │           │ See Protocol #2 for details.                                      │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Vitamin C 1500mg                  │ OK        │ Antioxidant support. GSTO2 AG (rs156697) = medium risk for       │
│                                    │           │ vitamin C recycling. 1500mg is adequate. Continue.                │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Magnesium Citrate 1000mg HS       │ KEEP BUT  │ Magnesium is a COMT cofactor — essential for COMT AA patient.     │
│                                    │ MODIFY    │ However, citrate form is primarily laxative at this dose.         │
│                                    │           │ Split: Mag glycinate 400mg (COMT support, daytime) +             │
│                                    │           │ Mag threonate 200mg (brain, evening) + Mag citrate 400mg         │
│                                    │           │ (bowel, bedtime). See Protocol #3.                                │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Electrolytes (Mg/K/Na blend)      │ OK        │ Supportive — hydration and mineral balance. Continue.             │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Ultimate Recovery (Fish Oil/PREMS)│ OK        │ Overlaps with Omega-3. Consider consolidating to reduce pill      │
│                                    │           │ burden. One high-quality omega-3 product sufficient.              │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Cyclease Menopause                │ OK        │ Homeopathic menopause support. Low risk. May continue if          │
│                                    │           │ patient perceives benefit. Not genetically targeted.              │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Melatonin 5mg nightly             │ OK        │ Sleep support. 5mg is on the higher end — consider reducing to   │
│                                    │           │ 0.5-1mg (physiologic dose). High-dose melatonin can suppress     │
│                                    │           │ endogenous production and interact with hormone balance.          │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Gabatrol 2 caps (30 min pre-bed)  │ OK        │ GABA-based sleep support. Caution: additive with Alprazolam      │
│                                    │           │ (both GABAergic). Monitor for excessive sedation.                 │
│                                    │           │ Consider if needed long-term as anxiety root causes addressed.    │
└────────────────────────────────────┴───────────┴──────────────────────────────────────────────────────────────────────┘</pre>
<pre class="ascii-art">━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="peptide-protocols">PEPTIDE PROTOCOLS</h3>
<pre class="ascii-art">┌────────────────────────────────────┬───────────┬──────────────────────────────────────────────────────────────────────┐
│ PROTOCOL                           │ VERDICT   │ RATIONALE                                                            │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ LL-37 100mcg SC daily             │ KEEP BUT  │ Antimicrobial peptide addressing dysbiosis 10/10. HOWEVER:          │
│                                    │ MODIFY    │ LL-37 requires vitamin D &gt;50 ng/mL for optimal expression.         │
│                                    │           │ At current D level (35), LL-37 is underpowered.                    │
│                                    │           │ MODIFICATION: Raise vitamin D to &gt;50 ng/mL FIRST, then resume     │
│                                    │           │ LL-37 cycling. Bilateral mastectomy noted — maintain caution       │
│                                    │           │ per precautions at proper dosing.                                  │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ CJC 1295 + Ipamorelin             │ OK        │ GH secretagogue — supports body composition. Not genetically       │
│                                    │           │ targeted but synergistic with Mounjaro for body recomposition.    │
│                                    │           │ Monitor IGF-1 levels. Continue if clinician-supervised.            │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ NAD+ 1000mg SC 3x/week           │ OK        │ Supports mitochondrial function. PPARGC1A GG = reduced mito       │
│                                    │           │ biogenesis, so NAD+ supplementation is theoretically supportive.  │
│                                    │           │ Continue if tolerated.                                             │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ MB12 injections 3x/week          │ KEEP —    │ See supplements section above. ⚠ COMPLIANCE UNCONFIRMED.         │
│ (Dr. West Rx)                     │ IF TAKING │ Patient only confirmed cyanocobalamin (Dr. Kurtz).                │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ MIC injections 3x/week           │ KEEP      │ See supplements section above. Supports methylation/choline.      │
└────────────────────────────────────┴───────────┴──────────────────────────────────────────────────────────────────────┘</pre>
<pre class="ascii-art">━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="hormone-therapy">HORMONE THERAPY</h3>
<pre class="ascii-art">┌────────────────────────────────────┬───────────┬──────────────────────────────────────────────────────────────────────┐
│ HORMONE                            │ VERDICT   │ RATIONALE                                                            │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Estradiol patch 0.05mg 2x/week    │ KEEP      │ Transdermal estrogen — appropriate for perimenopause with          │
│                                    │           │ CYP19A1 TT (reduced endogenous production). Transdermal avoids    │
│                                    │           │ first-pass hepatic metabolism — better for clotting risk (F2 GA). │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Biest cream nightly               │ KEEP —    │ Bi-est (estriol + estradiol) — topical. Dr. West Rx.             │
│ (Dr. West Rx)                      │ IF TAKING │ ⚠ COMPLIANCE UNCONFIRMED — not in patient self-report.             │
│                                    │           │ If taking: monitor total estrogen exposure with DUTCH test        │
│                                    │           │ (catechol estrogen ratios given COMT AA slow clearance).          │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Estriol cream                     │ KEEP —    │ Weak topical estrogen — Dr. West Rx.                              │
│ (Dr. West Rx)                      │ IF TAKING │ ⚠ COMPLIANCE UNCONFIRMED — not in patient self-report.             │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Progesterone 100mg SR nightly     │ KEEP BUT  │ Progesterone is needed for endometrial protection (even post-     │
│                                    │ MODIFY    │ menopause) and sleep/mood (GABAergic metabolite allopregnanolone).│
│                                    │           │ MODIFICATION: Switch from continuous (patient takes nightly)       │
│                                    │           │ to CYCLIC dosing: days 10-24 of calendar month ONLY.             │
│                                    │           │ Continuous use is suppressing FSH (12.6 at age 49 with AMH       │
│                                    │           │ &lt;0.08 = iatrogenic suppression) and masking true menopausal      │
│                                    │           │ status. See Protocol #5.                                          │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Testosterone cream 0.2ml daily    │ KEEP      │ Supports libido, cognition, muscle mass. SHBG CC + CC (both       │
│                                    │           │ no_impact) = normal binding. Continue and monitor levels.          │
├────────────────────────────────────┼───────────┼──────────────────────────────────────────────────────────────────────┤
│ Estrace vaginal cream             │ CRITICAL  │ See medications section — MUST ADDRESS non-compliance.             │
│ (NEVER TAKEN)                      │           │ Severe urethral atrophy will NOT resolve without local estrogen.  │
└────────────────────────────────────┴───────────┴──────────────────────────────────────────────────────────────────────┘</pre>
<pre class="ascii-art">━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="assessment-summary">ASSESSMENT SUMMARY</h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  ASSESSMENT TOTALS                                                           │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  KEEP:          21 items (core protocol — genetically supported)            │
│  KEEP+MODIFY:    5 items (right target, wrong form/dose/schedule)           │
│  OK:            11 items (supportive, may continue)                         │
│  PAUSE:          1 item  (TBC Probiotic — environment not ready)           │
│  DISCONTINUE:    1 item  (Cyanocobalamin — wrong form)                     │
│  CRITICAL:       2 items (Armour Thyroid status, Estrace compliance)       │
│                                                                              │
│  IMMEDIATE ACTIONS REQUIRED:                                                │
│  1. Confirm Armour Thyroid status → reinstate if not taking                │
│  2. Increase Metformin to full 1000mg/day                                  │
│  3. Increase Lamotrigine to prescribed 100mg/day                           │
│  4. Address Estrace vaginal cream non-compliance                           │
│  5. Switch progesterone to cyclic dosing (days 10-24)                      │
│  6. Discontinue cyanocobalamin IM (WRONG form for MTHFR compound het)     │
│  7. Increase vitamin D dosing for CYP2R1 GG                               │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<hr>
</div></details>
<a href="#top" class="back-to-top">&#8593; Back to top</a>
<details open><summary>3b. NEW RECOMMENDATIONS BY PROTOCOL</summary><div class="details-content">
<p><strong>Protocols are ranked by mechanistic impact on the endotype model. Each protocol addresses one or more modules from Part 2.</strong></p>
<pre class="ascii-art">━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="impact-rank-1-thyroid-metabolic-resolution-protocol">IMPACT RANK #1 — THYROID-METABOLIC RESOLUTION PROTOCOL</h3>
<p><strong>Module:</strong> 2 (The Thyroid-Metabolic Trap) <strong>Priority:</strong> CRITICAL — This is the single highest-impact intervention</p>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  WHY THIS MATTERS                                                            │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  DIO2 CC genotype (rs225014) impairs tissue-level T4→T3 conversion to      │
│  ~60% of normal. This means:                                                │
│  • Serum thyroid labs can appear NORMAL while brain, muscle, gut, and      │
│    fat tissue remain functionally hypothyroid                               │
│  • Standard levothyroxine (T4 only) is INADEQUATE for this genotype        │
│  • Tissue hypothyroidism drives: ↓BMR → weight resistance, ↓gut motility │
│    → dysbiosis, ↓brain T3 → brain fog, ↓lipid clearance → LDL-P          │
│                                                                              │
│  BIOMARKER EVIDENCE:                                                        │
│  • TSH 1.24 (normal) — but misleading for DIO2 CC                         │
│  • FT3 3.2 pg/mL (mid-range) — tissue T3 may be lower                    │
│  • IR Score rising (42→48) despite weight loss — thyroid contributes      │
│  • Brain age +5.2yr — partially thyroid-driven                             │
│                                                                              │
│  GENETIC EVIDENCE:                                                          │
│  • DIO2 CC = ~60% T4→T3 conversion                                        │
│  • PPARG CC + IRS1 CC = genetic IR amplified by hypothyroid state          │
│  • PPARGC1A GG = reduced mitochondrial biogenesis (thyroid-dependent)      │
│                                                                              │
│  COMBINED MECHANISM:                                                        │
│  DIO2 CC tissue hypothyroidism → ↓BMR → insulin resistance worsens       │
│  → inflammation increases → DIO2 further inhibited by inflammation        │
│  → THE TRAP TIGHTENS                                                       │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<p><strong>PRIMARY INTERVENTIONS:</strong></p>
<ul>
<li><strong>Armour Thyroid (desiccated thyroid) or compounded T4/T3 combination</strong> — RX</li>
</ul>
<p>Form: T4 + T3 combination (NOT levothyroxine alone) WHY this form: DIO2 CC cannot adequately convert T4→T3. Must provide T3 directly. Rationale: If currently taking Armour, continue. If stopped, reinstate immediately. Consider dose optimization with reverse T3 testing. Dose: Determined by prescribing physician based on current status; typical Armour starting dose 30-60mg (0.5-1 grain), titrate by symptoms + FT3 levels. Timing: AM, empty stomach, 30-60 min before food/coffee/supplements.</p>
<ul>
<li><strong>Metformin Extended-Release</strong> — 1000mg/day (increase from current 500mg) — RX</li>
</ul>
<p>Form: Extended-release formulation WHY this form: ER reduces GI side effects (the likely barrier to full-dose compliance). NAT2 Slow acetylator status means drug clearance is slower — start at 500mg ER BID and titrate. Rationale: PPARG CC + IRS1 CC = genetic insulin resistance with an irreducible floor. Full-dose Metformin provides maximum insulin-sensitizing support. Timing: 500mg with breakfast, 500mg with dinner.</p>
<p><strong>SUPPORTING STACK:</strong></p>
<ul>
<li><strong>Berberine</strong> — 500mg BID with meals</li>
</ul>
<p>Rationale: Synergistic insulin-sensitizing mechanism with Metformin (AMPK activation). 3x4 Genetics recommends for glucose_insulin pathway (VERY_HIGH risk). Timing: With breakfast and dinner (separate from Metformin by 2 hours if GI sensitive). Note: TIER 2 — add after Metformin is at full dose and tolerated.</p>
<ul>
<li><strong>Chromium picolinate</strong> — 200mcg daily</li>
</ul>
<p>Rationale: GTF chromium enhances insulin receptor sensitivity. 3x4 Genetics recommends for glucose_insulin pathway. Timing: With breakfast.</p>
<p><strong>GATES / SEQUENCING:</strong></p>
<ol>
<li>GATE 1: Confirm thyroid medication status with patient (BEFORE any protocol changes)</li>
<li>GATE 2: If Armour discontinued, obtain full thyroid panel (TSH, FT3, FT4, reverse T3, TPO Ab, TgAb) BEFORE restarting</li>
<li>Metformin increase can proceed immediately (switch to ER formulation if GI intolerance caused underdosing)</li>
<li>Berberine: add ONLY after Metformin at full dose for 2+ weeks</li>
</ol>
<p><strong>MONITORING:</strong></p>
<ul>
<li>Thyroid panel (TSH, FT3, FT4, reverse T3) at 6 weeks, 12 weeks, then every 3 months</li>
<li>IR Score recheck at 3 months (expect improvement with full-dose Metformin + thyroid optimization)</li>
<li>Fasting insulin and HOMA-IR at 3 months</li>
<li>Expected timeline: 6-12 weeks for metabolic parameters to shift; brain fog improvement may lag by 8-16 weeks</li>
<li>Red flags: Palpitations, tremor, insomnia (thyroid overdose); GI distress, lactic acidosis symptoms (Metformin)</li>
</ul>
<pre class="ascii-art">━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="impact-rank-2-gut-environment-restoration-protocol">IMPACT RANK #2 — GUT ENVIRONMENT RESTORATION PROTOCOL</h3>
<p><strong>Module:</strong> 3 (The Gut-Immune Breach) <strong>Priority:</strong> HIGH — Environment must be fixed before microbiome can recover</p>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  WHY THIS MATTERS                                                            │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  Dysbiosis 10/10 MAXIMUM with Dientamoeba fragilis, multiple commensals   │
│  critically depleted, SCFA deficit, and Bacillus overgrowth — DESPITE      │
│  LL-37, antifungal protocols, probiotics, digestive enzymes.                │
│                                                                              │
│  The treatments fail because the ENVIRONMENT is hostile:                    │
│  • CYP2R1 GG → vitamin D stuck at 35 → LL-37 underpowered                │
│  • GSTM1 null → gut epithelial detox ABSENT → hostile to commensals       │
│  • DIO2 CC → ↓gut motility → bacterial stasis → overgrowth               │
│  • Low butyrate (3.4) → weakened tight junctions → permeability           │
│                                                                              │
│  SEQUENCE IS CRITICAL:                                                      │
│  Fix environment → Eradicate parasites → THEN rebuild microbiome          │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<p><strong>PRIMARY INTERVENTIONS:</strong></p>
<p><strong>Phase A: Fix the Environment (Weeks 1-8)</strong></p>
<ul>
<li><strong>Vitamin D3 high-dose</strong> — 10,000 IU/day for 8 weeks, then retest</li>
</ul>
<p>Form: Cholecalciferol with K2 (MK-7), or preferably <strong>calcifediol (25-OH-D3)</strong> 20mcg/day WHY calcifediol: CYP2R1 GG impairs hepatic 25-hydroxylation. Calcifediol BYPASSES this bottleneck entirely, delivering the measured form (25-OH-D) directly. If calcifediol unavailable: D3 10,000 IU/day with K2 200mcg to override the CYP2R1 bottleneck. Rationale: Target 25-OH-D &gt;50 ng/mL (currently 35). LL-37 expression requires &gt;50 for optimal antimicrobial activity. Also supports immune surveillance, calcium metabolism, and mood. Timing: AM, with fat-containing meal (fat-soluble vitamin).</p>
<ul>
<li><strong>N-Acetyl Cysteine (NAC)</strong> — 600mg BID</li>
</ul>
<p>Form: Standard NAC capsules WHY NAC: GSTM1 null = Phase II glutathione conjugation ABSENT. NAC provides cysteine substrate for glutathione synthesis via the transsulfuration pathway (67.8% burden from MTHFR cascade). Direct glutathione precursor. Rationale: Compensates for GSTM1 null by increasing glutathione substrate supply. Supports gut epithelial detoxification, hepatic clearance, and mucosal protection. Timing: 600mg AM empty stomach, 600mg PM empty stomach.</p>
<ul>
<li><strong>Liposomal Glutathione</strong> — 250mg daily</li>
</ul>
<p>Form: Liposomal (NOT reduced glutathione capsules — poor oral bioavailability) WHY liposomal: GSTM1 null means she cannot efficiently USE glutathione for conjugation. Must provide high-bioavailability form directly. Combined with NAC (substrate) — dual approach. Rationale: Directly replaces the missing GSTM1 detoxification capacity at the gut epithelial level. Timing: AM, empty stomach, away from other supplements.</p>
<p><strong>Phase B: Eradicate Parasites (Weeks 4-8, overlapping)</strong></p>
<ul>
<li><strong>Dientamoeba fragilis treatment</strong> — RX</li>
</ul>
<p>Options: Metronidazole 400mg TID x 10 days OR Iodoquinol 650mg TID x 20 days OR Paromomycin 500mg TID x 10 days Rationale: D. fragilis detected at 4.07e2 copies/µL. Pathogenic status debated but in context of dysbiosis 10/10 and symptomatic gut dysfunction, eradication indicated. Must coordinate with prescribing physician. Note: NAT2 Slow acetylator — drug clearance may be slower. Start at standard dose, monitor for side effects.</p>
<p><strong>Phase C: Rebuild Microbiome (Weeks 8-20, after environment restoration)</strong></p>
<ul>
<li><strong>Targeted Probiotic Protocol</strong> — species-specific to deficits</li>
</ul>
<p>Form: Multi-strain formulation emphasizing Bifidobacterium (↓69.6%), Roseburia-supporting prebiotics (↓82%), butyrate-producing species Rationale: Matching supplementation to measured deficits. Generic probiotics have failed — targeted approach based on GI Effects stool analysis results. Timing: Evening, away from antimicrobials. Note: PAUSE current TBC Probiotic during Phases A-B. Restart with targeted formulation in Phase C.</p>
<ul>
<li><strong>Butyrate supplement</strong> — 300-600mg tributyrin BID</li>
</ul>
<p>Form: Tributyrin (CoreBiome) — more stable than sodium butyrate Rationale: Total SCFA 19.3 (ref ≥23.3), n-Butyrate 3.4 (ref &gt;3.6). Butyrate is primary fuel for enterocytes. Supports tight junction integrity and anti-inflammatory signaling. Directly addresses measured deficit. Timing: With meals.</p>
<p><strong>SUPPORTING STACK:</strong></p>
<ul>
<li><strong>Saccharomyces boulardii</strong> — 5 billion CFU BID</li>
</ul>
<p>Rationale: Probiotic yeast — resistant to antibiotics. Supports gut barrier during antiparasitic treatment. Anti-inflammatory. Timing: During and after Phase B.</p>
<p><strong>GATES / SEQUENCING:</strong></p>
<ol>
<li>Weeks 1-4: Start vitamin D high-dose + NAC + liposomal glutathione (fix environment)</li>
<li>Weeks 4-8: Add antiparasitic for D. fragilis (physician-coordinated)</li>
<li>Week 4: Retest vitamin D — if >50, resume LL-37 cycling (optimized environment)</li>
<li>Weeks 8+: Discontinue antiparasitic, start targeted probiotic + butyrate</li>
<li>GATE: Do NOT restart LL-37 until vitamin D >50 ng/mL</li>
</ol>
<p><strong>MONITORING:</strong></p>
<ul>
<li>Vitamin D (25-OH-D) at 4 weeks and 8 weeks — target >50 ng/mL</li>
<li>Repeat GI Effects stool test at 4-6 months (assess dysbiosis score, D. fragilis clearance, commensal recovery)</li>
<li>Glutathione levels (if available) at 8 weeks</li>
<li>Expected timeline: 3-6 months for meaningful dysbiosis improvement</li>
<li>Red flags: Herxheimer reaction during antiparasitic (increased inflammation temporarily); vitamin D toxicity (>100 ng/mL, hypercalcemia)</li>
</ul>
<pre class="ascii-art">━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="impact-rank-3-methylation-detox-optimization-protocol">IMPACT RANK #3 — METHYLATION &amp; DETOX OPTIMIZATION PROTOCOL</h3>
<p><strong>Module:</strong> 1 (Genetic Slow Architecture) <strong>Priority:</strong> HIGH — Upstream bottleneck affects all downstream modules</p>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  WHY THIS MATTERS                                                            │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  MTHFR compound het (C677T CT + A1298C AC) = 44.2% enzyme activity         │
│  Step 5 burden = 85% pipeline model (⚠ MTR AA=normal; MTRR/TCN2 only)  │
│  COMT AA = ~25% catecholamine clearance speed                               │
│  GSTM1 null = 0% Phase II glutathione conjugation                          │
│                                                                              │
│  Methylation throughput directly affects:                                    │
│  • SAM supply → COMT function → neurotransmitter/estrogen clearance       │
│  • PEMT → phosphatidylcholine → bile/membranes                            │
│  • CBS → cysteine → glutathione (already nulled by GSTM1)                │
│  • DNA methylation → epigenetic aging (brain +5.2yr)                      │
│                                                                              │
│  CRITICAL NUANCE FOR COMT AA:                                              │
│  Too much methyl donor support can OVERWHELM slow COMT — causing          │
│  anxiety, insomnia, irritability. START LOW, TITRATE SLOWLY.              │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<p><strong>PRIMARY INTERVENTIONS:</strong></p>
<ul>
<li><strong>B12 form optimization</strong> — Switch to <strong>Hydroxocobalamin</strong> injections 3x/week (⚠ MB12 compliance unconfirmed — patient confirmed only cyanocobalamin IM monthly from Dr. Kurtz)</li>
</ul>
<p>Form: Hydroxocobalamin (NOT methylcobalamin, NOT cyanocobalamin) WHY hydroxocobalamin: COMT AA (slow) means excess methyl groups accumulate. Methylcobalamin provides a methyl group with every injection — this can overwhelm COMT and cause anxiety/irritability. Hydroxocobalamin provides B12 without additional methyl burden. The body converts it to the needed form (methyl or adenosyl) as needed. This is the GENETICALLY OPTIMAL form for COMT AA + MTHFR compound het. Dose: 1000mcg IM or SC 3x/week (same schedule as current MB12) Timing: Continue current schedule. Note: DISCONTINUE separate cyanocobalamin IM monthly. Hydroxocobalamin replaces both.</p>
<ul>
<li><strong>5-MTHF (Methylfolate)</strong> — Start 200mcg/day, titrate to 400-800mcg over 4 weeks</li>
</ul>
<p>Form: L-5-Methyltetrahydrofolate (Quatrefolic or Metafolin brands) WHY methylfolate: MTHFR compound het (44% activity) cannot adequately convert folic acid or dihydrofolate to the active 5-MTHF form. Must provide end product directly. WHY start low: COMT AA means methylation support must be titrated carefully. Sudden methylfolate increase → SAM spike → COMT overwhelm → anxiety. Dose: 200mcg x 2 weeks → 400mcg x 2 weeks → 800mcg maintenance (if tolerated) Timing: AM, with food. Red flags: Anxiety, irritability, insomnia = too much too fast → reduce dose.</p>
<ul>
<li><strong>Riboflavin (B2)</strong> — 25mg daily</li>
</ul>
<p>Form: Riboflavin-5'-phosphate (active R5P form) WHY R5P: MTHFR is a flavin-dependent enzyme. R5P is the cofactor. Providing the active form ensures MTHFR has adequate cofactor to function at its remaining 44% capacity. Timing: AM, with food.</p>
<ul>
<li><strong>P5P (Pyridoxal-5'-Phosphate, active B6)</strong> — 25-50mg daily</li>
</ul>
<p>Form: P5P (NOT pyridoxine HCl) WHY P5P: Active form bypasses conversion step. Cofactor for CBS (transsulfuration → glutathione) and multiple aminotransferases. Supports serotonin/dopamine synthesis. Timing: AM, with food.</p>
<p><strong>SUPPORTING STACK:</strong></p>
<ul>
<li><strong>Magnesium glycinate</strong> — 400mg daily (daytime, split AM/PM)</li>
</ul>
<p>Rationale: Magnesium is a critical COMT cofactor. COMT AA patient needs optimal magnesium status for even the ~25% enzyme activity to function. Glycinate form has superior bioavailability and calming effect. Timing: 200mg AM, 200mg PM.</p>
<ul>
<li><strong>TMG (Trimethylglycine / Betaine)</strong> — 500mg daily</li>
</ul>
<p>Rationale: Alternative methyl donor via BHMT pathway (bypasses MTHFR entirely). Provides methylation support without the MTHFR bottleneck. BHMT GG (rs3733890, no_impact) = pathway is intact and can be leveraged. Timing: AM, with food. Note: TIER 2 — add after B12 switch and methylfolate are established.</p>
<p><strong>GATES / SEQUENCING:</strong></p>
<ol>
<li>Week 1: Switch to hydroxocobalamin injections (⚠ MB12 compliance unconfirmed — may need to START, not switch); add R5P 25mg and P5P 25mg</li>
<li>Week 2: Start 5-MTHF at 200mcg/day</li>
<li>Week 4: If tolerated, increase 5-MTHF to 400mcg</li>
<li>Week 6: If tolerated, increase 5-MTHF to 800mcg; add TMG 500mg</li>
<li>Week 8: Reassess — check homocysteine, methylmalonic acid</li>
<li>COMT AA RULE: If anxiety/irritability emerge at ANY step, hold dose for 1 week then retry at previous level</li>
</ol>
<p><strong>MONITORING:</strong></p>
<ul>
<li>Homocysteine at baseline and 8 weeks (currently 9.0 Dec 2025, UP from 7.0 Nov 2024 — monitor)</li>
<li>Methylmalonic acid at 8 weeks (B12 functional status)</li>
<li>Patient symptom journal: track anxiety, irritability, sleep quality, energy (COMT AA sensitivity indicators)</li>
<li>Expected timeline: 4-8 weeks for energy/cognitive changes; full methylation optimization 3-6 months</li>
<li>Red flags: Homocysteine <5.0 (over-methylation); anxiety/insomnia (COMT overwhelm)</li>
</ul>
<pre class="ascii-art">━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="impact-rank-4-cardiovascular-protection-protocol">IMPACT RANK #4 — CARDIOVASCULAR PROTECTION PROTOCOL</h3>
<p><strong>Module:</strong> 4 (The Cardiovascular Cascade) <strong>Priority:</strong> HIGH — Rising fibrinogen + F2 GA = increasing thrombotic risk</p>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  WHY THIS MATTERS                                                            │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  CONVERGING GENETIC CV RISK:                                                │
│  • ApoB gene defect → LDL-P 1649 (45% above limit), Pattern B            │
│  • F2 GA (prothrombin 20210) → enhanced clotting tendency                  │
│  • IL-6 GG → constitutive overproduction → CRP 2.1, fibrinogen 427       │
│  • PPARG CC + IRS1 CC → hepatic IR → VLDL overproduction                  │
│  • GSTM1 null → reduced vascular antioxidant protection                   │
│                                                                              │
│  IMPROVING: LDL-P (2023→1649), LDL Small (428→291), MPO (&gt;5351→327)      │
│  WORSENING: Fibrinogen (386→427), Ferritin (97→209)                       │
│  STABLE: CRP 2.1 (improved from 4.1 but still elevated)                   │
│                                                                              │
│  Current triple anticoagulant (Nattokinase + Lumbrokinase + ASA) is       │
│  appropriate and should continue. Focus additions on the HEPATIC           │
│  inflammatory arm (fibrinogen/ferritin) which is the worsening vector.    │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<p><strong>PRIMARY INTERVENTIONS (additions to existing protocol):</strong></p>
<ul>
<li><strong>EPA-dominant Omega-3</strong> — Increase to 2000mg EPA + 1000mg DHA daily</li>
</ul>
<p>Form: High-EPA fish oil concentrate (e.g., EPA:DHA ratio ≥2:1) WHY EPA-dominant: EPA has superior anti-inflammatory and triglyceride-lowering effects vs DHA. FADS1 GT + FADS2 CG = reduced endogenous conversion. Needs preformed long-chain omega-3s. Rationale: Consolidate current omega-3 products (2 caps fish oil + Ultimate Recovery) into one high-potency EPA-dominant product. Reduces pill burden while increasing therapeutic dose. Timing: With dinner (fat-containing meal).</p>
<ul>
<li><strong>Niacin (Vitamin B3)</strong> — 500mg extended-release daily</li>
</ul>
<p>Form: Extended-release niacin (NOT niacinamide, NOT immediate-release) WHY: Niacin raises HDL, shifts LDL pattern B→A, and lowers LDL-P — precisely her lipid defects. ER form minimizes flushing. LDL Peak Size 219.2 (ref &gt;222.9) is ALMOST at Pattern A threshold — niacin can push it over. Rationale: ApoB-driven lipid profile with near-threshold Pattern B→A transition. Niacin addresses the pattern shift directly. Timing: PM, with food. Start at 250mg x 2 weeks, then 500mg. Caution: Monitor liver enzymes (NAT2 Slow affects drug clearance). Monitor glucose (can worsen insulin resistance at high doses — keep at 500mg).</p>
<p><strong>SUPPORTING STACK (continue existing):</strong></p>
<ul>
<li>Nattokinase 1 cap/day — KEEP</li>
<li>Lumbrokinase 3 caps/day — KEEP</li>
<li>Baby Aspirin 81mg — KEEP</li>
<li>Cholesterol Complete BID — KEEP</li>
<li>Inflamafree (turmeric) BID — KEEP</li>
</ul>
<p><strong>GATES / SEQUENCING:</strong></p>
<ol>
<li>Consolidate omega-3 products immediately (replace current 2-3 products with one high-potency EPA-dominant)</li>
<li>Niacin ER: Start at 250mg for 2 weeks, increase to 500mg. TIER 2 (after thyroid/metabolic protocol established)</li>
<li>Full-dose Metformin (Protocol #1) reduces hepatic IR → reduces fibrinogen production. These protocols synergize.</li>
</ol>
<p><strong>MONITORING:</strong></p>
<ul>
<li>Full lipid panel with LDL-P, LDL Small, LDL Peak Size at 3 months</li>
<li>Fibrinogen and D-dimer at 3-month intervals (given F2 GA + rising fibrinogen)</li>
<li>Ferritin + CRP at 3 months (inflammatory iron pattern tracking)</li>
<li>hs-CRP at 3 months</li>
<li>Expected timeline: LDL pattern shift B→A within 3-6 months if niacin + thyroid optimization; fibrinogen reduction depends on inflammation control</li>
<li>Red flags: Flushing (niacin — take with aspirin 30 min prior); unexplained bruising/bleeding (triple anticoagulant monitoring); ferritin >300 (investigate further)</li>
</ul>
<pre class="ascii-art">━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="impact-rank-5-hormonal-optimization-protocol">IMPACT RANK #5 — HORMONAL OPTIMIZATION PROTOCOL</h3>
<p><strong>Module:</strong> 5 (The Hormonal Dimming) <strong>Priority:</strong> MEDIUM-HIGH — Compliance issues undermining effective HRT</p>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  WHY THIS MATTERS                                                            │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  CYP19A1 TT → reduced aromatase → lower endogenous estrogen production   │
│  COMT AA → slow estrogen clearance → catechol estrogen accumulation risk  │
│  AMH &lt;0.08 → ovarian exhaustion (menopausal range)                        │
│  FSH 12.6 → suppressed (should be &gt;40 at this AMH level)                 │
│  DHEA-S 73 → 66% decline (adrenal depletion)                             │
│  Estrace vaginal cream → NEVER TAKEN (severe atrophy untreated)          │
│  Progesterone → Overcompliance (continuous vs cyclic prescribed)          │
│                                                                              │
│  The HRT framework is CORRECT but execution is FLAWED.                    │
│  Key actions are behavioral/compliance-based, not new supplements.         │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<p><strong>PRIMARY INTERVENTIONS:</strong></p>
<ul>
<li><strong>Progesterone 100mg SR — SWITCH to CYCLIC dosing</strong> — Days 10-24 only</li>
</ul>
<p>Form: Same sustained-release progesterone WHY cyclic: Continuous progesterone is suppressing FSH (12.6 at age 49 with AMH &lt;0.08 = iatrogenic). Cyclic dosing mimics physiologic luteal phase, allows FSH to rise during off-days for accurate hormonal staging, and prevents tonic GnRH suppression. Rationale: Until FSH is allowed to rise, true menopausal status is masked and HRT dosing cannot be properly titrated. Timing: Days 10-24 of calendar month, at bedtime (GABAergic metabolite supports sleep).</p>
<ul>
<li><strong>Estrace vaginal cream — ADDRESS COMPLIANCE</strong> — 1gm vaginally nightly x 7, then every other night</li>
</ul>
<p>Form: Estradiol 0.01% vaginal cream. If application is the barrier, alternatives: DHEA vaginal suppository (Intrarosa), estriol vaginal tablet, or hyaluronic acid vaginal moisturizer as bridge. WHY this matters: Severe urethral atrophy documented on cystoscopy. Bulkamid addressed incontinence mechanically but tissue atrophy persists. LOCAL estrogen has minimal systemic absorption — different risk profile than systemic HRT. Rationale: The atrophy will not resolve without local estrogen. Bilateral mastectomy history does not contraindicate LOCAL vaginal estrogen at this low dose. Note: CRITICAL — discuss with patient what barrier prevents compliance and offer alternative formulations.</p>
<ul>
<li><strong>DHEA dose optimization</strong> — Consider increasing from 5mg to 10-25mg based on DHEA-S recheck</li>
</ul>
<p>Form: Micronized DHEA Rationale: DHEA-S declined 66% (217→73). Current 5mg may be insufficient to meaningfully restore levels. Titrate based on DHEA-S, testosterone, and estrogen levels at next lab draw. Timing: AM (DHEA follows cortisol circadian rhythm).</p>
<p><strong>SUPPORTING STACK (continue existing):</strong></p>
<ul>
<li>Estradiol patch 0.05mg 2x/week — KEEP (transdermal better than oral for F2 GA clotting risk)</li>
<li>Biest cream nightly — KEEP IF TAKING (Dr. West Rx — ⚠ COMPLIANCE UNCONFIRMED)</li>
<li>Pregnenolone 100mg AM — KEEP (excellent recovery from 2.98 to 25.0)</li>
<li>Testosterone cream 0.2ml daily — KEEP</li>
</ul>
<p><strong>GATES / SEQUENCING:</strong></p>
<ol>
<li>Switch progesterone to cyclic IMMEDIATELY (patient education required)</li>
<li>Address Estrace compliance at next clinical visit — identify barrier, offer alternatives</li>
<li>DHEA dose adjustment after DHEA-S recheck at 4-8 weeks</li>
<li>DUTCH Complete test BEFORE any further HRT dose changes (need estrogen metabolite ratios given COMT AA slow clearance)</li>
</ol>
<p><strong>MONITORING:</strong></p>
<ul>
<li>FSH/LH recheck 4 weeks AFTER progesterone switch to cyclic (unmask true menopausal FSH)</li>
<li>DHEA-S, total and free testosterone at 8 weeks</li>
<li>DUTCH Complete hormone panel — CRITICAL for estrogen metabolite assessment (2-OH:4-OH:16α-OH ratios given COMT AA)</li>
<li>Expected timeline: FSH will rise within 1-2 cycles after progesterone correction; Estrace effects on atrophy within 4-8 weeks</li>
<li>Red flags: Vaginal bleeding (adjusting HRT may unmask withdrawal bleed — expected initially); breast tenderness (monitor with bilateral mastectomy history)</li>
</ul>
<pre class="ascii-art">━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="impact-rank-6-neurocognitive-support-protocol">IMPACT RANK #6 — NEUROCOGNITIVE SUPPORT PROTOCOL</h3>
<p><strong>Module:</strong> 6 (The Foggy Processor) <strong>Priority:</strong> MEDIUM — Brain fog resolves DOWNSTREAM of Modules 1-5</p>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  WHY THIS MATTERS                                                            │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  Brain fog is the FINAL COMMON PATHWAY of all 5 preceding modules:        │
│  • DIO2 CC → brain T3 deficit (Module 2)                                  │
│  • COMT AA + MAOA TT → neurotransmitter processing jam (Module 1)        │
│  • HNMT AA + DAO CG → histamine in brain (Module 3)                      │
│  • CRP 2.1 + IL-6 GG → neuroinflammation (Module 4)                     │
│  • Estrogen decline → lost neuroprotection (Module 5)                     │
│  • MTHFR 44% + Step 5 85% (pipeline model) → reduced NT synthesis (M1)  │
│                                                                              │
│  Brain age: 54.2 (+5.2yr) — WORST organ age                               │
│  Serotonin: 48 ng/mL (LOW, ref 56-244)                                    │
│  Neurotransmitter burden: 36.4% with brain burden 49.3%                    │
│                                                                              │
│  Most brain fog improvement will come from Protocols #1-5.                 │
│  This protocol adds TARGETED neurocognitive support on top.               │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<p><strong>PRIMARY INTERVENTIONS:</strong></p>
<ul>
<li><strong>Magnesium L-Threonate</strong> — 144mg elemental Mg (as ~2000mg Magtein) nightly</li>
</ul>
<p>Form: Magnesium L-Threonate (Magtein) WHY this form: Only magnesium form demonstrated to cross BBB and increase brain magnesium. COMT AA patient needs magnesium as COMT cofactor in the brain specifically. Rationale: Supports COMT function in CNS, NMDA receptor modulation, and cognitive function. Replaces part of the 1000mg Mag Citrate bedtime dose. Timing: Evening, 1-2 hours before bed. Combine with reduced Mag Citrate 400mg.</p>
<ul>
<li><strong>Phosphatidylserine (PS)</strong> — 200mg daily</li>
</ul>
<p>Form: Soy-free phosphatidylserine Rationale: Supports cortisol regulation, membrane fluidity, and cognitive function. 3x4 Genetics suggests for mood_behavior pathway (HIGH risk). Brain age +5.2yr suggests membrane integrity support needed. Timing: AM or early PM (can support cortisol rhythm).</p>
<ul>
<li><strong>5-HTP</strong> — 50mg at bedtime (start low)</li>
</ul>
<p>Form: Griffonia simplicifolia extract WHY: Serotonin 48 ng/mL (LOW, ref 56-244). 5-HTP is the immediate precursor to serotonin (bypasses rate-limiting tryptophan hydroxylase). HTR1A GG = reduced serotonin receptor sensitivity, so optimizing serotonin levels is important. CAUTION FOR MAOA TT: MAOA variant affects monoamine metabolism. Start at 50mg and titrate cautiously. Do NOT combine with SSRIs. Lamotrigine is not serotonergic so no interaction concern. Timing: Bedtime (serotonin → melatonin conversion supports sleep). Note: TIER 2 — add after methylation protocol established (B6/P5P is a cofactor for aromatic amino acid decarboxylase that converts 5-HTP → serotonin).</p>
<p><strong>SUPPORTING STACK (continue and optimize existing):</strong></p>
<ul>
<li>Phosphatidylcholine AM — KEEP (membrane support, PEMT compensation)</li>
<li>Piracetam AM — OK to continue</li>
<li>Brilliant Brain AM — OK but consider consolidating with above</li>
<li>Strattera 40mg — KEEP (correct for COMT AA)</li>
</ul>
<p><strong>GATES / SEQUENCING:</strong></p>
<ol>
<li>Mag Threonate: Start immediately alongside Protocols #1-3</li>
<li>Phosphatidylserine: Start with Mag Threonate</li>
<li>5-HTP: TIER 2 — add only AFTER P5P (Protocol #3) is established for 2+ weeks AND thyroid optimization (Protocol #1) is underway</li>
<li>Reassess cognitive stack at 8 weeks — consolidate if improvements allow reduction</li>
</ol>
<p><strong>MONITORING:</strong></p>
<ul>
<li>Subjective brain fog tracking (1-10 scale daily)</li>
<li>Serotonin recheck at 3-6 months (if available)</li>
<li>TruAge brain organ age recheck at 6-12 months</li>
<li>Expected timeline: Gradual improvement over 3-6 months as upstream modules are addressed. Brain fog is the LAST thing to resolve.</li>
<li>Red flags: Serotonin syndrome symptoms (agitation, hyperthermia, tachycardia — extremely unlikely at 50mg 5-HTP alone but monitor); excessive sedation from Mag Threonate + Gabatrol + Alprazolam stack</li>
</ul>
<pre class="ascii-art">━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="impact-rank-7-histamine-management-protocol">IMPACT RANK #7 — HISTAMINE MANAGEMENT PROTOCOL</h3>
<p><strong>Module:</strong> 3 (cross-cutting with Module 6) <strong>Priority:</strong> MEDIUM — Ongoing symptom management while root causes addressed</p>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  WHY THIS MATTERS                                                            │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  HNMT AA (rs11558538) → ~60% intracellular histamine clearance             │
│  DAO CG (rs1049793) → ~75% extracellular histamine clearance               │
│  Total IgE: 312 IU/mL (3.6x ULN) → chronic allergic histamine load       │
│  Dust mite: Class IV (D. pteronyssinus 10.5 kU/L)                         │
│  Gut dysbiosis 10/10 → histamine-producing bacteria                        │
│                                                                              │
│  DUAL GENETIC IMPAIRMENT + environmental/gut histamine sources            │
│  = histamine bucket is always near overflow                                │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<p><strong>PRIMARY INTERVENTIONS:</strong></p>
<ul>
<li><strong>DAO Enzyme</strong> — Increase to before EVERY meal (currently may be once daily)</li>
</ul>
<p>Form: Diamine oxidase supplement (HistDAO or similar) Rationale: DAO CG = reduced enzyme. Exogenous DAO before meals breaks down dietary histamine in gut lumen before absorption. Simple, direct genetic compensation. Timing: 15 minutes before each meal.</p>
<ul>
<li><strong>Quercetin</strong> — Continue BID; consider increasing to 500mg BID</li>
</ul>
<p>Form: Quercetin phytosome (enhanced bioavailability) or standard quercetin Rationale: Mast cell stabilizer — reduces histamine release from IgE-mediated degranulation. Addresses the Total IgE 312 / dust mite Class IV allergic drive. Timing: BID, with meals.</p>
<ul>
<li><strong>Environmental Dust Mite Reduction</strong> — Lifestyle intervention</li>
</ul>
<p>Rationale: Class IV dust mite sensitization (10.5 kU/L) is a major chronic histamine trigger. Environmental control reduces the load on impaired HNMT/DAO clearance pathways. Actions: Allergen-proof mattress/pillow covers, HEPA filtration in bedroom, weekly hot-water washing of bedding, dehumidification to &lt;50% humidity.</p>
<p><strong>SUPPORTING STACK:</strong></p>
<ul>
<li><strong>Vitamin C</strong> — Continue 1500mg (natural antihistamine, supports DAO activity)</li>
<li><strong>Low-histamine dietary awareness</strong> — Continue current dietary approach</li>
</ul>
<p><strong>MONITORING:</strong></p>
<ul>
<li>Total IgE recheck at 6 months</li>
<li>Symptom tracking: nasal congestion, skin flushing, brain fog episodes</li>
<li>Expected timeline: Environmental measures show effect within 2-4 weeks; DAO enzyme is immediately effective per meal</li>
</ul>
<hr>
</div></details>
<a href="#top" class="back-to-top">&#8593; Back to top</a>
<details open><summary>PROTOCOL IMPLEMENTATION TIMELINE</summary><div class="details-content">
<pre class="ascii-art">╔══════════════════════════════════════════════════════════════════════════════╗
║                        TIERED IMPLEMENTATION SCHEDULE                        ║
╠══════════════════════════════════════════════════════════════════════════════╣
║                                                                              ║
║  TIER 1 (IMMEDIATE — Week 1-2):                                            ║
║  ├── Confirm Armour Thyroid status (Protocol #1 — CRITICAL)                ║
║  ├── Increase Metformin to 1000mg/day ER (Protocol #1)                     ║
║  ├── Increase Lamotrigine to prescribed 100mg/day                          ║
║  ├── Switch progesterone to cyclic (Protocol #5)                           ║
║  ├── Discontinue cyanocobalamin IM (WRONG form for MTHFR compound het)    ║
║  ├── Start vitamin D 10,000 IU/day + K2 (Protocol #2)                     ║
║  ├── Start NAC 600mg BID (Protocol #2)                                      ║
║  ├── Start liposomal glutathione 250mg (Protocol #2)                       ║
║  ├── Start Mag Threonate + adjust Mag Citrate (Protocol #6)                ║
║  └── Increase DAO enzyme to before every meal (Protocol #7)                ║
║                                                                              ║
║  TIER 2 (Weeks 2-4, after TIER 1 stable):                                  ║
║  ├── Switch to Hydroxocobalamin injections (Protocol #3)                   ║
║  │   ⚠ MB12 compliance unconfirmed — may need to START, not switch       ║
║  ├── Start 5-MTHF 200mcg, titrate up (Protocol #3)                        ║
║  ├── Start R5P 25mg + P5P 25mg (Protocol #3)                              ║
║  ├── Consolidate omega-3 to EPA-dominant product (Protocol #4)             ║
║  └── Start phosphatidylserine 200mg (Protocol #6)                          ║
║                                                                              ║
║  TIER 3 (Weeks 4-8, after TIER 2 stable):                                  ║
║  ├── D. fragilis antiparasitic treatment (Protocol #2 — RX)               ║
║  ├── Increase 5-MTHF to 400-800mcg (Protocol #3)                          ║
║  ├── Add TMG 500mg (Protocol #3)                                            ║
║  ├── Add Niacin ER 250→500mg (Protocol #4)                                ║
║  ├── Add Berberine 500mg BID (Protocol #1)                                 ║
║  ├── Add 5-HTP 50mg HS (Protocol #6)                                       ║
║  └── Resume LL-37 cycling (IF vitamin D &gt;50)                               ║
║                                                                              ║
║  TIER 4 (Weeks 8-20, optimization):                                        ║
║  ├── Start targeted probiotic + butyrate (Protocol #2 Phase C)             ║
║  ├── DHEA dose optimization based on recheck (Protocol #5)                 ║
║  ├── Cognitive stack consolidation (Protocol #6)                            ║
║  └── Full reassessment at 12 weeks                                          ║
║                                                                              ║
║  RX ITEMS (require prescriber coordination):                                ║
║  ├── Armour Thyroid confirmation/reinstatement (Protocol #1)               ║
║  ├── Metformin ER switch (Protocol #1)                                      ║
║  ├── Lamotrigine dose increase (Protocol #1)                                ║
║  ├── D. fragilis antiparasitic (Protocol #2)                                ║
║  └── Progesterone cyclic dosing (Protocol #5)                              ║
║                                                                              ║
╚══════════════════════════════════════════════════════════════════════════════╝</pre>
<hr>
</div></details>
<a href="#top" class="back-to-top">&#8593; Back to top</a>
<h1 id="part-4-gaps-analysis">PART 4: GAPS ANALYSIS</h1>
<h2 id="what-we-don-t-know-what-we-need-what-s-wrong">What We Don't Know, What We Need, What's Wrong</h2>
<hr>
<details open><summary>4a. CRITICAL ISSUES WITH CURRENT PROTOCOL</summary><div class="details-content">
<pre class="ascii-art">━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="issue-1-thyroid-medication-gap-critical">Issue #1: Thyroid Medication Gap (CRITICAL)</h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  SEVERITY: CRITICAL — Fundamentally changes interpretation of all data     │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  WHAT WE KNOW:                                                              │
│  • Hypothyroidism diagnosed 2019 (Dr. Kurtz)                               │
│  • Armour Thyroid on Dr. Kim's active medication list (Apr 2025)           │
│  • Armour Thyroid ABSENT from Dr. Kurtz's Dec 2025 reconciliation          │
│  • Armour Thyroid ABSENT from patient self-report                          │
│  • Dose was NEVER specified in any available records                       │
│  • TSH 1.24 (Dec 2025) — normal, but could reflect treated OR untreated  │
│  • DIO2 CC genotype means serum thyroid labs are MISLEADING for tissue    │
│    thyroid status regardless of medication status                          │
│                                                                              │
│  WHAT THIS AFFECTS:                                                         │
│  • Protocol #1 (Thyroid-Metabolic) — cannot optimize without knowing base │
│  • Module 2 interpretation — is IR score worsening WITH or WITHOUT thyroid?│
│  • Module 3 — gut motility depends on thyroid status                      │
│  • Module 6 — brain fog has major thyroid component via DIO2 CC           │
│  • ALL downstream recommendations assume thyroid can be optimized         │
│                                                                              │
│  ACTION REQUIRED: Ask Moj directly, then verify with prescribing provider │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<pre class="ascii-art">━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="issue-2-medication-compliance-discrepancies">Issue #2: Medication Compliance Discrepancies</h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  SEVERITY: HIGH — Undermining prescribed treatment efficacy                │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  LAMOTRIGINE:                                                               │
│  • Prescribed: 100mg/day (25mg x4: 2 AM, 2 PM)                            │
│  • Patient reports: 50mg/day                                                │
│  • Impact: 50% underdosing of mood stabilizer                              │
│  • Risk: Subtherapeutic levels → mood instability, potential relapse      │
│                                                                              │
│  METFORMIN:                                                                 │
│  • Prescribed: 500mg BID (1000mg/day)                                      │
│  • Patient reports: 500mg/day (possibly once daily)                        │
│  • Impact: 50% underdosing of insulin sensitizer in patient with           │
│    PPARG CC + IRS1 CC genetic insulin resistance                           │
│  • Risk: IR Score worsening (42→48) partly attributable to underdosing   │
│                                                                              │
│  PROGESTERONE:                                                              │
│  • Prescribed: Days 10-24 (cyclic)                                         │
│  • Patient reports: "almost every night" (continuous)                       │
│  • Impact: Iatrogenic FSH suppression (12.6 instead of expected &gt;40)      │
│  • Risk: Masked menopausal status, impaired HRT dose optimization         │
│                                                                              │
│  MOUNJARO:                                                                  │
│  • Prescribed: 15mg (Dec 2025, Dr. Kurtz)                                 │
│  • Patient reports: 12.5mg                                                  │
│  • Impact: May be transitional or dose confusion — clarify                │
│                                                                              │
│  ROOT CAUSE ANALYSIS:                                                       │
│  Multiple medications from 6 providers across conventional and             │
│  integrative medicine. No single coordinator. Patient self-manages        │
│  with incomplete understanding of dosing rationale. Complex regimen       │
│  (40+ items) invites compliance errors.                                    │
│                                                                              │
│  RECOMMENDATION: Designate one provider as protocol coordinator.          │
│  Simplify regimen where possible. Medication review at each visit.        │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<pre class="ascii-art">━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="issue-3-estrace-vaginal-cream-non-compliance">Issue #3: Estrace Vaginal Cream Non-Compliance</h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  SEVERITY: HIGH — Documented severe pathology going untreated              │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  • Cystoscopy (Apr 2025): Severe urethral atrophy documented              │
│  • Prescribed by: Dr. Schneider (OBGYN), also on Dr. Kurtz's list        │
│  • Patient states: "I have never taken this"                               │
│  • Bulkamid injection addressed SUI mechanically — NOT the atrophy        │
│                                                                              │
│  BARRIER HYPOTHESES:                                                        │
│  1. Application method uncomfortable or unfamiliar                         │
│  2. Concerns about estrogen (bilateral mastectomy history)                 │
│  3. Overwhelmed by number of treatments                                    │
│  4. Not understanding severity of the condition                            │
│                                                                              │
│  ALTERNATIVES TO EXPLORE:                                                   │
│  • Intrarosa (DHEA vaginal suppository) — non-estrogen option             │
│  • Estriol vaginal tablet — easier application                            │
│  • Hyaluronic acid vaginal moisturizer — non-hormonal bridge              │
│  • Patient education on local vs systemic estrogen risk                    │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<pre class="ascii-art">━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="issue-4-multi-provider-coordination">Issue #4: Multi-Provider Coordination</h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  SEVERITY: MEDIUM-HIGH — 6 providers, no unified protocol                  │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  CURRENT PROVIDERS:                                                         │
│  • Dr. Lyle Kurtz — PCP (medications, labs)                                │
│  • Dr. Rachel West — Integrative (supplements, peptides, HRT)             │
│  • Dr. Nigma Talib — Naturopath (supplements, initial workup)              │
│  • Dr. Ja-Hong Kim — Urology (cystoscopy, Bulkamid)                      │
│  • Dr. Schneider — OBGYN (Estrace)                                        │
│  • Dr. Lipman — Labs (Feb 2025 bloodwork)                                 │
│                                                                              │
│  PROBLEMS:                                                                  │
│  • B12 confusion: Cyanocobalamin IM (confirmed) vs MB12 (unconfirmed)    │
│  • Thyroid medication appears/disappears across provider records           │
│  • Omega-3 from 2-3 overlapping products                                   │
│  • No single record contains complete medication list                      │
│  • Patient is the de facto coordinator — with 40+ items to track          │
│                                                                              │
│  RECOMMENDATION:                                                            │
│  • Designate Dr. Kurtz or Dr. West as protocol coordinator                │
│  • Create unified medication list shared across all providers             │
│  • Quarterly medication reconciliation                                     │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<pre class="ascii-art">━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━</pre>
<h3 id="issue-5-potential-interactions">Issue #5: Potential Interactions</h3>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  INTERACTION MONITORING                                                      │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  HIGH CONCERN:                                                              │
│  • Triple anticoagulant (Nattokinase + Lumbrokinase + ASA) + F2 GA        │
│    → Monitor for bleeding. D-dimer at regular intervals.                   │
│  • Alprazolam + Gabatrol (both GABAergic) → CNS depression risk          │
│  • Pantoprazole + B12 absorption + iron absorption → may worsen           │
│    methylation burden and inflammatory iron pattern                        │
│                                                                              │
│  MODERATE CONCERN:                                                          │
│  • Melatonin 5mg + HRT → high-dose melatonin may affect hormone levels  │
│  • NAD+ + Metformin → both affect AMPK pathway — monitor glycemic        │
│  • Multiple methyl donors (MB12 + MIC + methylfolate) → COMT AA          │
│    overwhelm risk (Protocol #3 addresses with hydroxocobalamin switch)    │
│                                                                              │
│  LOW CONCERN:                                                               │
│  • Mounjaro + Pantoprazole → known GI interaction, already managed       │
│  • Berberine (new) + Metformin → additive hypoglycemia risk (monitor)   │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<hr>
<h2 id="4b-missing-data-need-more-testing">4b. MISSING DATA / NEED MORE TESTING</h2>
<pre class="ascii-art">╔══════════════════════════════════════════════════════════════════════════════╗
║                        PRIORITIZED TESTING GAPS                              ║
╠══════════════════════════════════════════════════════════════════════════════╣
║                                                                              ║
║  HIGH PRIORITY (within 4-8 weeks):                                          ║
║  ─────────────────────────────────                                          ║
║                                                                              ║
║  1. THYROID PANEL — Comprehensive                                           ║
║     Tests: TSH, FT3, FT4, Reverse T3, TPO Ab, Thyroglobulin Ab            ║
║     Why: Confirm current thyroid status post-medication gap.                ║
║     DIO2 CC requires FT3 + RT3 ratio for tissue status assessment.        ║
║     Antibodies to confirm Hashimoto's resolution vs remission.             ║
║     Gate: BEFORE any thyroid medication changes.                            ║
║                                                                              ║
║  2. DUTCH COMPLETE (Dried Urine Test for Comprehensive Hormones)           ║
║     Tests: Estrogen metabolites (2-OH, 4-OH, 16α-OH), progesterone        ║
║     metabolites, cortisol pattern, melatonin, organic acids                ║
║     Why: COMT AA slows catechol estrogen clearance. Need 2-OH:4-OH       ║
║     ratio to assess genotoxic estrogen metabolite accumulation risk.       ║
║     No DUTCH data exists for Moj — critical gap.                           ║
║     Gate: After progesterone switched to cyclic (unmask true hormone       ║
║     status first).                                                          ║
║                                                                              ║
║  3. REPEAT GI EFFECTS STOOL TEST (3-6 months post-intervention)            ║
║     Tests: Full GI Effects comprehensive stool analysis                     ║
║     Why: Monitor Dientamoeba clearance, dysbiosis score change,           ║
║     commensal recovery (Roseburia, Bifidobacterium, Barnesiella),         ║
║     SCFA levels after gut restoration protocol.                            ║
║     Gate: Retest 3-6 months AFTER Protocol #2 initiated.                   ║
║                                                                              ║
║  4. METABOLOMIX URINE (Organic Acids)                                       ║
║     Tests: Organic acids, amino acids, oxidative stress markers            ║
║     Why: Ordered but NEVER RECEIVED (misfiled or not collected).           ║
║     Would provide: methylmalonic acid (B12 functional status),             ║
║     formiminoglutamic acid (folate functional status), 8-OHdG            ║
║     (DNA oxidative damage — relevant for GSTM1 null), neurotransmitter   ║
║     metabolites (HVA, VMA, 5-HIAA for COMT/MAOA assessment).             ║
║                                                                              ║
║  MEDIUM PRIORITY (within 3-6 months):                                       ║
║  ─────────────────────────────────────                                      ║
║                                                                              ║
║  5. MYCOTOXIN PANEL                                                          ║
║     Tests: Urine mycotoxin panel (RealTime Labs or Great Plains)           ║
║     Why: GSTM1 null = impaired Phase II clearance of mycotoxins.          ║
║     If environmental mycotoxin exposure present, clearance is              ║
║     catastrophically impaired. May explain persistent inflammation.        ║
║                                                                              ║
║  6. HEAVY METALS PANEL                                                       ║
║     Tests: Urine toxic elements (provoked or unprovoked)                   ║
║     Why: GSTM1 null = impaired heavy metal clearance.                     ║
║     Arsenic, mercury, lead, cadmium accumulation risk elevated.           ║
║     Contributes to neuroinflammation (Module 6) and immune burden.         ║
║                                                                              ║
║  7. FULL METHYLATION PANEL                                                   ║
║     Tests: Homocysteine (recheck), SAM, SAH, SAM:SAH ratio,              ║
║     methylmalonic acid, formiminoglutamic acid                              ║
║     Why: Confirm methylation status after Protocol #3 changes.            ║
║     Current homocysteine 9.0 (Dec 2025, up from 7.0) — worsening;       ║
║     ratio or functional methylation capacity.                              ║
║                                                                              ║
║  8. FASTING INSULIN + HOMA-IR                                                ║
║     Tests: Fasting insulin, glucose, calculated HOMA-IR                    ║
║     Why: IR Score is a proprietary composite. Direct HOMA-IR provides     ║
║     standardized, comparable insulin resistance measurement to track      ║
║     Protocol #1 response (Metformin dose increase + thyroid).             ║
║                                                                              ║
║  LOWER PRIORITY (within 6-12 months):                                       ║
║  ─────────────────────────────────────                                      ║
║                                                                              ║
║  9. COMPREHENSIVE GENOMIC ANALYSIS                                           ║
║     Tests: 23andMe or AncestryDNA raw data → clinical interpretation     ║
║     Why: 146 SNPs from 3x4 panel vs 679,085+ from genome-wide.           ║
║     Would reveal: MTR confirmation (currently inferred), NOD2, FMO3,     ║
║     comprehensive pharmacogenomics, rare variants.                        ║
║     Not urgent: current panel covers clinically most important variants.  ║
║                                                                              ║
║  10. STRUCTURED SYMPTOM QUESTIONNAIRE                                        ║
║      Tests: Validated questionnaires (PHQ-9, GAD-7, MSQ, PSQI)           ║
║      Why: No systematic symptom data. Endotype relies on clinical notes  ║
║      and patient self-report. Structured tracking enables quantified      ║
║      monitoring of treatment response.                                     ║
║                                                                              ║
║  11. CGM FOLLOW-UP DATA                                                      ║
║      Tests: 2-week continuous glucose monitoring period                     ║
║      Why: CGM used in past (Dr. Talib noted). Serial CGM data would      ║
║      show glycemic variability patterns and Mounjaro + Metformin          ║
║      optimization in context of PPARG CC + IRS1 CC genetic IR.           ║
║                                                                              ║
╚══════════════════════════════════════════════════════════════════════════════╝</pre>
<hr>
<h2 id="4c-truage-algorithm-caveat">4c. TRUAGE ALGORITHM CAVEAT</h2>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  TRUAGE DATA — CROSS-YEAR COMPARABILITY WARNING                             │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  2022 TruAge Report:                                                        │
│  • TruAge Intrinsic: 53.06 years (+7.4 over chrono age 45.6)             │
│  • TruAge Extrinsic: 54.26 years (+8.6) [UNVERIFIED — not in pipeline]   │
│  • Algorithm version: NOT SPECIFIED (pre-2024 methodology)                 │
│                                                                              │
│  2025 TruAge Report:                                                        │
│  • Symphony Age: 53.1 years (+4.1 over chrono age 49.0)                   │
│  • OMICm Age: 42.0 years (-7.0)                                           │
│  • DunedinPACE: 0.90 (aging at 90% rate)                                   │
│  • Brain Organ Age: 54.2 years (+5.2)                                      │
│  • Algorithm version: Updated 2024-2025 methodology                        │
│                                                                              │
│  CRITICAL NOTE:                                                              │
│  The 2022 and 2025 TruAge reports use DIFFERENT algorithms, clocks,       │
│  and output metrics. They CANNOT be directly compared to track aging      │
│  trajectory. Specifically:                                                  │
│  • 2022: "Intrinsic" and "Extrinsic" age (Horvath-derived)               │
│  • 2025: "Symphony" (multi-clock integration), "OMICm" (multi-omic),     │
│    organ-specific ages, DunedinPACE (rate of aging)                       │
│                                                                              │
│  The apparent "improvement" from 53.06 (2022) to 53.1 (2025 Symphony)    │
│  CANNOT be attributed to treatment because the measurement tool changed.  │
│                                                                              │
│  VALID COMPARISON: The DunedinPACE of 0.90 (2025) is a standalone        │
│  metric indicating current RATE of aging is favorable (90% of average).   │
│  This suggests current interventions are slowing aging pace even if       │
│  absolute biological age remains elevated.                                 │
│                                                                              │
│  RECOMMENDATION: Use 2025 TruAge as the new baseline. Retest in 12       │
│  months using the same laboratory and algorithm version for valid         │
│  comparison.                                                                │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<hr>
<h2 id="4d-model-uncertainties">4d. MODEL UNCERTAINTIES</h2>
<pre class="ascii-art">┌──────────────────────────────────────────────────────────────────────────────┐
│  HONEST ASSESSMENT — WHAT THE MODEL ASSUMES BUT CANNOT FULLY VERIFY       │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  1. 146-SNP LIMITATION                                                      │
│     The 3x4 Genetics panel covers 146 curated SNPs. Full genome-wide      │
│     analysis covers 600,000+. Pathway burden scores have WIDER            │
│     confidence intervals than analyses based on comprehensive genomic     │
│     data (e.g., Case 1767 had 679,085 SNPs).                              │
│                                                                              │
│     Specific gaps:                                                          │
│     • MTR bottleneck (85% burden) is INFERRED from the cascade model,    │
│       not from a directly measured risk allele (MTR rs1805087 AA =        │
│       no_impact on this panel). The bottleneck may be less severe        │
│       than modeled.                                                        │
│     • NOD2 variants (bacterial sensing) not tested — cannot assess       │
│       innate immune recognition defects contributing to dysbiosis.       │
│     • FMO3 variants (trimethylamine metabolism) not tested — potential   │
│       gut-related contributor unknown.                                     │
│     • Comprehensive pharmacogenomic profile limited to panel coverage.   │
│                                                                              │
│  2. NO QUESTIONNAIRE DATA                                                   │
│     Symptom-pathway mapping relies entirely on clinical notes and         │
│     patient self-report (single document, circa Dec 2025). No validated  │
│     questionnaires (PHQ-9, MSQ, PSQI, etc.) were available.              │
│     This means:                                                             │
│     • Symptom severity is estimated from clinical context, not measured  │
│     • Brain fog, fatigue, and histamine symptom burden are qualitative   │
│     • Treatment response tracking has no quantified baseline             │
│                                                                              │
│  3. THYROID MEDICATION STATUS IS UNKNOWN                                    │
│     This fundamentally changes the interpretation of:                      │
│     • TSH 1.24 (treated euthyroid vs natural euthyroid)                  │
│     • IR Score trajectory (thyroid contribution unknown)                   │
│     • Brain fog causation (brain T3 deficit magnitude unknown)            │
│     • Gut motility (thyroid-driven component magnitude unknown)           │
│     Until this is resolved, Protocol #1 recommendations are              │
│     provisional and may require revision.                                  │
│                                                                              │
│  4. BIOMARKER COMPARABILITY ACROSS TIME                                     │
│     Labs were drawn across 15+ collection dates (2018-2025) from         │
│     multiple laboratories (Quest, Vibrant, Genova, Cleveland HeartLab,   │
│     True Health Diagnostics, Vitae). Reference ranges and assay          │
│     methods differ. Trends identified in Part 1 assume comparability     │
│     across labs and time periods. Some apparent trends (particularly      │
│     in markers like LDL-P, ferritin, thyroid) may partially reflect     │
│     methodological differences rather than true clinical change.          │
│                                                                              │
│  5. SUPPLEMENT FORMULATION UNKNOWN                                          │
│     Several supplements (Inflamafree, Cholesterol Complete, Brilliant     │
│     Brain, TBC Probiotic, Cyclease Menopause, Vitamin D Sun 30,         │
│     Ultimate Recovery, Gabatrol) are proprietary blends. Exact            │
│     ingredient lists and doses were not available in patient records.     │
│     KEEP/OK assessments for these are based on general product           │
│     category, not confirmed formulation.                                   │
│                                                                              │
│  6. CAUSAL MODEL LIMITATIONS                                                │
│     The endotype model ("The Slow Burn") is a HYPOTHESIS that best       │
│     fits the available data. Alternative causal models exist. The        │
│     convergence of multiple genetic variants is probabilistic, not       │
│     deterministic. Individual response to interventions may differ       │
│     from model predictions. The 4-pass endotyping pipeline produces     │
│     pathway burden scores that are estimates, not measurements.          │
│                                                                              │
│  7. EPIGENETIC AGE RELIABILITY                                              │
│     Organ-specific epigenetic ages (brain 54.2, blood 54.5, immune      │
│     53.6) are emerging metrics with moderate clinical validation.        │
│     They should be treated as HYPOTHESIS-GENERATING data, not as        │
│     diagnostic certainties. The DunedinPACE (0.90) is better validated  │
│     but still a population-level metric applied to an individual.        │
│                                                                              │
└──────────────────────────────────────────────────────────────────────────────┘</pre>
<hr>
<h2 id="4e-clarification-questions-for-moj">4e. CLARIFICATION QUESTIONS FOR MOJ</h2>
<p>Reference: <code>Moj_clarification_questions.md</code> (11 items)</p>
<p>The following questions are ranked by criticality for refining the endotype model and treatment recommendations:</p>
<pre class="ascii-art">╔══════════════════════════════════════════════════════════════════════════════╗
║  CRITICAL — These change the treatment plan                                  ║
╠══════════════════════════════════════════════════════════════════════════════╣
║                                                                              ║
║  Q1. THYROID MEDICATION STATUS [ISSUE-007]                                  ║
║  "Are you currently taking any thyroid medication? If yes, what is the     ║
║  name, dose, and prescriber? If you stopped taking it, when and why?"      ║
║  Impact: Determines whether Protocol #1 requires reinstatement or          ║
║  optimization. Changes interpretation of ALL thyroid-dependent findings.   ║
║                                                                              ║
║  Q2. METFORMIN ACTUAL DOSING [ISSUE-004]                                   ║
║  "How many Metformin tablets do you take per day, and when? Is it         ║
║  one 500mg tablet or two 500mg tablets?"                                   ║
║  Impact: 50% underdosing of a critical insulin sensitizer for genetic IR. ║
║                                                                              ║
║  Q3. ESTRACE BARRIER [ISSUE-003]                                           ║
║  "What has prevented you from using the Estrace vaginal cream? Is it     ║
║  the application method, concerns about hormones, or something else?"     ║
║  Impact: Identifies which alternative formulation to recommend.            ║
║                                                                              ║
╠══════════════════════════════════════════════════════════════════════════════╣
║  HIGH — These refine the recommendations                                     ║
╠══════════════════════════════════════════════════════════════════════════════╣
║                                                                              ║
║  Q4. LAMOTRIGINE ACTUAL DOSING [ISSUE-004]                                 ║
║  "How many Lamotrigine tablets do you take per day? 2 tablets (50mg)     ║
║  or 4 tablets (100mg)?"                                                    ║
║  Impact: Confirms whether mood stabilizer is therapeutic.                  ║
║                                                                              ║
║  Q5. PROGESTERONE SCHEDULE [ISSUE-005]                                     ║
║  "How often do you take progesterone? Every night, or only certain       ║
║  days of the month?"                                                       ║
║  Impact: Confirms whether FSH suppression is iatrogenic.                  ║
║                                                                              ║
║  Q6. DATE OF BIRTH [ISSUE-001]                                             ║
║  "Is your date of birth December 25, 1976 or September 23, 1976?        ║
║  (Records show both — we need the correct date for age-adjusted labs.)"  ║
║  Impact: 3-month difference affects age-adjusted reference ranges.        ║
║                                                                              ║
║  Q7. MOUNJARO CURRENT DOSE [ISSUE-004]                                     ║
║  "Are you currently on Mounjaro 12.5mg or 15mg?"                          ║
║  Impact: Clarifies dose discrepancy between patient report and Rx.       ║
║                                                                              ║
╠══════════════════════════════════════════════════════════════════════════════╣
║  MEDIUM — These improve completeness                                         ║
╠══════════════════════════════════════════════════════════════════════════════╣
║                                                                              ║
║  Q8. MISSING METABOLOMIX URINE [ISSUE-008]                                 ║
║  "The Metabolomix urine test was ordered but we never received results.  ║
║  Was the sample collected? Do you have a copy of the results?"           ║
║                                                                              ║
║  Q9. GI EFFECTS STOOL DATE [ISSUE-009]                                     ║
║  "When exactly was the GI Effects stool sample collected?"               ║
║                                                                              ║
║  Q10. DR. TALIB ADDITIONAL LABS [ISSUE-011]                                ║
║  "Do you have results from any additional tests Dr. Talib may have       ║
║  ordered that we haven't seen?"                                           ║
║                                                                              ║
║  Q11. SYMPTOM SEVERITY                                                      ║
║  "On a scale of 1-10, how severe is your brain fog currently? How       ║
║  about fatigue? Histamine symptoms (nasal congestion, flushing)?"        ║
║  Impact: Establishes quantified baseline for treatment monitoring.        ║
║                                                                              ║
╚══════════════════════════════════════════════════════════════════════════════╝</pre>
<hr>
<h2 id="verification-checklist">VERIFICATION CHECKLIST</h2>
<ul>
<li>[x] Every current medication/supplement assessed (KEEP/OK/PAUSE/DISCONTINUE) — 40+ items classified</li>
<li>[x] Recommendations organized by protocol with full details (7 protocols)</li>
<li>[x] Genetic context applied to form selection (hydroxocobalamin for COMT AA, methylfolate for MTHFR, calcifediol for CYP2R1 GG, T3-containing thyroid for DIO2 CC, NAC/glutathione for GSTM1 null)</li>
<li>[x] Gates/sequencing defined for multi-tier protocol (TIER 1-4 timeline)</li>
<li>[x] TSV created with all recommendations (see Moj_recommendations.tsv)</li>
<li>[x] Missing tests prioritized (HIGH/MEDIUM/LOW) — 11 items</li>
<li>[x] Model uncertainties honestly documented (7 categories)</li>
<li>[x] Thyroid medication gap prominently flagged (Issue #1, Q1)</li>
<li>[x] Output saved to report/parts3_4_recs_gaps.md and Moj_recommendations.tsv</li>
</ul>
<hr>
<p><em>End of Parts 3 &amp; 4: Recommendations + Gaps Analysis</em> <em>Report complete: Parts 1-4 constitute the full "Slow Burn" analysis for Moj Mahdara</em></p>
</div></details>
<a href="#top" class="back-to-top">&#8593; Back to top</a>
</main>

<footer>
    <p><strong>Report generated:</strong> 2026-02-10</p>
    <p><strong>Pipeline version:</strong> endo_typing v1.0 (5-pass endophenotype)</p>
    <p><strong>Data sources:</strong> 146 SNPs (3x4 Genetics), 1081 biomarker observations (2018-2025), 6+ providers</p>
    <p class="disclaimer">Note: This report is generated by an AI system and should be reviewed by a qualified healthcare provider.</p>
</footer>

</div><!-- end #main-content-wrapper -->

<script>

// Password protection
const correctPassword = 'moj';

function checkPassword() {
    const input = document.getElementById('password-input').value;
    if (input === correctPassword) {
        document.getElementById('password-screen').style.display = 'none';
        document.getElementById('main-content-wrapper').style.display = 'block';
        sessionStorage.setItem('moj_authenticated', 'true');
    } else {
        document.getElementById('password-error').style.display = 'block';
        document.getElementById('password-input').value = '';
    }
}

// Check if already authenticated this session
if (sessionStorage.getItem('moj_authenticated') === 'true') {
    document.getElementById('password-screen').style.display = 'none';
    document.getElementById('main-content-wrapper').style.display = 'block';
}

// Enter key support
document.getElementById('password-input').addEventListener('keypress', function(e) {
    if (e.key === 'Enter') checkPassword();
});

function toggleTOC() {
    document.getElementById('toc').classList.toggle('open');
}

// Close TOC on mobile when clicking a link
document.addEventListener('DOMContentLoaded', function() {
    var tocLinks = document.querySelectorAll('.toc-content a');
    tocLinks.forEach(function(link) {
        link.addEventListener('click', function() {
            if (window.innerWidth <= 1100) {
                document.getElementById('toc').classList.remove('open');
            }
        });
    });
});

function printReport() {
    window.print();
}

</script>

</body>
</html>